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Over the next 20 years, more than 36 million people are expected to die of 
Mycobacterium tuberculosis (Mtb) related illness.  We may prevent this only by 
learning as much as possible about the Mtb-mediated exploitation of the human 
immune system and successfully implementing that knowledge to combat the 
pathogen.  One Mtb virulence mechanism involves inhibition of host apoptosis.  An 
Mtb laden macrophage will attempt cell suicide, subsequently destroying any 
intracellular bacteria.  In prior work, a large gain-of-function screen identified Mtb 
genomic regions involved in host apoptotic suppression; one such region is “K20.”   
A loss-of-“gain-of-function” (LoGoF) screen involving in vitro transposon (Tn) 
mutagenesis of a K20 expressing vector identified individual gene(s) of K20 
potentially responsible the virulence phenotype.  This LoGoF screen found two 
unique K20 Tn-clones that consistently induced significant host apoptosis.  These 
  
Tn’s disrupted expression of K20 genes Rv2666 ( probable truncated transposase) and 
Rv2667 ( possible Clp ATPase). 
A Himar1 Tn mutant of Rv2666 was obtained through the TARGET mutant 
library project.  Upon infection of human macrophages, TnRv2666 induced 
significantly more host apoptosis than wild type (WT) and complement, confirming 
Rv2666 as an anti-apoptotic gene of Mtb. There are no current publications 
suggesting a specific role for transposase-based virulence in Mtb; Rv2666 may affect 
an anti-apoptotic phenotype by modulating transcription of factors important for the 
suppression of host apoptosis.   
The second LoGoF identified gene, Rv2667/clpC2/clpX’, was not available 
through TARGET; a recombinant ΔclpC2 mutant was generated.  Comparing induced 
host apoptosis of ΔclpC2 infected macrophages to WT revealed Rv2667/clpC2 has no 
essential role as an anti-apoptotic gene of Mtb.  ΔclpC2 was further characterized to 
explain the discrepancy between the initial LoGoF data and the ΔclpC2 Mtb results.  
Study of ΔclpC2 determined that it bears no significant differences with WT in terms 
of in vitro growth, host necrosis-induction, in vivo survival and induced host TNFα 
secretion levels.  However, ΔclpC2 induces significantly more host IL-1β release than 
WT Mtb.  The reason for this effect is unknown; ClpC2 may aid Mtb pathogenicity 
by limiting host inflammation, thus permitting infecting Mtb a “head start” against a 




Pulmonary tuberculosis (TB), primarily caused Mycobacterium tuberculosis 
(Mtb) infection, kills over two million people every year.  Curable in most cases, the 
misuse of antibiotics, often due to sporadic access to adequate health care in third-
world locales, has given rise to drug-resistant Mtb.  These Mtb super-strains 
essentially return us to a pre-antibiotic era in terms of limiting patient TB treatment 
and are cause for great concern in all nations, developing and industrialized.  Creation 
of a vaccine is one of the best methods we have for total disease eradication. 
On that note, we may be able to generate an effective vaccine by exploiting 
cellular apoptosis, or “cell suicide.”  In the same way that defective, pre-cancerous 
cells of a person’s body seem to altruistically sacrifice themselves in order to prevent 
cancer from spreading, white blood cells such as macrophages will self-destruct when 
infected with pathogens such as Mtb.  Apoptosis of a host macrophage kills the 
bacteria within; this event also helps to generate a long-term memory response to 
prevent future infections.  Understandably, Mtb employs several tactics of its own to 
prevent host apoptosis and protect itself.   
An effective anti-TB vaccine may be created by genetic modification of Mtb.  
In this case, scientists will target the Mtb genes responsible for prevention of host 
apoptosis and remove them, attenuating the bacteria.  When this attenuated Mtb strain 
is used as a vaccine, great amounts of host apoptosis will result, leading to a robust 
long-term immune system memory response and, hopefully, provide humanity with a 
vaccine that will eliminate TB once and for all.  This dissertation explores that 
concept and specifically identifies an anti-apoptosis gene of Mtb, Rv2666. 
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Chapter 1: Introduction 
1.1 TB: A Historical and Cultural Perspective  
 
1.1.1 TB: Prehistoric Origins 
Pulmonary tuberculosis (TB) is one of the oldest diseases specifically 
plaguing mankind.  Mycobacterium tuberculosis (Mtb) is the primary causative agent 
of pulmonary TB in humans; however, other mycobacterial species have also been 
known to cause TB. The entire cluster of organisms responsible for TB is referred to 
as belonging to the Mycobacterium tuberculosis complex (MTBC); MTBC is 
generally considered to be composed of the species Mtb, M. africanum, M. 
pinnipedii, M. microti, M. bovis, and M. caprae [1].  Recent work has suggested that 
the MTBC cluster, or its immediate progenitors, arose in concert with early 
Paleolithic era hominids, prior to the existence of hunter-gatherer Homo sapiens 
sapiens in what is now East Africa [1][2].  Specifically, it is believed the Mtb species 
arose from a clonal expansion event occurring during an evolutionary bottleneck 
approximately 35,000 years before present [1]. Until recently, M. bovis was 
considered to be the parent species of Mtb.  However current bioinformatics work has 
suggested that M. bovis has branched from a human specific pathogen as a result of 
cohabitation of humans and cattle during the earliest time of bovine domestication 
and herding, approximately 13,000 to 15,000 years ago [3] (Figure 1).   
In 2001, Rothschild et al. identified fragments of MTBC DNA in the skeletal 




years old [4]. The earliest current biochemical indication of human Mtb infections 
comes from the remains of a mother and child living about 8,500 years ago in the 
ruins of Atlit-Yam, a Neolithic settlement that is now submerged in the Eastern 
Mediterranean Sea.  Researchers concluded that both individuals had been infected 
with Mtb prior to their deaths.  Tissue for both was well-preserved in mud and 
brackish sea water; by testing the samples the investigators were able to identify Mtb 
specific DNA fragments and mycolic acids exclusive to the MTBC within the ancient 
tissue [5].   Greater detail regarding the phylogenetic origins of Mtb and the earliest 
days of the pathogen’s niche in prehistoric civilizations will surely come to light as 







Figure 1. Coevolution of Homo sapiens sapiens and MTBC.   
The Mycobacterium tuberculosis complex (MTBC) is generally considered to be 
composed of the species Mtb, M. africanum, M. pinnipedii, M. microti, M. bovis, and 
M. caprae.  It is believed the Mtb species specifically arose from a clonal expansion 
event occurring during an evolutionary bottleneck approximately 35,000 ago [1]. M. 
bovis may have branched from a human specific pathogen during early bovine 
domestication, approximately 13,000 to 15,000 years before present. (Figure is 
obtained from [2] and is keeping with the terms of the Creative Commons Attribution 






1.1.2 TB: Ancient civilizations through the modern era 
Mtb has had an enormous and well-evidenced impact on the course of human 
history.  Many ancient Egyptian mummies have been identified as carriers of the Mtb 
pathogen or the closely related M. africanum species [6].  Thousand-year-old Andean 
mummies of South America were also burdened with the disease in their lifetime [7], 
suggesting the indigenous peoples of the Americas brought the pathogen with them 
when crossing the Bering Strait ages ago.  Various ancient Sanskrit texts describe a 
disease similar to modern-day TB and recommend treatments of milk, rest, alcohol 
and relocation to higher altitudes [8]; interestingly these are some of the very same of 
treatments recommended for TB through the early 20
th
 century.  The ancient scholars 
Pliny the Younger, Hippocrates and Aristotle all wrote about a disease that shared the 
hallmarks of TB [9].  What held true for the ancient Greeks of the Mediterranean held 
true for the rest of Europe as well.  For thousands of years, endemic TB was one of 





 centuries, TB was known as the “Great White Plague”;  it killed one in 100 
Londoners in 1660 and 25 percent of the European population at its peak in the 19
th
 
century [10].   
TB had a significant impact on European mythology and literature.  It is 
believed that the idea of the vampire, gaunt and ashen, began with the wasting and 
atrophy of TB victims who were occasionally buried during a period of extended 
unconsciousness and, when later excavated, were found to have scratched the insides 




A slow death from TB led to emaciation and a characteristic pallor in victims; 
morbid paleness and sallow features were considered to be marks of great beauty by 
European culture during much of the last millennium [11].  Additionally, TB or “the 
Consumption,” as it became commonly known was oddly romanticized as a condition 
that conferred a great burst of artistic innovation and ability just prior to claiming the 
lives of the affected.  Of course, this old wives’ tale is more a testament to the 
ubiquity of the disease across all social classes and educational ranks than any 
indicator of actual creative benefit.  Frederic Chopin, Anton Chekov, Voltaire, several 
members of the Brontë family, Stephen Crane, Robert Louis Stevenson and George 
Orwell all died of pulmonary TB.  The great poets Alexander Pope and Giacomo 
Leopardi both suffered from “Pott’s disease,” the disseminated  form of Mtb infection 
that spreads into victims’ vertebral bones and leads, in extreme cases, to severe  
physical disability, cosmetic deformity and great suffering [12].  Those unfortunate 
individuals burdened by extreme cases of TB during the pre-antibiotic era typically 
suffered the additional psychological fallout caused by severely limited physical 
mobility and great social ostracism.   
The lack of effective TB treatments persisted through the early 20
th
 century.  
TB was the second-leading cause of death in the United States in the year 1900, with 
about 200 of every 100,000 records deaths due to the illness [13].  The advent of a 
moderately successful vaccine, much-improved sanitation and effective antibiotics 
later reduced the lethality of pulmonary TB within industrialized nations, though the 





1.2 TB: Pathology 
 
Mtb is typically spread when an infected individual aerosolizes the bacteria by forceful 
coughing, and bystanders inhale the aerosolized droplets.  The inhaled bacillus travels to the 
pulmonary alveoli where it is phagocytosed by alveolar macrophages.  By employing a range 
of survival mechanisms to prevent lysosomal digestion and immune system detection, the 
pathogen establishes itself within the host macrophage, where it begins to replicate.    
The progression of the TB disease often depends on the individual immune response of 
the host, with about 10% of infected individuals progressing to an active form of TB.  A case 
of TB is “active” if Mtb has established itself and is actively replicating within the infected 
individual’s lungs; active TB is the disease state characterized by outward clinical 
manifestations of the disease.  A patient in this disease state may experience a host of 
symptoms, including local tissue inflammation, necrosis and lesions, a hacking cough 
producing blood and sputum, severe weight loss, weakness, fatigue and often death, if the 
disease is allowed to progress without antibiotic treatment.  An individual who is infected with 
the pathogen but demonstrates no obvious, outward signs of pathology has “latent TB;” this is 
typically characterized by an asymptomatic dormancy of the bacterial infection.  The immune 
response (IR) of a person with latent TB has contained the contained the pathogen and 
prevented it from disseminating, but has not completely eliminated the infection [15].  This 
host IR-mediated quarantine of the infection often produces a granuloma.   
A granuloma, a hallmark characteristic of TB infection, is formed by what seems to be 
a complex balancing act of host-pathogen interactions.  (Incidentally, it is from this granuloma, 
or “tubercle,” that we derive the name for tuberculosis disease [16].)  Macrophages infected 
with Mtb will migrate to the epithelial layer [17]; simultaneously, activated CD4
+




migrate to the site of infection, where they will recruit additional macrophages [15].  The site 
of infection quickly becomes a hot-spot of host inflammation and chemoattractant signaling.  
Newly arriving macrophages, neutrophils and monocytes will surround the infected 
macrophage from all sides, with a three-dimensional wall of leukocytes ultimately containing 
the infection without actually eliminating it; the infected macrophage may become a lipid-
filled foamy macrophage [18].  Lymphocytes will surround this layer creating a hypoxic 
fibrous cuff, which is the granuloma [17]. 
It is important to note that the separation between the active and latent states of TB 
infection is dynamic.  At any point, a latent infection may “awaken” or a granuloma may 
collapse or turn necrotic and cavitate, releasing the pathogen into the surrounding tissue.  The 
occurrence of the latent to active shift is especially likely when an infected individual has 
become immunocompromised.  This is sometimes the case when an individual contracts 
HIV/AIDS, becomes weakened with advanced age or is treated with anti-inflammatory 
compounds [19, 20].  In the some cases of uncontrolled TB infection, the bacteria may 
disseminate from the lungs to the liver, spleen and central nervous system, often leading to TB 
meningitis in infected children  [21, 22].  In the most severe instances, the bacteria may even 
spread to an individual’s spine, specifically to the intervertebral joints, which produces a 
painful and debilitating clinical condition referred to as Pott’s disease or tuberculous 
spondylitis [23]. 
1.3 TB: Epidemiology 
 
Mycobacterium tuberculosis (Mtb), the pathogen primarily responsible for 
pulmonary tuberculosis (TB), has infected roughly one-third of the world’s 




about 10% of those immunocompetent infected individuals will experience the active 
disease state in their lifetimes, the other approximately 1.8 billion individuals 
harboring latent infections will continue to fall victim to the disease, should they 
become immunocompromised at some point in their lifetime.  Most of these new TB 
infections occur in developing regions of the world (Figure 2).  A of political 
stability, poor access to health care and sanitation issues often exacerbate the spread 
of TB and limit the ability of medical workers to adequately contain, treat and prevent 
the disease.   Compounding the manner, TB is often a central factor in claiming the 
lives of individuals who are infected with HIV.  People who have both HIV and TB 
are at twice the risk of dying from TB as those who are infected with TB alone [24].  
The current syndemic of HIV-TB occurring in developing nations compounds the 
problem even further [14, 17, 25].   At the current pace of TB-HIV syndemic growth, 
the World Health Organization-established goal of TB elimination by the year 2050 
will not be achieved without significant advancements in prevention, diagnosis and 






Figure 2. Global instances of TB in 2010 according to WHO. 
World Health Organization (WHO) Global TB control report 2011 highlighting new 
reported instances of TB per 100,000 within a population. Gray scale identifies 





1.4 TB: Treatment and prevention of TB, clinical approaches 
1.4.1 Treatment of TB: Prehistoric approaches through the Enlightenment 
era 
 
In ancient Greece, the physicians and philosophers of the day recognized TB 
as a collection of symptoms composing a condition they referred to as phthisis.  
These men did not agree on the specific cause of phthisis. Hippocrates believed the 
disease was inherited, as the condition often seemed to occur in families and within 
small, related communities [9].  (Incidentally, Hippocrates recognized phthisis as one 
of the greatest diseases of his time and considered it absolutely terminal.  He barred 
his pupils from attempting to treat victims, as their eventual deaths would damage the 
reputation of the attending physician.)   The vast majority of the ancient Greeks 
agreed that phthisis was hereditary, with the notable exception of Aristotle, who 
contended that the disease was actually contagious [9].  It would be roughly 2,200 
years before Robert Koch would prove Aristotle correct. 
  By the European Middle Ages, understanding and treatment of TB, much like 
the rest of science, had progressed very little since the heyday of the toga.  One 
“treatment” of sorts was a proto-faith healing practice known as the “King’s Touch.”  
The general idea was that a person afflicted with phthisis could be cured of their 
disease when a king or queen, with healing powers ordained by God, laid hands upon 
the infected individual [26].   
The Age of Enlightenment brought new focus and attention to how people 
thought of TB.   Investigators into human anatomy discovered small, granular 
tubercles in the lungs of deceased individuals who had succumbed to phthisis.  The 




phthisis and subsequently blamed the tubercles themselves; the novel term 
“tuberculosis” arose to describe the condition from this discovery.  The actual cause 
for the lung tubercles was still unknown at this time.   





 century, science had made relatively large leaps in understanding 
the disease.  In 1865, Jean Antoine Villemin was able to infect rabbits with 
tuberculosis by injecting them with portions of tubercles obtained from cadavers, thus 
establishing the transmissible nature of tuberculosis.  A few years later, Robert Koch 
conclusively identified the causative agent of TB as the bacillus Mycobacterium 
tuberculosis by testing the sputum samples of tuberculosis patients with a novel 
staining technique he developed.  (To place the importance and impact of his 
discovery into greater context, at the time he made his announcement on March 24
th
, 
1882, 1 in every 7 human deaths was attributable to tuberculosis.)  Koch received the 
1905 Nobel Prize in Physiology or Medicine and would be remembered as one of the 
fathers of microbiology for establishing his famous “Koch’s postulates.”   
Although understanding of the disease and its transmission progressed greatly 
in the 19
th
 century, the actual treatments for tuberculosis were lagging.  As TB 
became generally accepted as contagious, containment and prevention became the 
focus of the day.  Across the industrialized nations, sanatoriums were constructed to 
house individuals with obvious, active cases of TB.  These sanatoriums were often 
built in high altitude locales, with the belief that the thinner air would assist patients’ 




containment first and foremost.  These facilities were run as semi-quarantine from the 
general public as well as a form of treatment for a patient.  The medical consensus of 
the day believed that an infected individual’s body should be able to heal itself, or at 
least wall-off or contain the bacteria within tubercles, if given fresh air, much food 
and plenty of rest.  This “cure” was very similar to treatments prescribed in 
Ayurvedic texts of ancient India, indicating that TB treatment had progressed very 
little in over 2,000 years [8].  Sanatoriums also functioned as hospice homes for the 
terminally ill; it was generally understood that few people in sanatoriums ever fully 
recovered.   





 centuries.  Health-activist groups such as the National Tuberculosis 
Association, now the American Lung Association, raised funds to build sanatoriums 
and educate the public on proper hygiene to limit the spread of TB [27].  The NTA’s 
anti-TB and hygiene propaganda was so effective that it contributed immensely to the 
decline of the public-use spittoon in the United States [27]. 
  Although the late 19
th
 century brought great strides in understanding of the 
TB disease and public sanitation, very little improvement had been made in 
preventing infection and colonization by the Mtb pathogen or in treating those people 
who were already infected.  It was to that end that Albert Calmette and Camille 
Guérin began developing a vaccine for TB.  In order to do this, Camette and Guérin 
subcultured M. bovis on an artificial media for 13 years.  Camette and Guérin’s M. 
bovis strain eventually lost its innate virulence for humans and became an attenuated 




Once the strain was no longer able to establish disease in laboratory animals, a 
vaccine was created.  In 1921, the Bacille Calmette-Guérin, or BCG, vaccine was first 
used in humans.  Theirs is the “parent” of the same strain that is still used to create 
vaccines in many modern nations.  BCG has been quite successful in preventing the 
disseminated form of TB in children [28]; however, there is a very high degree of 
variability in the ability of the vaccine to prevent pulmonary TB [29].  Some studies 
estimate that the variable effectiveness of BCG in this capacity ranges from 80 to 0% 
[30], with the broad range considered to be at least partially dependent on 
environmental and/or genetic factors [31]. 
Even with the development of this moderately effective vaccine, there was 
still a great need for an effective treatment to aid those already infected.  That need 
would be filled by the development of antibiotics. 
Antibiotics were an accidental discovery.  While working in his laboratory in 
1928, Alexander Fleming noted a blue-green mold had grown on a Petri dish that was 
being used to culture Staphylococcus.  Fleming noted that the contaminating mold 
was preventing the growth of the bacteria.  He purified the Penicillium notatum mold 
and was subsequently awarded the 1945 Nobel Prize in Physiology or Medicine for 
isolating the world’s first successful antibiotic.  Around the same time that Fleming 
received his Nobel Prize, Selman Waksman’s lab at Rutgers University isolated 
streptomycin from Streptomyces griseus, which functions by binding to the 30S 
subunit of the bacterial ribosome, ultimately blocking protein translation.   In 1952, 
Dr. Waksman was awarded the Nobel Prize in Physiology or Medicine for his work in 




the first oral antibiotic, isoniazid, which treats actively-replicating Mtb by blocking 
mycolic acid synthesis.  It is still one of the primary drugs being used to treat TB.  
1967 saw the advent of rifampicin, another first-line antibiotic still in use, which 
blocks prokaryotic mRNA synthesis by inhibiting a bacterial RNA polymerase beta-
subunit. The two other major compounds used in the treatment of TB, pyrazinamide 
and ethambutol, came in 1952 and 1961, respectively.   
In 1950, TB was the eighth leading cause of death in the United States; in 
comparison, vascular disease was the ninth greatest cause of death that same year.  By 
1985, there were only 1,752 TB-related fatalities in the U.S. [32].   Anti-TB antibiotic 
compounds have been proven quite successful at treating individuals infected with 
most strains of Mtb.  However, the typical course of drug treatment is up to 9 months 
of daily dosages of drugs that tend to be rather hepatotoxic; even longer treatments 
with additional drugs may be required in some cases.  Additionally, some bacteria 
may evade the bactericidal treatment by virtue of their inaccessibility within a 
patient’s granulomas.  The major anti-TB drugs only target actively replicating 
bacteria, further compounding this problem; latent-phase bacteria are much more 
likely to evade destruction [33, 34].  The emergence of antibiotic-resistant Mtb is 
rapidly becoming a major threat to global public health. 
1.4.3 Treatment of TB: Problems of the present day 
The increased use, and subsequent misuse, of antibiotics to treat TB has created a 
corresponding rise in antibiotic-resistant Mtb.  Lack of strict adherence to prescribed antibiotic 
regimen has spawned new strains of Mtb.  These super-strains are resistant to both first-line 




amikacin, capreomycin and kanamycin), leading to classification of these strains as MDR-TB 
(multi-drug resistant TB) and XDR-TB (extensively drug resistant TB), respectively [14].   
XDR is considered particularly threatening and each case is individually treated, sometimes 
with surgical removal of infected lung tissue being the only option remaining.  Cases of XDR 
essentially return the ability of physicians to treat Mtb to the days before antibiotics existed. 
The rapidly increasing prevalence of these MDR and XDR strains is a great cause for concern 
in both developing countries with endemic levels of TB and in the industrialized world.  This 
increased alarm extends to those nations such as the United States that have had the benefit of 
improved hygiene and widespread access to healthcare and thus no substantial 
mortality/morbidity from TB.   
In a recent example from within the United States, in 2007, Andrew Speaker, a newly-
married personal injury lawyer from Atlanta, Georgia, was diagnosed with TB and warned by 
medical professionals that he should avoid travel.  Speaker ignored their advice and traveled to 
Greece for a postnuptial vacation.  Shortly thereafter, further testing by the Center for Disease 
Control revealed Speaker’s strain of Mtb to be drug resistant.  Initially classified as XDR, but 
later proven to be MDR, Speaker fled Greece, flew to Canada and sneaked across the border 
into the U.S., where he was taken into custody and placed into quarantine [35] to receive 
appropriate medical treatment [36].  Though Speaker’s particular strain was not as deadly as 
initially thought, the extensive media coverage of the entire debacle, especially “TB Andy’s” 
flights across the Atlantic Ocean that put hundreds of lives at risk, did a great deal to raise 





1.4 Summary and conclusion of introductory remarks 
 
The efficacy of first line antibiotics has progressively diminished as the prevalence of 
multi-drug resistant (MDR) TB and extreme-drug resistant (XDR) TB rises throughout the 
world.  The variable effectiveness of the BCG vaccine and the increasing prevalence of MDR-
TB and XDR-TB demonstrate the urgent need for new methods of preventing or treating Mtb 
infections. As previously mentioned, a large portion of new TB cases originate from 
individuals acting as a reservoir of infection.  Within the infected individual, there is an 
“activation” of latent TB, which is then transmitted by exhalation to uninfected hosts.  
Currently, the vast majority of TB treatment compounds are designed to inhibit the 
growth of Mtb, as entirely preventing infection itself is quite impractical.   By targeting active, 
replicating bacteria, these anti-TB drugs decrease the overall bacterial burden, lessening the 
number of individual cases of active TB and, correspondingly, instances of individuals 
harboring latent TB.  In light of BCG’s obvious shortcomings, it seems only reasonable to 
approach the TB “vaccination problem” by examining or retooling BCG in a manner that 
complements the pharmaceutical approach.  Current vaccine development projects should aim 
to prevent Mtb colonization of pulmonary alveoli and generate long-term immunological 
memory; one of the best ways of doing this is by understanding, exploring, and exploiting the 
various mechanisms and survival strategies an Mtb bacillus employs as it attempts to hijack a 
macrophage and shelter itself within a host.  Our current needs for improved treatments such as 
superior antibiotics and, especially, an effective vaccine against Mtb is as urgent today as it 




Chapter 2: Background 
2.1 Mycobacteria 
 
2.1.1 M. tuberculosis (Mtb) 
Mtb is a pathogenic species of mycobacteria that is the primary agent of 
pulmonary TB.  The bacterium is a rod shaped bacillus 1.0-4.0µm in length and 
between 0.3-0.6µm in width. Technically considered a  Gram positive species due to 
the lack of an outer cell membrane, Mtb has a thick waxy cell wall composed of a 
great deal of mycolic acid, which makes the bacteria resistant to Gram staining; acid-
fast staining, such as Ziehl-Neelsen stain, is typically employed as a suitable 
alternative.  In addition to mycolic acid, the cell wall contains peptidoglycan, 
arabinogalactan, lipoarabinomannans and phosphatidylinositol mannosides.  The 
complex make-up of the Mtb cell wall assists the pathogen in resisting medicinal and 
noxious compounds, as well as protecting the bacteria in the potentially hostile 
environment of a host phagosome [37].    
The genome of the Mtb H37Rv laboratory strain  is composed of 4,411,529  
nucleotides (nt) in a circularized chromosome and contains an estimated 4,000 genes 
[38]; Mtb Erdman, another common lab strain, has a chromosome that is 4,392,353nt 
in size and codes for approximately 4,250 genes [39].  Both of these lab strains have 
guanine-cytosine (GC) content of 65.6%.  In terms of rate of replication, Mtb is 
relatively slow-growing with a doubling time of about 24 hrs in vitro [40].  The 
bacteria produces a roughly-textured cream-colored colony when plated onto solid 




The clinical isolate CDC1551 is another strain commonly used to study Mtb.  
The strain was isolated following a US-based TB outbreak in 1995, near the 
Tennessee-Kentucky border [41].   Reports have suggested CDC1551 is typically 
hypervirulent relative to Mtb strains H37Rv and Erdman in most laboratory uses [42]. 
 
2.1.2 M. bovis and M. bovis-BCG 
M. bovis is a member of the Mycobacterium TB complex (MTBC), along with 
Mtb and a handful of other virulent mycobacteria species (M. africanum, M. 
pinnipedii, M. microti, and M. caprae) that are capable of giving rise to pulmonary 
TB.  Mtb is the primary causative agent of TB in humans, and M. bovis can be 
considered the primary agent of TB in cattle, though the pathogen is cable of bovine 
to human zoonotic transfer.  Years before pasteurization of dairy products became 
common, M. bovis was responsible for a large number of cases of human TB, 
particularly in children [43].  Incidentally, it was the subculturing and attenuation of 
M. bovis by Albert Calmette and Camille Guérin that gave us the BCG vaccine which 
has been effective at preventing the disseminated form of Mtb infection in children.  
This attenuation has been primarily attributed to the loss of RD1 [44, 45], or “region 
of difference 1” which contains 9 specific genes: Rv3871, Rv3872 (PE35), Rv3873 
(PPE68), Rv3874 (esxB), Rv3875 (esxA), Rv3876, Rv3877, Rv3878 and Rv3879c.  A 
deletion of these corresponding genes from Mtb generates a virulence phenotype 
more similar to BCG than WT Mtb, establishing the loss of RD1 as important for the 




 BCG (and to a lesser extent M. bovis) is of interest to researchers for obvious 
reasons.  In addition to a great deal of genetic similarity, Mtb and M. bovis employ 
similar infection and survival strategies, life cycles and counter-immunity 
mechanisms.  Additionally, BCG is a Bio-Safety Level 2 (BSL2) pathogen, which 
means it is classified as “relatively safe” for research scientist usage, while Mtb is 
classified as a BSL3 pathogen.  Working with BCG significantly lowers the 
equipment and training costs associated with mycobacterial research.  Finally, one of 
the more provocative notions in Mtb vaccine research is the idea that a much more 
effective vaccine against Mtb may be created by retooling the BCG vaccine [46], 
something that may be much safer than attempting to create a new recombinant 
vaccine against TB by genetic manipulation and attenuation of an Mtb species [47, 
48].  A sort of hybrid-variation of this theme has been attempted with promising 
results.  A Danish group has recently shown in CB6F1 mice [49] and cynomolgus 
macaques [50] significantly reduced rates of clinical disease, increased survival and 
lowered latent TB reactivation when given both the standard BCG vaccine and a 
recombinant booster employing the Mtb antigens Ag85B and ESAT-6 (both Mtb 
secreted proteins) and Rv2660c (Mtb stress-induced protein).  
 
2.1.3 Other mycobacterial model species used in our studies 
The Mycobacteria genus consists of many species beyond the aforementioned 
Mtb and M. bovis species.  This group of organisms consists of a wide variety of 
pathogenic, opportunistic pathogenic and nonpathogenic organisms.  Many of these 




pathogenesis. For the Briken lab, our study of mycobacterial-mediated suppression of 
host apoptosis makes two particular model species tremendously valuable: M. 
smegmatis and M. kansasii.  
 M. smegmatis (Msmeg), first isolated in 1884 from ulcers of patients with 
syphilis, is one of the most widely employed model species used in the study of Mtb, 
for a variety of reasons.  Msmeg is considered to be a nonpathogenic species and can 
be employed in research laboratories with only BSL1 precautions.  This greatly 
reduces the initial cost of specialized facilities, employee health monitoring and 
safety equipment generally associated with Mtb research.  Additionally, Msmeg 
replicates relatively quickly, with a doubling time of about four hrs, versus the 
approximately 24 hour doubling time of Mtb [51].  Both of these factors make the 
organism a preferred model for many TB researchers.  There also exists specially 
developed laboratory strains such as Albert Einstein College of Medicine’s “mc
2
155” 
strain; this strain specifically chosen and propagated for its excellent transformation 
efficiency [52].  These properties make Msmeg an excellent Mtb model species, 
especially for use in early stage, high volume screening and any desired molecular 
cloning or expression work where rapid results are desired [53]. 
 The opportunistic pathogen M. kansasii (Mkan) is another useful organism for 
modeling Mtb.  It was initially isolated from human pulmonary secretions, and it is 
believed that impure tap water may act as a reservoir of transmission [54]. Mkan 
seems to lie somewhere between Msmeg (nonpathogenic) and M. bovis (obligate 
pathogen) on a scale of mycobacterial virulence in humans; it is typically an 




to Msmeg, has greater homology with the more virulent mycobacterial species such 
as Mtb.  While Mkan is relatively slow-growing (it replicates with a doubling time of 
about 20-24 hrs), it shares greater life cycle similarity with other pulmonary TB 
producing organisms (compared to the nonpathogenic Msmeg-mc
2
155, our fast-
growing Mtb model). The species is thus quite useful for studying many of the 
survival, persistence and virulence mechanisms of more highly-pathogenic species 
under more controlled, less hazardous research conditions.  Moreover, the increased 
genetic homology with Mtb (relative to Msmeg) often makes Mkan a “more 
stringent” model for screening and expression work, which has been quite important 
for the mycobacteria-mediated host anti-apoptotic phenotype of interest to the Briken 
lab [53]. 
2.2 Experimental systems: cell lines and model organisms 
 
As the primary residence of Mtb, the human alveolar macrophage would be the ideal 
cell type for exploring host-pathogen interactions.  However, the only way to obtain these 
particular macrophages is by branchoalveolar lavage, a process that is difficult, time-
consuming, relatively expensive and rather uncomfortable for a donor.  With that in mind, we 
must employ alternative models suitable for studying Mtb pathogenesis.   
2.2.1 THP-1 cell line  
THP-1 cells (an acute myelomonocytic leukemia cell line) [58] are routinely employed 
in mycobacterial infection studies.   They possess a relatively rapid replication time of about 24 
hrs and have C3b and Fc receptors, enabling enhanced phagocytosis of complemented bacteria, 




added stimulator such as phorbol
 
myristate acetate (PMA).  In terms of simulating in vivo 
infections with Mtb, PMA-activated THP-1s will effectively phagocytize complemented 
mycobacteria and subsequently apoptose in a manner similar to primary macrophages.  The 
consistency of the cell line in vitro apoptosis-induction response and the ability to quickly 
grow large quantities of the THP-1s make them ideal for screening and large-scale studies of 
mycobacteria-induction/suppression of host apoptosis interactions [53].  As a tumor cell line, 
THP-1s are wonderful a model for rapid, large scale experiments, but the correlation to real 
world in vivo conditions may cause some to question the validity of observed outcomes; 
therefore, it is necessary to establish observed phenotypes in primary macrophages as well. 
 
2.2.2 Primary human monocyte-derived macrophages (HMDMs) 
   In order to best recreate an in vitro approximation of alveolar macrophage infection by 
Mtb, TB researchers often culture macrophages from a pool of undifferentiated human 
monocytes.  Primary human monocyte-derived macrophages (HMDMs) are obtained by 
drawing blood from a donor, isolating the buffy coat (leukocytes) by ficoll centrifugation 
separation, plating undifferentiated monocytes and then driving these monocytes to CD14
+
 
macrophage maturation by culturing them with cytokines such as Granulocyte-Macrophage 
Colony Stimulating Factor (GM-CSF) or Macrophage Colony Stimulating Factor (M-CSF) for 
roughly a week [59].  These monocytes themselves are derived from CD34
+
 myeloid 
progenitor cells within the bone marrow; monocytes enter the blood stream and migrate to 
various tissues, where they can differentiate into a variety of specialized resident macrophage 
types.  Two of these polarized, macrophage subtypes are classified by the established 




“classically activated macrophage subtype” and M2 macrophages possessing an “alternatively 
activated” macrophage response to stimuli.  As a rule of thumb, M1 macrophages act as 
effectors of Th1-type immune response (IR); they are proficient manufacturers of 
inflammatory cytokines such as IL-6, TNFα and IL-1β, and quickly generate substantial 
quantities of  reactive oxygen species (ROS) and reactive nitrogen intermediates (RNI) [60].   
The M2 polarized macrophages are quite different.  M2 cells have a variable ability to generate 
an inflammatory response and typically produce low levels of IL-1β and caspase-1 and high 
levels of the IL-1 receptor agonist (IL-1Ra), all in stark contrast to M1 polarized macrophages 
[60, 61].   The M2 macrophage will typically play role a in Th2-type response and promote 
foreign body encapsulation and destruction [62].  In terms of culturing HMDMs, it has been 
previously reported that culturing monocytes in a media supplemented with human GM-CSF 
will produce a M1-like macrophage while monocytes cultured in the presence of human M-
CSF generate M2-like macrophages. 
 When culturing HMDMs to maturity, M-CSF and GM-CSF are both commonly, and 
separately, used to differentiate monocytes into macrophages.  Evidence established by 







) GM-CSF cultured HMDMs have greater 
similarity to alveolar macrophages than M-CSF derived HMDM.  M-CSF cultured HMDM 
may be more analogous to peritoneal macrophages with their “spindle-shape” morphology, and 




).   Furthermore, the group noted that 
alveolar macrophages and GM-CSF HMDMs are both strong scavengers of H2O2 by way of a 
pronounced basal level of catalase activity and induction, while M-CSF HMDMs have 




approximately 50-fold more sensitive to exogenous H2O2 than either GM-CSF HMDMs or 
alveolar macrophages.  At the same time, relatively large amounts of H2O2 are generated by the 
addition of heat-killed S. aureus to M-CSF HMDMs, while GM-CSF HMDMs do not exhibit 
this effect [59].    
Taken together, the data suggest that GM-CSF generated HMDMs may be more 
analogous to native alveolar macrophages than M-CSF generated HMDMs in terms of in vitro 
culturing and subsequent experimentation behaviors.  This line of thought is in agreement with 
accepted literature suggesting GM-CSF is essential for the generation of human alveolar 
macrophages [63, 64] and that M1-like macrophages (GM-CSF derived HMDMs) promote a 
Th1 type immunity activation when faced with a mycobacterial challenge, while similarly 
challenged M2-like macrophages (M-CSF derived HMDM’s) fail to efficiently promote and 
sustain a Th1-type immune response [65].  We would therefore assume GM-CSF to be the 
preferred HMDM differentiating cytokine for the in vitro modeling of Mtb/host interactions.  
However, a major point of contention arises where the specific needs of the Briken lab are 
concerned.  It has been established that M-CSF generated HMDMs require the continued 
presence of the cytokine in order to survive; the removal of M-CSF will allow for apoptosis of 
the macrophage.  In contrast, GM-CSF created HMDMs are much more resistant to apoptosis 
upon removal or depletion of the cytokine [66].  This poses a dilemma for research groups, 
such as the Briken lab, who are interested in the study of host/pathogen interactions and 
subsequent host-apoptosis outcomes.  The Briken lab tested various HMDM differentiation 
approaches in several pre-experimental optimization studies (B. Hurley, data not shown); it 
was ultimately decided that GM-CSF differentiation of monocytes is not a viable option for our 




monocytes into mature alveolar macrophages is likely a dynamic spectrum of competing and 
collaborating cytokine interactions; rapidly fluctuating cytokine doses with varying durations 
of exposure, ultimately dependent on the tissue microenvironment, only further complicates the 
in vitro modeling efforts of Mtb researchers. 
2.2.3 Murine model system  
The murine model is the most commonly employed animal model in Mtb studies.  
Within the various genetic backgrounds of the mouse model, C57Black/6 (B6 hereafter) may 
be the mouse most commonly used to model human disease [67, 68].  The B6 strain is inbred, 
so upon Mtb infection, every animal should theoretically produce an immunological response 
similar to its litter mates and any other B6 mice used in follow-up experiments.  The relative 
ease of breeding B6 mice and the availability of a wide range of transgenic mutants within this 
genetic background also contribute to their ubiquity as animal models [67].  In order to 
distinguish B6 from other strains, it is helpful to classify them by their response to a bacterial 
infection, as this is how the usefulness of a particular strain in Mtb infection studies will be 
gauged.   
Generally speaking, it is believed that B6 mice generate a Th1-type (“cell-mediated 
immunity”: macrophage, IFN-gamma, and TNF-beta associated) of response to Leishamania 
major, while a strain such as Balb/C generates a Th2-type  (“humoral-mediated immunity”: B-
cells, various interleukins) of response [69, 70].  The Balb/C strain itself is another commonly 
used strain.  Balb/C mice tend to be more docile in temperament than the aforementioned B6 
strain [67], but unlike in B6 mice few transgenic and substrain models exist. 
  One of the most important substrains of the Balb/C line is the severe combined 




substrains of Balb/C mice, generally homozygous for a “Prkdc
SCID
” mutation on chromosome 
16, which results in a lack of V(D)J recombination.  This particular mutation results in 
lymphoid organs 10%  of normal size and a lack of functional T and B cells, meaning the 
animal possesses an immature immune system with no true humoral response and a cell-
mediated immunity that is more-to-less compromised depending on the particular SCID 
substrain [67].  SCID mice are consequently excellent animal models for studying T cell 
subsets as well as exploring cell-mediated immunity in an environment of limited variables.  
SCID mice, therefore, provide an animal model system for studying the mycobacterial/host 
interaction in a controlled, relatively short-term manner.   
In this experimental scenario, SCID mouse infection-survival and morbidity 
progression outcomes can be taken as indication of virulence at the level of cell-mediated 
immunity- an extrapolation that is especially striking when the evidence is considered in 
tandem with corresponding in vitro work.  However, it has been suggested that the murine 
model may not be the best animal model for mycobacterial infection studies, due to the 
inability of the mouse to form a “true granuloma,” defined as the granuloma that occurs in 
humans and other primates [71].  While the mouse is relatively inexpensive, reproducible and 
wel-characterized [68], and mimics the sterilizing effect of the first-line anti-TB drugs rifampin 
and pyrazinamide in Mtb infection, the murine granuloma itself is formed of fairly loose 
cellular aggregates, making murine histology quite different from human granulomas [72].  
Some researchers have suggested this issue diminishes the value of the mouse as a TB model; 
these scientists suggest turning to other model species to more thoroughly explore the 





2.2.4 Hartley guinea pig model 
Other TB modeling species, which better approximate the Mtb-granuloma seen in 
humans, would be non-human primates [73, 74], rabbits [75, 76] and guinea pigs [77, 78].  Of 
these three species, the guinea pig is by far the most practical animal model for any “early 
stage” experimentation not currently seeking vaccine/treatment approval from the Food and 
Drug Administration.  The “Hartley” strain is currently the guinea pig breed most commonly 
used in laboratory work.   
In terms of value as an accurate model of Mtb infection, guinea pig experimentation is 
arguably superior to the murine model due to its formation of a “true granuloma,” which more 
accurately represents the granuloma histology seen in human infections.  Specifically, the 
guinea pig produces a caseous granuloma, which is histologically reminiscent of the human 
granuloma and distinct from the loose aggregates of cells seen in the murine “granuloma.”  
Also, the murine “granuloma” lacks tissue hypoxia; hypoxia is a hallmark of human 
granulomas and occurs within the granulomas of guinea pigs and rabbits [79].  The primary 
difference in the human and guinea pig granulomas seems to occur at the point of late-stage 
necrosis, in which granulomas in humans will liquefy and cavitate, ultimately resulting in 
lesions leading to increased aerosol transmission [72].   Studies involving the guinea pig as a 
viable animal model of TB have not been limited to survival studies and in vivo work; recently, 
David McMurray’s group has demonstrated the usefulness of guinea pig macrophages in in 
vitro studies [77].   
One of the most interesting studies has indicated differing roles for alveolar and 
peritoneal macrophage based on responses to in vitro infections with heat-killed mycobacteria 




peritoneal macrophages were collected.  The macrophages were infected with live or heat-
killed Mtb.  Alveolar macrophages demonstrated no change in H2O2 production, no significant 
increase in MHC class II expression and a “post-vaccine” Th1-type cytokine response (IL-12 
expression) that did not significantly rise above the basal levels of response seen in naïve 
animals; peritoneal macrophages tended to have much greater H2O2 production, significantly 
greater MHC class II expression and elevated IL-12 production compared to naïve animals 
(however, the overall levels of cytokine production were greater in the alveolar macrophages). 
The data seem to indicate that BCG vaccination of guinea pigs and/or treatment with 
recombinant guinea pig TNFα or IFNγ provided significantly greater enhancement of cytokine-
induced functions in peritoneal macrophages compared to alveolar macrophages.  The 
McMurray group proposes that alveolar macrophages are likely constitutively activated in situ 
due to regular contact with inhaled environmental substances [77], which would lead to 
diminished shifts in cytokine production when stimulated with mycobacteria under in vitro 
conditions.  They suggest that this may not be an in vitro experimental artifact, but rather that a 
diminished alveolar macrophage-generated cytokine response to exogenous antigens in situ, 
may be important for limiting inflammatory damage to lung tissue. 
2.3 Mtb survival strategies 
 
Believed to have evolved as a human specific pathogen, Mtb has developed many 
measures to counter the human immune system.  Notably, the inhibition of 
phagosome/lysosome fusion [80] and interference with the macrophage-generated toxicity of 
reactive nitrogen intermediates [81] have been two of best-characterized survival mechanisms 





2.3.1 Mtb phagolysosome fusion inhibition 
To take other examples of this virulence tactic, the cell wall lipid mannose-capped 
lipoarabinomannan (manLAM) and the Mtb PknG kinase are two mechanisms Mtb uses to 
inhibit phagolysosomal fusion. The manLAM component of Mtb has been extensively 
researched.  It seems to function by inhibiting host Vps34, a PI3-kinase, which prevents PI3P 
from accumulating; this disables recruitment of early endosome antigen 1 (EEA1), a tethering 
molecule that interacts with SNARE and is necessary for endosomal trafficking [80, 82].  
PknG, a eukaryotic-like serine/threonine protein kinase, is not a requisite for in vitro growth, 
but is necessary for survival within the host macrophage.  Mtb expressing a kinase-disabled 
form of PknG are quickly transferred to lysosomes and destroyed following phagocytosis [83].  
Also, PknG has been detected in the cytosol of host macrophages infected with live but not 
killed mycobacteria [83].  Moreover, a lysosomal associated membrane protein (LAMP) 
labeling study has indicated that M. smegmatis, which does not express PknG, seems to block 
phagolysosomal fusion when transformed with a pknG expressing; compared to WT M. 
smegmatis, the PknG
+
 bacteria shows lower levels of LAMP staining [83].   For both 
mechanisms, the halt of phagosomal maturation allows for protection of the bacteria and 
provides an opportunity for replication and further mycobacterial colonization.   
 
2.3.2 Mtb response to reactive nitrogen intermediates (RNI) and reactive 
oxygen intermediates (ROI) 
 
Another well-characterized antimicrobial mechanism of the macrophage is the 
production of RNIs and nitric oxide.  RNIs are believed to control Mtb infection, and 




peroxiredoxin-alkyl-hydroperoxide-reductase subunit C (AhpC) protein seems to play 
a role in protecting Mtb by catalytically catabolizing peroxynitrate anions, a powerful 
oxidant that forms as a reaction product of nitric oxide and superoxide anion [81].  In 
a later study, the same group found that AhpC, along with Lpd, SucB and AhpD, 
forms an antioxidant complex that possesses peroxynitrite reductase activity [85].  
Shortly thereafter, a large-scale transposon screen identified seven genes that aid Mtb 
in RNI resistance [86]. More recently, OsmC was shown to be important for 
protecting Mtb from oxidative stress by contributing significant peroxide reductase 
activity to the pathogen [87].   
Additionally, the Mtb protein Lsr2 is a dimer that protects the pathogen from 
ROI-mediated DNA damage; it does this by binding adenine-thymine rich portions of 
the Mtb chromosome and physically protecting the bacterial nucleic acids in that 
region from harm [88, 89].  As with mechanisms preventing phagolysosomal fusion, 
Mtb is protected and afforded a chance to replicate.  These two survival strategies are 
hardly the full extent of Mtb defensive maneuvering; one of the Mtb virulence 
mechanisms of greatest interest to the Briken lab is the suppression of host-
macrophage apoptosis.   
2.4 Mtb survival strategy: prevention of host-cell apoptosis 
 
In the give-and-take world of host-pathogen interaction, it stands to reason that hosts 
will have developed countermeasures to override Mtb’s attempts at concealment and to prevent 
the bacteria’s replication and ensuing colonization.  One manner in which the host macrophage 
accomplishes this is by the induction of apoptosis, a well-controlled form of cell suicide [90, 




well-regulated self-destruction stands in sharp contrast to necrosis, which is a relatively chaotic 
event that occurs when cells die as a result of an unregulated physical or chemical occurrence.  
Correspondingly, it is believed that Mtb possesses mechanisms adapted to counter this 
particular host defense mechanism, preventing the programmed cell death of its host and 
ensuring the survival of the pathogen.  
2.4.1 Apoptosis as a host defense mechanism against Mtb: innate 
immunity 
 
In terms of Mtb infection, apoptosis can be considered a significant component of the 
innate immune response (IR), in that macrophages undergoing the controlled cell-suicide 
process destroy the invading intracellular mycobacteria [90]; the unregulated event of infected 
macrophage necrosis does not result in obliteration of the bacteria [93, 95].  This seemingly 
altruistic role played by the apoptotic infected macrophage is a successful defense strategy that 
has been observed in other bacteria burdened cells [96]; Shigella flexneri, Yersinia spp. and 
Salmonella spp. have all been shown to induce macrophage apoptosis following infection. 
Numerous papers have indicated that infection of macrophages with mycobacteria often 
results in host cell death.  This host cell death can take the form of apoptosis (a host-mediated 
cell suicide that is bactericidal) or necrosis.  Necrosis can be a pathogen-mediated form of host 
death resulting in unregulated cell lysis that causes contents of the cell to spill out into the 
extracellular space, resulting in local tissue damage and a hyper-inflammatory response.  This 
further propagates the spread of the bacterial pathogen into newly recruited macrophages and 
neutrophils and assists the pathogen in avoiding immunosurveillance [97, 98].    
The degree of pulmonary virulence of a mycobacterial strain can be used as an indicator of 




more necrosis [99] it induces; less virulent mycobacteria will induce more apoptosis and less 
necrosis.  This has been demonstrated within Mtb; virulent H37Rv actively induces necrosis 
[100, 101] and suppresses apoptosis, while the avirulent H37Ra does not have this phenotype 
[95].  This rule of thumb extends to other mycobacterial species and attenuated strains as well; 
M. smegmatis [53], M. kansasii [53, 91] and BCG [91] have all been established as “high-
inducers” of host cell apoptosis.  The inability of these organisms to suppress apoptosis makes 
them useful model organisms for gain-of-function (GoF) screens that attempt to identify anti-
apoptotic virulence genes of Mtb [53]. 
2.4.2 Apoptosis as a host defense mechanism against Mtb: acquired 
immunity/cross-presentation  
 
As in innate immunity, the apoptosis of infected macrophages also plays a critical role in 
acquired immunity by way of cross-presentation of mycobacterial antigens.  A series of events 
occurs in the course of macrophage apoptosis: cytoplasmic shrinkage occurs, the chromosomes 
condense, chromatin degradation occurs and the cell membrane begins to form small blebs, 
ultimately resulting in the creation of apoptotic bodies.  These newly formed apoptotic bodies 
are then rapidly captured by proximal antigen presenting cells (APCs), such as dendritic cells 
(DCs), as a way of averting a situation in which these cellular contents might generate an 
inappropriate immune response [102].  If a mycobacterial bacillus was contained within the 
macrophage at the time of its apoptosis, then mycobacterial antigens would likely be contained 
within the apoptotic bodies.  These antigenic molecules, phagocytosed and processed by the 
proximal DC, can be presented by major histocompatibility complex (MHC) molecules on the 
surface of the DC [103].  If this DC is concurrently expressing the requisite costimulatory 




molecular patterns (PAMPs) derived from additional antigenic mycobacterial products also 
contained within the apoptotic bodies [104], then T cells specific to the presented 
mycobacterial antigen will achieve activation when coming into contact with said DC, and this 
cross-priming will ultimately lead to an advantageous and desirable adaptive immune response 
for the host [103].  The theory of macrophage apoptosis inducing cross-presentation and cross-
priming adaptive immunity was supported by a 2006 study under in vivo conditions.  In this 
study, CD8
+
 T cells were activated by inoculating mice with apoptotic vesicles obtained from 
macrophages infected with pro-apoptotic ΔsecA2 mycobacteria; the vesicle inoculated, cross-
primed mice were subsequently protected against later challenge by Mtb [105].  The benefits 
and safety of a similarly retooled, pro-apoptotic ΔsecA2-based recombinant vaccine were also 
seen in immunocompromised mice [106] and were found to be safe when tested in 
immunosuppressed SIV-infected infant macaques [47].   
2.4.3 Virulent mycobacteria species suppress host apoptosis 
A correlation can be drawn between the specific, qualitative degree of virulence associated 
with an infecting mycobacterial strain and the apoptotic rate of host macrophages.  More 
virulent strains of mycobacteria (the causative agents at work in pulmonary TB) such as M. 
tuberculosis H37Rv, M. tuberculosis Erdman, and M. bovis,  have previously been shown to 
induce significantly less apoptosis in host macrophages than the more avirulent strains M. 
tuberculosis H37Ra, M. bovis BCG, and M. kansasii [91].  While the colony forming units 
(CFU) of intracellular virulent strains increased, the CFU of intracellular avirulent strains 
decreased suggesting that the apoptosis of infected macrophages may help reduce the quantity 
of intracellular mycobacteria [91]. 




anti-apoptotic phenotype to the bacteria.  Genes such as nuoG [53], pknE [107], 
secA2 [106], Rv3165c (S. Gurses, unpublished), Rv3167c (S. Gurses, unpublished), 
sigH [108]and Rv3654c-55c [94] have all been shown to encode players operating in 
the Mtb-mediated inhibition of host apoptosis.  NuoG seems to operate as part of the 
Mtb type I NADH complex and may function by neutralizing host NOX2 activity 
[109].  PknE is involved in countering host induced nitric oxide stress [110],[107].  
SecA2 is an important secretion mechanism for Mtb and when it is functionally 
disrupted [111], the anti-apoptotic mechanism SodA cannot be exported thus the host 
is able to induce apoptosis [112].  SodA will convert host superoxide to H2O2 once it 
has been secreted by the pathogen.  H2O2 can then be cleared by Mtb KatG [113].  
Rv3165c and Rv3167c have been recently characterized by Briken lab member 
Serdar Gurses; a working model suggests the two proteins function together as a 
membrane integrated signal transduction receptor and a corresponding transcription 
factor that will act in a stress-response capacity.   SigH is an important stress response 
factor [108] and is essential for in vivo infection of primates [114].  Rv3654c and 
Rv3655c seem to be proteins that are secreted from Mtb into the cytoplasm of the 
host and suppress apoptosis by inhibition of the extrinsic pathway [94]; the same 
research group that reported an anti-apoptotic phenotype for these two proteins 
recently identified another secreted virulence factor, Rv3364c, that seems to operate 
by binding to host serine protease cathepsin G and preventing caspase-1 activation, 
thus preventing host programmed cell death [115].  Taken together, it seems that 
prevention of ROS or nitric oxide species is the central goal of these Mtb anti-




apoptosis or it may be one of many different approaches the pathogen employs and 
may simply be the most noticeable of the virulence apoptosis-modulating tactics in 
play.  As one might expect, some Mtb proteins, such as Rv0183 [116] , have been 
shown to actually induce greater levels of host apoptosis; this, of course, only serves 
to further highlight the tumultuous push-pull relationship between pathogen and host 
[117].   
2.4.4 Host-apoptosis: A potential means to an improved vaccine 
In light of BCG’s obvious shortcomings, it seems only reasonable to approach the TB 
“vaccination problem” by examining or retooling BCG in a manner that complements the 
pharmaceutical approach.  Current vaccine development projects should aim to effectively 
prevent Mtb colonization of pulmonary alveoli and generate long-term immunological 
memory; one of the best ways of doing this is by understanding, exploring, and exploiting the 
various mechanisms and survival strategies Mtb employs as it attempts to hijack macrophages 
and harbor itself within a host.  
The background literature previously discussed has highlighted the importance of host 
cell apoptosis as a protective response to mycobacterial infection.  Identification of the specific 
genes of Mtb responsible for “inhibition of host apoptosis” counter-measures would be quite 
beneficial; these genes could be studied, reconfigured, and employed in the production of novel 
vaccine strains which could induce high levels of host macrophage apoptosis.  Thus any 
recombinant vaccine strains created would be expected to generate a greater degree of host 
cellular immunity via apoptosis with subsequent increases in cross-presentation to CD8
+  
T 
cells; this will ultimately produce a vaccine superior to BCG by generating a more desirable 




identification and characterization of Mtb apoptosis-inhibiting genes and gene products will 
likely reveal many new targets for the generation of novel anti-mycobacterial pharmaceuticals. 
In January of 2012, a study was published in Clinical and Vaccine Immunology 
showing that a highly attenuated, pro-apoptotic Mtb strain (ΔsecA2-based) was a both safe and 
effective preventative measure against Mtb when tested in immunosuppressed infant 
macaques.  Such a vaccine should theoretically be safe for use in children and, critically, those 
individuals infected with HIV and most susceptible to infection by Mtb [47]. 
2.5 M. tuberculosis: transposases and Clp proteases 
 
Mtb transposases and Clp proteases factor heavily into this dissertation.  A brief summary 
of both follows. 
2.5.1 Transposases 
 Transposases (Enzyme Commission number 2.7.7.) are enzymes that catalyze the 
movement of transposons, regions of nucleic acids, from one place in to another; this cut-and-
paste mechanism often occurs within a genome, but will occasionally jump between genomes 
of the same species, or even into entirely new species [119].  The transposition typically 
involves three mechanisms: the transposase enzyme, the transposon and a target region of 
DNA to accept the insertion.  These three elements function by a “cut-and-paste” mechanism 
in which a transposases act as the enzymes catalyzing a reaction where DNA is double-nicked, 
the transposon element is excised with a hairpin formation,  the transposon “breaks free” of its 
point of origin and transposases carry the element to a new, suitable nucleic acid region where 
it is physically inserted.  The discovery and characterization of transposons and transposition is 




Physiology or Medicine for her work.  Transposases have been called the most prevalent genes 
found in nature [120].   
A computational analysis group published a 2010 study in which the authors had analyzed 
over 10.0 x 10
6
 protein encoding genes and gene-tags from a wide variety of sequenced 
eukaryotic, bacterial, viral and archaeal genomes.  The group found that genes encoding 
transposases were the most abundant and commonly occurring genes in their genome pool 
[120].  This was, of course, a study limited to currently annotated genes, and was therefore 
subject to the biases inherent in such an approach.  However, the authors’ central premise, that 
transposase genes are both ancient and ubiquitous, is certainly valid.   
Transposase genes can be found in all currently known forms of biological life; they can be 
considered the archetypal “selfish gene.”  It is believed that some transposases are maintained 
within their host genomes due to some survival advantage conferred upon the host, that their 
existence may be more “symbiotic” and less “parasitic” than the term “selfish gene” might 
imply.  The advantage transposases offer a host is probably derived from their mobile nature; 
as they promote nucleic acid rearrangement and, subsequently, genetic diversity.  It is believed 
transposases may do this by the induction of advantageous mutations, bringing novel genes 
into a genome or enhancing the fitness of a host.  Specifically, insertion of a transposon into a 
new region may disrupt an encoded gene, disrupt a native repressor or promoter or may 
increase distance between a regulatory element and the associated gene, which may 
significantly alter gene expression.  Additionally, many transposase and transposon elements 
are associated with a constitutive promoter [121] or possibly a promoter inducible by 
environmental stress [122].  Some transcription factors [123], certain centromere-binding 




[125] have been shown to have evolved from transposase genes.  For immunologists, the 
transposition-inducing proteins RAG1 and RAG2 are known to be essential for generating 
immunodiversity [126, 127]. 
In mycobacteria, there are at least 12 established insertion (IS) elements [128].  Very few 
publications specifically exploring and characterizing Mtb transposases currently exist.  The 
vast majority of literature details methods in which IS-elements may be used for clinical 
diagnostics or, more recently, large-scale phylogenetic analyses of the relationship between 
strains and species of mycobacteria.  The IS6110 elements appear to be exclusive to MTBC, 
and the detection of IS6110 has been used as a tool for clinical diagnosis of Mtb infection [129, 
130, 131]; however, recent detection of an IS6110-like element in M. smegmatis has suggested 
that horizontal transfer of genetic material between co-habiting mycobacterial species can and 
does occur [132].  Additionally, a recent publication has linked the important Mtb hypoxia 
response system, DosR/DevR, to proximal transposase genes in nine distinct blocks throughout 
the Mtb genome.  Perhaps important for our interests, a significant portion of the K20 genomic 
region of interest to this dissertation encodes transposase and phage-related elements.  Rv2666, 
a predicted truncated transposase gene for IS1081, is relatively proximal to several phage 
integrase-related genes, Rv2650c to Rv2659c, as well as transposase genes which precede these 
phiRV2 prophage genes. It has been suggested that this particular region of the Mtb 
chromosome was apparently a hot-spot for many mobile elements at some point in the 
evolution of Mtb [133].  This particular region may have been a switch site of GC-skew 
(sGCS) for Mtb at one time [134].  Little has been done to characterize this region, leaving 




2.5.2 M. tuberculosis Clp proteases 
The intracellular regulation and recycling of aberrant and misshapen protein by 
protease activity is absolutely essential for the survival of all organisms. Abrogation 
of clpP and clpX in E. coli has been observed to lead to an over 50-fold increase in 
frameshift mutations.  This phenotype can primarily be attributed to the role of ΔclpP 
(29 fold), with ΔclpX showing a slight (2 fold) increase and ΔclpA showed no 
discernible increase in frameshift mutations [135].  Protease importance is even more 
readily apparent in pathogens such as Mtb that spend a significant portion of their life 
cycle dealing with the ramifications of phagocytosis by alveolar macrophages and 
subsequent acidification of the intraphagosomal space. The activity of the Clp 
proteases of Mtb is an essential part of the organism’s arsenal for dealing with the 
relatively high-stress conditions of the intraphagosomal space. 
Recently, investigators employing transposon site hybridization (TraSH) 
screening of Mtb Tn-mutant libraries have shown that protease subunits 
ClpP1/Rv2561c  and ClpP2/Rv2460c, ATPase subunits ClpX/Rv2457c and 
ClpC1/Rv3596c, and clpB/Rv0384c are all essential for the in vitro growth of Mtb 
[136, 137, 138].  Additionally, studies examining  the Clp ATPase subunits clpX and 
clpC1, and the Clp proteolytic subunits clpP1and clpP2 have all provided additional 
levels of evidence supporting the essentiality of these genes [139, 140, 141, 142].  
Mtb caseinolytic (Clp) protease activity is thought to be composed of two basic 
elements, a proteolytic subunit (ClpP1 or ClpP2) responsible for substrate lysis and 
an ATPase subunit (ClpC1, ClpC2 or ClpX) which assists the lytic process by 




is thought to be comprised of two heptameric rings stacked on top of each other 
creating a chamber that carries out lysis with an active serine protease site.  An 
attached ATPase subunit unfolds the substrate for catalysis in the ClpP lytic barrel 
[143]. 
Recent publications have suggested that there may be many different roles for the 
various Clp family members.  Mycobacteria are somewhat unique in that they possess 
two Clp proteolytic subunits, while the majority of bacteria have only a single Clp 
proteolytic subunit. Also, most bacteria encode four classes of ATPase (Lon, FtsH, 
HslUV and Clp) while Mtb only encodes two, (FtsH and Clp) [144].  It has been 
noted that ClpP1 and ClpP2 are sufficient for the generation of a functional protease 
capable of peptide lysis; however, the addition of a Clp ATPase provides the complex 
with a boost of specificity and efficiency [141].  Alternative reports suggest that a 
complex of ClpC1P2 is the central player in the inactivation of RseA, the anti-sigma 
factor of the Mtb SigE stress response regulator [145].  Additionally, it was noted that 
ClpP1 and ClpX could not be substituted for ClpP2 or ClpC1, respectively [145].  
Furthermore, studies have shown that ClpP1 overexpression is toxic while 
corresponding overexpression of ClpP2 seems relatively innocuous from the 
standpoint of toxicity [142]; additionally, recent publications have suggested that 
ClpX expression alteration can lead to aberrant bacterial replication due to 
interactions with FtsZ [140].  All of these studies taken together suggest the various 
Clp family members are likely functioning in differing capacities in Mtb.  
Beyond their well-established role in general cell housekeeping, functional Clp 




enzymes, directing various regulators by elimination of repressors and/or possibly 
carrying out roles similar to helicases [146].   Moreover, Clp protease activity has 
been shown to be important for the virulence of Listeria monocytogenes [147], 
Streptococcus pneumonia [148, 149] and Salmonella typhimurium [150].  Also,  
ClpC1P2 assembly was shown to be important in the activating the Mtb SigE stress 
response [145] and several papers have established a Clp family stress response 
orchestrated as part of the ClgR regulon [151][152][108].  However, a Clp family 
homologue clpC2/Rv2667 was not shown to be part of the ClgR regulon).  
Rv2667/ClpC2/ClpX’ is a Clp protease family outlier in terms of ClgR regulation of 
the gene; evidence by other groups indicate clpC2 may be a “black sheep” in the 
important Mtb Clp protease family [151]; Mehra and Kushal specifically exclude 
clpC2 as a Clp-group outlier in their 2009 study of the Mtb stress response [153].  
However, one study found clpC2 expression to be upregulated following reaeration 
after a period of hypoxia [152], a condition one would expect a following new 
infection or shift from a latent to an active TB state.  
 It was recently shown that Mtb is susceptible to antibiotic treatment with cyclomarin, 
which functions by targeting and inactivating ClpC1function [154]; this compound may also 
interfere with the other Mtb ATPases ClpC2 and ClpX.  ClpP1 and ClpP2 have also been 
suggested as potential drug targets [142].  These studies make the Mtb Clp protease family an 





Chapter 3: Materials and Methods 
All animal studies were approved by the Institutional Care and Use Committee of The 
University of Maryland- College Park and were conducted in accordance with the 
IACUC guidelines and the National Institutes of Health Guide for the Care and Use 
of Laboratory Animals. 
3.1 Bacterial strain maintenance and media 
3.1.1 H37Rv work 
M. tuberculosis (Mtb) H37Rv (ATCC 25618) cultures were maintained in a 
BSL3 facility. All strains were grown in complete 7H9 media supplemented with 
10% ADC and 0.05% Tween-80 unless otherwise stated.  Strains were thawed from 
freezer stocks and maintained at 37 ºC in a shaking incubator at concentrations as 
near an OD600 = 0.600-0.800 as possible (but never higher) for a time of more than 1, 
but less than 3, week(s) to be considered viable for our experiments.  
ΔclpC2::complement (pMV261 episomal vector) was grown and maintained in 40 
µg/mL kanamycin in order to maintain the episomal pMV261 plasmid of interest. All 
H37Rv recombinant mutants involved were initially selected using appropriate 
antibiotic, and the antibiotic cassette integrity was maintained by inclusion of the 
selective antibiotic every second passage of the mutant. Prior to use in infection all 
cultures were washed in PBSTween, resuspended and centrifuged at a low-speed (80 x 
g) for 5 min to pellet any bacterial clumps.  Bacteria used in the subsequent infection 





3.1.2 CDC 1551 work- TnRv2666 and complement generation 
Cultures were maintained in a BSL3 facility under identical conditions to 
H37Rv cultures. Prior to use in infection all cultures were washed in PBSTween, 
resuspended and centrifuged at a low-speed (80 x g) for 5 min to pellet any bacterial 
clumps.  Bacteria used in the subsequent infection were taken from the resulting 
supernatant and MOI was calculated from this suspension.  
M. tuberculosis strain CDC1551 and mutants were obtained through the 
TARGET (Tuberculosis Animal Research and Gene Evaluation Taskforce) project 
[155, 156, 157], a transposon mutant library operated through a collaboration of 
Johns Hopkins University and Colorado State University.   TARGET scientists used 
Himar1 based transposon mutagenesis [158] to create a large pool of individual Mtb 
transposon mutants (Tn) in the CDC1551 strain background and made these Tn-
mutants available by request.  A Tn-mutant for Mtb gene Rv2666 (TARGET id: 
JHU2740A-322) and wild type (WT) CDC1551 were requested and obtained by the 
Briken lab.   
A complement for TnRv2666 was generated by cloning the gene in the 
streptomycin resistant integrating vector, pDB60.  A significant upstream region of 
the gene was also cloned to ideally include the native promoter; at this time, it is 
unknown whether this upstream region actually includes an Rv2666 promoter.  
Primers (see below) were designed with respective KpnI and EcoRI restriction 
enzyme sites orientation specific ligation into the pDB60 vector.  Plasmid was 
initially transformed into E. coli DH5α, and then plasmid was miniprepped and 




the purpose of genetic complementation. The method of transformation is described 
below in the “Electroporation of plasmids” section.  
Rv2666 complementation primers: 
5’ GCTTTTTTTTGGTACCGCCGGTGGGCGTGTCGTAGC 3’ 
5’ GCTTTTTTTTGAATTCATGGCGTTGATGAGCTCGTC 3’ 
3.1.3 M. kansasii and M. smegmatis studies 
M. kansasii (strain Hauduroy ATCC 12478) cultures were maintained in a 
BSL3 facility; M. smegmatis strain mc
2
-155[52] cultures were maintained in a BSL2 
facility.  All strains were grown in complete 7H9 media supplemented with 10% 
ADC and 0.05% Tween-80 unless otherwise stated.  Strains were thawed from freezer 
stocks and maintained at 37 ºC in a shaking incubator as near to OD600 = 0.600-0.800 
as possible for a time of more than one but less than 3 weeks to be considered viable 
for our experiments.  The method of plasmid transformation is seen below in the 
“Electroporation of plasmids” section. Plasmid transformed M. kansasii and M. 
smegmatis strain mc
2
-155 cultures were grown in 50 µg/mL of hygromycin or 40 
µg/mL kanamycin, as the case warranted. Prior to use in infection all cultures were 
washed in PBSTween, resuspended and centrifuged at a low-speed (80 x g) for 5 min to 
pellet any bacterial clumps.  Bacteria used in the subsequent infection were taken 







3.2 ΔclpC2 recombinant mutant construction and complementation 
 
The ΔclpC2 recombinant mutant was constructed within the H37Rv (common 
laboratory strain) background of Mtb; it carries a hygromycin resistance cassette in 
the place of a functionally coding copy of the clpC2/Rv2667/clpX’ gene seen in WT 
H37Rv. 
3.2.1 ΔclpC2 recombinant mutant construction 
 
 The ΔclpC2 recombinant mutant was generated by specialized phage 
transduction and subsequent homologous recombination (Figure 3) [159]. An allelic 
exchange substrate (AES) employed for clpC2 homologous recombination was 
created by PCR amplification of two regions flanking the gene including the first and 
last ~50 base pairs of the clpC2 (see primer list below).  The flanking regions were 
digested with Van91I (Fermentas) and ligated into p004S vector (a pjsc347 
background vector) containing a hygromycin resistance cassette and then sequence 
confirmed.  The AES was linearized with PacI (Fermentas) and ligated into 
mycobacterial phAE159 phage DNA.  The resulting phasmid product was packaged 
with MaxPlax phage packaging kit (Epicentre) and then E. coli HB101 was 
transformed with the phasmid.  Phasmid was screened for correctness and then 
electroporated into mc
2
155 M. smegmatis; mc
2
 155 was mixed with Noble agar, and 
plated on 7H10 and grown for 4 days at 30 ºC.  Plaque formation indicated phage 
generation.  Individual plaques were selected and high-titer phage was obtained by 
repeating the process with individual plaques at a 30 ºC lytic temperature, then 




MgSO4, 150 mM NaCl, 2 mM CaCl2) and gently shaking the plates at room 
temperature for 2 hrs.  Purification of the phage by 0.22 µm filtration followed.   
10mL of WT H37Rv was grown to mid-log phase and then washed once with 
37 ºC MP buffer. The culture was then pelleted at 2,000 x g and resuspended in 1 mL 
of 37 ºC MP buffer. The prepared Mtb was incubated with the high-titer phage (10 
phage : 1 bacterium) for 24 hrs at 37 ºC for transduction. The transduced bacteria 
were plated onto 37 ºC 7H10 agar plates containing 50 µg/mL of hygromycin for 
selection of recombinant mutants. Colonies of recombinant mutants were then 
selected for inoculation at 3-4 weeks post-plating. The ΔclpC2 mutant of H37Rv was 
confirmed by PCR of genomic DNA, RT-PCR of RNA and Southern blot (see 
respective “Methods” sections).   
ΔclpC2 knock-out (KO) generation primers: 
 5’ TTTTTTTCCATAAATTGGATGCCGGCCCGTATACCTTC 3’ 
5’ TTTTTTTTCCATTTCTTGGATGGCGTTGATGAGCTCGTC 3’ 
5’  TTTTTTTTCCATAGATTGGCCGGCTGAGGCGAGCGACCC 3’ 
5’  TTTTTTTTCCATCTTTTGGCGACAATTCGGCCGTCATGG 3’ 
ΔclpC2 KO confirmation primers: 
5’ GCTTCAGCAGCAGGAGATCG 3’ 







Figure 3. The AES and specialized phage transduction creation of ΔclpC2. 
Null mutant of clpC2/Rv2667 in Mtb was created by introducing a hygromycin 
antibiotic resistance cassette into the H37Rv genome by specialized phage 
transduction and homologous recombination. (As described in 3.2) 
(1) An allelic exchange substrate (AES) employed for clpC2 homologous 
recombination was created by PCR amplification of two regions flanking the gene 
including the first and last ~50 base pairs of the clpC2. (2) The flanking regions were 
digested with Van91I and ligated into a carrying vector with a hygromycin resistance 
cassette. (3) AES and phage DNA (4) were cut with PacI (5) and the digested DNA 
fragments were ligated together. (6)  The resulting product was then packaged with a 
phage packaging kit; a high-titer phage was obtained and purified by filtration. (7) 
WT H37Rv was grown to mid-log phase and incubated with the high-titer phage (10 
phage : 1 bacterium) for 24 hrs at 37 ºC for transduction. The transduced bacteria 
were plated onto 37 ºC 7H10 agar plates containing 50 µg/mL of hygromycin for 
selection of recombinant mutants. (8) Phage transduction progresses at 37 ºC for 24 
hrs. (9) A clpC2 abrogation mutant is created upon a homologous recombination 
event. (10) ΔclpC2 mutants are selected for (and unsuccessful transductions 






3.2.2 ΔclpC2 mutant complementation 
 
A ΔclpC2 complement was created by cloning clpC2 tagged with BamHI and 
EcoRI restriction sites into both a pMV261 episomal expression vector and pMV361 
attB integrating vector; both complementation vectors feature a kanamycin resistance 
gene and a groEL2 constitutive promoter [160].  The resultant plasmids were 
confirmed by sequencing and used to transform the ΔclpC2 mutant for 
complementation. (The transformation method employed is described in 
“Electroporation of plasmids” section 3.4 below.)  Successfully transformed bacteria 
were selected on plates of 7H10 media containing 40 µg/mL kanamycin.  
Complementation of ΔclpC2 was confirmed by PCR and RT-PCR. 
clpC2 complementation primers: 
5’ GCTTTTTTTTGGATCCGGTCGACACAATGCATAACG 3’ 
5’ GCTTTTTTTTGAATTCACCTTCGCATGATTGCACAC 3’ 
3.3 In vitro transposon mutagenesis for Loss-of-Gain-of-Function 
(LoGoF) screening 
 
*Generation of the K20 LoGoF mutant pool was carried out by Briken lab 
member Serdar Gurses.  In vitro transposon mutagenesis of the original K20 vector 
was undertaken with a commercially available kit (HyperMu™ Transposon Tools, 
Epicentre Biotechnologies/Illumina, Cat. No. HMI032K). Following the 
manufacturer’s suggested protocol, HyperMu transposon insertion elements were 
randomly inserted into 15 genes of the 19-gene region of the K20 locus. The 
transposon cassette included a kanamycin resistance maker; this marker was used for 




used to transform susceptible E. coli. The resultant transposon mutants were 
sequenced for single insertion into the genes of interest. A confirmed transposon 
mutant for each respective K20 gene of interest was selected and subsequently 






Figure 4. Creation of LoGoF K20 transposon mutants. 
Briken lab member Serdar Gurses employed in vitro transposon mutagenesis of the 
K20 GoF vector.  HyperMu <KAN-1> Transposase
TM
  Kit (Epicentre 
Biotechnologies/Illumina, Cat. No. HMI032K), a kanamycin-transposon 
selection/insertion cassette, and the K20 GoF vector were incubated together.  
Transposon insertion elements were randomly inserted into the 19-gene region of 
K20 and the altered K20 mutants were used to transform E. coli, which was then 
plated onto kanamycin selection plates.  Individual colonies were selected, and 
episomal DNA was extracted and sequenced with bidirectional primers to determine 
the point of insertion.  Only mutants with an single transposon insertion into a K20 
gene were selected from the pool and used in LoGoF screening. (Figure adapted from 





3.4 Electroporation of plasmids 
 
For each plasmid electroporation, a 10 mL culture of OD600 = ~0.8 of the 
desired mycobacterial strain was used.  The 10 mL culture was pelleted at 2000xg for 
10 min at room temperature (or at 4 ºC for all steps concerning mc
2
155 M. smegmatis 
work unless otherwise noted).  The pellet was then washed with 10 mL of a solution 
composed of 10% glycerol and 0.05% Tween80; this wash and pelleting was repeated 
3 times. The fourth pellet was resuspended in 1mL of the washing solution and 400 µl 
of these bacteria was added to a 2 mm electroporation cuvette to which 2 μl of the 
desired plasmid had been previously added. The washed bacteria were then 
electroporated at 2.5 kV/25 µFD/1000 Ω in a BioRad GenePulser Xcell 
electroporator. Immediately following the pulse, 1ml of complete 7H9 medium was 
added to the bacteria.  The bacteria were allowed to recover at 37 ºC for 4 hrs for 
mc
2
155 M. smegmatis or 16 hrs for Mtb and M. kansasii. The transformed bacteria 
were then plated onto 7H10 agar plates containing the appropriate concentration of 
antibiotic for selection (50 µg/mL hygromycin or 40 µg/mL kanamycin or 100 µg/mL 
streptomycin).  The plates were incubated at 37 ºC for 4 days for mc
2
155 or 3-4 
weeks for Mtb and M. kansasii; plates were inspected for number of colonies relative 








3.5 THP-1 cell culture maintenance and differentiation. 
 
Cyrovials of THP-1 human acute myelomonocytic leukemia cell line 
(ATCC™ TIB-202) were stored in liquid nitrogen.  Individual cyrovials of cells were 
thawed in a 37 
o
C water bath and then washed once with plain RPMI.  Cells were 
then pelleted at 400 x g and then resuspended in 20 ml of RPMI plus 10% heat 
inactivated FBS. The THP-1s were grown at 37 
o
C/5% CO2.  Great care was taken to 
ensure the cells were passaged before growing to a confluency beyond 0.8 x 10
6
 
cells/mL. In order to infect THP-1 cells, 0.6-1.0 x 10
6
 cells/mL were seeded into 





3.6 THP1 infection and cell death quantification 
 
PMA differentiated THP-1 cells were infected with a desired MOI of 
mycobacteria grown to mid-log phase.  The infections were carried out for 2 hrs in 
the case of M. smegmatis infections or 4 hrs in the case of M. kansasii or Mtb 
infections.   Infection media consisted of RPMI plus 10% AB human serum (Gemini). 
After the desired infection time, all extracellular bacteria were removed from the 
wells by 2 washes of sterile PBS and chase media consisting of THP-1 culturing 
media containing 100 µg/mL gentamicin was added to each well.  Infections were 
allowed to proceed to a desired endpoint at which time the cells were lifted with 37 
ºC PBS/ 5 mM EDTA.  THP-1 death was then quantified by propidium iodide 





3.7 Southern blot analysis  
 
The ΔclpC2 knockout was additionally confirmed by Southern blotting. The 
probe was created from the primers used to generate the initial “5’/upstream arm” 
fragment of the original p004S AES (see ΔclpC2 recombinant mutant creation section 
3.2).  The primer sequences employed are provided below. The K20 vector of the 
original GoF screen served as template for PCR amplification. The probe was labeled 
using a BrightStar Psoralen-Bioten Kit (Ambion).  Genomic DNA was extracted from 
the clones and uniformly digested with Van91I.  Additionally, the original K20 vector 
was digested with the same enzyme to serve as a probe-control.  All digested DNA 
fragments were separated by agarose gel electrophoresis, and then transferred onto a 
charged nylon membrane.  A denaturing step with 0.4 M NaOH followed.  The probe 
was denatured at 90 ºC for 12 min, then immediately hybridized to the membrane in a 
57 ºC water bath for approximately 16 hrs.  The labeled membrane was then well 
washed, and adherent probe was detected with a BrightStar BioDetect Nonisotopic 
Detection Kit (Ambion).  The membrane was exposed to photosensitive film for a 
period of no less than 15 min; the film was immediately developed. 
Probe primers: 
5’ TTTTTTTCCATAAATTGGATGCCGGCCCGTATACCTTC 3’ 
5’ TTTTTTTTCCATTTCTTGGATGGCGTTGATGAGCTCGTC 3’ 
 
3.8 Genomic DNA isolation- Mycobacteria 
 
Following methods previously set forth [160], a 10 mL culture of a desired 




bacteria were then pelleted by centrifugation in a Sorvall “Legend” centrifuge at 2000 
x g for 20 min.  Culture supernatant was discarded, and the pellet was resuspended in 
1mL of GTE (25 mM Tris-HCl (pH 8.0), 10 mM EDTA and 50 mM glucose) 
solution.  The bacterial suspension was then transferred to a 2 mL screw-cap 
centrifuge tube and centrifuged for 10 min at 2000 x g in an Eppendorf “5415D” table 
top centrifuge. The resulting supernatant was discarded, and the pellet was 
resuspended in 450 µL of GTE solution and 50 µL of a 10 mg/mL lysozyme solution, 
and then incubated at 37 ºC, 5% CO2 overnight.  Next, 100 µL of 10% SDS detergent 
was added and gently mixed; this was followed by the addition of 50 µL of 10 
mg/mL proteinase K (Fermentas) and a 55 ºC heat block incubation for 45 min.  After 
the incubation, 200 µL of 5 M NaCl was gently mixed in order to block the binding 
of DNA to cetrimide.  160 µL of CTAB (dH2O, NaCl, and 10% cetrimide) heated to 
65 ºC was added, mixed and incubated in a heat block at 65ºC for 10 min.  An equal 
volume of chloroform-isoamyl alcohol (24:1) was added; the mixture was gently 
shaken, and then spun at maximum speed in for 5 min.  Following centrifugation, 900 
µL of the aqueous layer was transferred to a fresh microcentrifuge tube. The 
chloroform-isoamyl extraction was repeated with 800 µL of the aqueous layer 
reclaimed and transferred to a fresh microcentrifuge tube.  A 70% volume of 
isopropanol was added and mixed until DNA precipitated.  A 5 minute incubation at 
room temperature was followed by a 10 minute centrifugation at maximum speed. 
The supernatant was removed and the DNA pellet was washed once with 70% ETOH.  




aspirated and the DNA pellet was allowed to air dry for 15 min, and then resuspended 
with 50 µL dH2O.   
 
3.9 Reverse transcription PCR (RT-PCR) 
  
Purified total RNA was generated from bacterial cultures of interest following 
a standard methodology (see “RNA isolation- Mycobacteria section 3.2.10).  
Complementary DNA (cDNA) was then generated from 500 ng of this RNA using a 
Phusion® RT-PCR Kit (Fisher) for reverse transcription (RT) following the 
manufacturer’s provided protocol. “Reverse Transcriptase” negative controls were 
consistently employed in all cDNA generation reactions to ensure the lack of genomic 
DNA contamination in the RNA preps.  Following RT-PCR, the resultant cDNA was 
employed in a traditional PCR to confirm the presence or absence of expression of the 
clpC2 gene; sigA primers were employed as an expression control (see below).  A 
C1000 Thermal Cycler (BioRad) was used for all PCR work. 
sigA primers: 
5’ CGTCAAGCACGCAAGGA 3’ 
5’ TCGCTAAGCTCGGTCAT 3’ 
clpC2 primers: 
 5’ GCTTCAGCAGCAGGAGATCG 3’ 





3.10 RNA isolation- Mycobacteria 
 
Mycobacteria cultures of interest were grown in complete 7H9 growth media 
to OD600= 0.8, or late log phase.  Cultures were pelleted by centrifugation for 10 min 
at 2,000 x g.  Bacteria were resuspended by pipetting in chilled TRIzol Reagent 
(Invitrogen); the suspension was added to a chilled 2 mL screw-cap tube containing 
RNase free zirconia beads.  Lysis was carried out by a Biospec Mini-Beadbeater 8 
operating at maximum speed for a period of 10 min.  A 5 minute incubation at room 
temperature followed to allow for complete dissociation of nucleoprotein complexes.  
A 20% volume of chloroform was added to each tube, which was then hand-shaken 
for 30 seconds.  A second room temperature incubation of 2-3 min followed.  The 
sample was then centrifuged at 12,000 x g for 15 min at 4 °C.  The aqueous phase 
was extracted, and the chloroform extraction and 4 °C centrifugation was repeated.  
The resultant aqueous phase was mixed with an equivalent volume of isopropanol, 
and incubated at room temperature for 10 min.  A 12,000 x g spin for 10 min at 4 °C 
followed.  The supernatant was removed, and the RNA pellet was resuspended with 
50 µl RNase-free water.  To ensure complete removal of DNA from the samples, 
DNase treatment of the samples was carried out by employing a TURBO DNA-free 
(Ambion) kit.  Additionally, “reverse transcriptase negative controls” were 
consistently employed in all subsequent cDNA generation work to confirm the lack of 






3.11 Growth curve measurement 
 
Cultures of WT H37Rv, ΔclpC2 and episomal-plasmid ΔclpC2 complement 
and integrating ΔclpC2 complement (previously described) were inoculated in 
triplicate into 7H9 and Sauton’s minimal media at OD600=0.01.  Duplicate optical 
density readings were taken at 600 nm every day for 12 consecutive days for all 
cultures. The pMV261 and based episomal ΔclpC2 complement was grown in 40 
µg/mL kanamycin containing media in order to retain the plasmid; all other cultures 
were grown without any antibiotic unless stated otherwise. 
 
3.12 SCID mice aerosol infections  
 
(This experiment was carried out by Serdar Gurses and B. Hurley.)  All mice were 
observed daily and sacrificed once in a moribund state.  Disease progression was 
evaluated by the standards of the University of Maryland Institutional Animal Care 












3.12.1 Aerosol infection of SCID mice 
 
SCID mice (BALB/c background) were obtained from Jackson Laboratories. 
8 SCID mice were infected per strain.  Mice were exposed to aerosolized Mtb while 
contained in a Glas-Col® Inhalation Exposure System (A4212).  A 5 mL volume of 
bacteria (5 x 10
6
 bacteria/mL) suspended in PBSTween was employed for each aerosol 
infection. The following 3-step program was used in all infections:  
1) 1,800 seconds of nebulizing time 
   2) 1,800 seconds of cloud decay time 
       3) 900 seconds of decontamination time 
Following infection, all mice were caged and the nebulizer was cleaned, 
sterilized and prepped for another round of infection with a separate strain of Mtb. 
 
3.12.2 Colony forming unit (CFU) determination 
 
3 mice per condition were sacrificed the following day. Mice were sacrificed 
by cervical dislocation after being anesthetized with isoflurane. Lungs were excised 
and coarsely homogenized with scissors. The lung tissue was then thoroughly 
homogenized in a Stomacher® 80 Biomaster. The resulting homogenate was filtered 
through a strainer into a 50 mL conical tube and centrifuged for 15 min at 2000 x g. 
The resulting bacterial pellet was resuspended in PBSTween, plated onto 7H10 agar 
plates and incubated at 37 ºC. The plates were examined for colonies at 3-4 weeks 





3.13 Human monocyte derived macrophages (HMDMs) 
 
Elutriated human monocytes were obtained through our collaborators Dr. 
Allen Sher and Dr. Bruno Andrade at National Institutes of Health in Bethesda, MD.   
 
3.13.1 Human monocyte derived macrophages: culturing 
 
Monocytes were washed with plain RPMI media and pelleted at 1500 rpm for 
5 min at 4 ºC in Sorvall Legend centrifuge.  An RBC lysis was carried out using 1x 
lysis buffer (eBioscience.); cell pellets were resuspended in 2 mL of the buffer and 
incubated at room temperature for 5 min.  ACK buffer was diluted with 8mL of plain, 
chilled RPMI and pelleted at 1200 rpm for 5 min at 4 ºC; the RPMI wash was 
repeated and cells were pelleted a final time at 1000 rpm for 5 min at 4 ºC. The 
monocytes were then seeded at a concentration of 0.75 x 10
5
 cells/mL into 24 well 
flat-bottom plates in plain RPMI warmed to 37 ºC. The monocytes were allowed to 
adhere in a 37ºC, 5% CO2 calibrated incubator. After 2 hrs, RPMI was removed from 
all wells and the adherent monocytes were gently washed once with warmed, plain 
RPMI.  Culturing media was comprised of RPMI, 10% off-the-clot AB human serum 
(Gemini) and 10 ng/mL Human M-CSF (Peprotech).  The monocytes were 
differentiated to macrophage maturity by culturing in this media for seven days, 
replacing media with fresh media every two days. Macrophage maturity was verified 






3.13.2 Human monocyte derived macrophages: infection 
 
HMDMs were washed twice with sterile PBS. A 0.5mL volume of infection 
media comprised of RPMI and 10% AB human serum (Gemini) was added to each 
well of HMDMs.  Infections were carried out with Mtb strains of interest for 4 hrs.  
Following infection, HMDMs were gently washed twice with sterile PBS. Then 1 or 
2 mL of chase media (1x culturing/differentiation media + 100 µg/mL gentamycin) 
was added to each experimental well, with the volume depending on the duration of 
the particular study (1 mL of chase media for studies  less than or equal to 5 days; 2 
mL of chase media for studies greater 5 days).  All empty wells and chamber spaces 
within the plate were filled with sterile PBS to mitigate evaporation from 
experimental wells; these reservoirs were topped-off with sterile PBS every 2 days 
post-infection. 
 
3.13.3 Human monocyte derived macrophages: hypodiploid staining cell 
death quantification 
 
At a desired experimental endpoint post-infection, culture supernatants were 
collected from the wells of infected HMDMs and uninfected controls.  All HMDMs 
were lifted from the wells following a 37 ºC, 5% CO2, 20 minute incubation with 
PBS/ 5 mM EDTA/10% trypsin solution. HMDM trypsinization reaction was stopped 
by adding the previously collected supernatant back in to the respective well of 
origin.  All viable HMDMs and any cellular fragments within the supernatant 
resulting from induced cell death were then collected by gentle pipetting and added to 




plate by light microscopy ensured removal of all adherent HMDMs. The HMDMs 
and cellular fragments were pelleted at 400 x g for 10 min, then resuspended in 
chilled 70% ETOH and stored at -20 ºC for a minimum of 24 hrs to ensure fixation of 
the samples.  Following complete fixation, cell death was quantified by washing each 
sample once in PBS, pelleting at 400 x g and then resuspending the pellet in a 
propidium iodide/RNAse solution (BD Pharmingen) for the purpose of hypodiploid 
labeling all apoptotic cells.  Each well-sample was analyzed by flow cytometry 
approximately 20 min following the addition of the hypodiploid labeling solution.  
Rates of apoptosis were assessed by histogram analysis. 
3.14 Alveolar guinea pig macrophages 
3.14.1 Obtaining and culturing of guinea pig macrophages 
 
Guinea pig macrophages were obtained through our collaborators Dr. Petros 
Karakousis and Mr. Michael Pinn of Johns Hopkins University in Baltimore, MD. 
Hartley guinea pigs were sacrificed by CO2 asphyxiation and tissue was appropriately 
processed as follows. 
3.14.2 Infections of guinea pig alveolar macrophages 
 Lungs were excised from the animal and gently lavaged with sterile, chilled 
PBS.  The cells obtained were pelleted by centrifugation at 400 x g for 10 min and 
then resuspended in plain, chilled RPMI. Cells were transported to UMD College 
Park on ice. RBC lysis was carried out with 1x RBC lysis buffer (eBioscience) for 5 
min at room temperature.  Cells were then washed twice with plain, chilled RPMI.  
The alveolar macrophages that remained were counted and seeded overnight at 37 ºC, 




Seeding media was comprised of RPMI, 5% heat-inactivated FBS, and 1% Pen-Strep 
antibiotic.  Following overnight adherence, wells were gently washed twice with 
sterile PBS and added infection media comprised of RPMI and 5% FBS.  
Macrophages were infected with Mtb strains of interest for 4 hrs at 37 ºC, 5% CO2.  
Following infection, all wells were washed twice with sterile PBS, and a chase media 
composed of RPMI, 5% heat-inactivated FBS and 100 µg/mL gentamycin was added 
to each well.  At a chosen experimental endpoint, cells were fixed by the addition of 
4% PFA and placed at 4 ºC overnight.  Apoptosis of macrophages was assessed by 
TUNEL staining (Roche Applied Sciences) and DAPI labeling (ProLong Anti-fade 
Gold with DAPI from Invitrogen). Subsequent analysis was carried out by 
florescence microscopy using a Zeiss Axiovision florescence capable microscope.   
3.14.3 Infections of guinea pig peritoneal macrophages 
 
 Lavage of the peritoneal cavity was carried out by gently flushing the 
peritoneal cavity with 40 mL of sterile, chilled PBS.  The cells obtained were pelleted 
by centrifugation at 400 x g for 10 min and then resuspended in plain, chilled RPMI. 
Cells were transported to UMD College Park on ice. RBC lysis was carried out with 
1x RBC lysis buffer (eBioscience) for 5 min at room temperature.  Cells were then 
washed twice with plain, chilled RPMI.  The alveolar macrophages that remained 
were counted and seeded overnight at 37 ºC, 5% CO2 onto 24-well tissue-culture 
treated plates at 500,000 macrophages per well.  Seeding media was comprised of 
RPMI, 5% heat-inactivated FBS and 1% Pen-Strep antibiotic.  Following overnight 
adherence, wells were gently washed twice with sterile PBS and added infection 




of interest for 4 hrs at 37ºC, 5% CO2.  Following infection, all wells were washed 
twice with sterile PBS, and a chase media comprised of RPMI, 5% heat-inactivated 
FBS and 100 µg/mL gentamycin was added to each well.  At a chosen experimental 
endpoint, cells were fixed by the addition of 4% PFA and placed at 4 ºC overnight.  
Apoptosis of macrophages was assessed by TUNEL staining (Roche Applied 
Sciences) and subsequent flow cytometry.  
3.15 Adenylate kinase (AK) release assay 
 
Host cell necrosis was quantified by an adenylate kinase (AK) release assay. 
Toxilight® BioAssay (Lonza, Cat # LT07-217) was employed following the 
manufacturer’s suggested protocol. Cell-free aliquots of the desired experimental 
supernatants were analyzed in a white, bioluminescence compatible, flat-bottom 96-
well plate (Optiplate-96™ from Perkin-Elmer) read by a BioTek® “Synergy” plate 
reader. Three 20 µL samples of supernatant from each experimental well were 
collected and individually measured, unless otherwise stated. 
Lysis controls were generated as follows.  A single uninfected well per 
experiment was treated with a detergent to completely lyse all cells present; 
supernatants from this well were then used in the AK assay as “lysis-positive 
controls” that approximate the maximum possible AK release per well.  This 







3.16 Colony forming units (CFUs) study 
 
To assess the in vivo viability of our bacterial strains, CFU studies were 
undertaken.  Infections of HMDMs were carried out for 4 hrs at MOI of 3 with Mtb 
strains WT H37Rv, ΔclpC2 and the complement previously described.   All wells 
were washed twice with sterile PBS, and 2 mL of culturing media (RPMI, 5% off-the 
clot AB human serum and 10 ng/mL M-CSF) was added.  Zero-hour samples, day 3 
samples and day 10 samples were collected for each strain by lysing all HMDMs with 
0.1% Triton® X-100 detergent and pipetting thoroughly. A dilution series was 
created for each replicate and then samples were plated onto 7H10 media.  Each 
sample plate was evaluated at 4 weeks post-plating and CFU values were assessed at 
that time. 
 
3.17 ELISA assays  
 
3.17.1 TNFα ELISA 
 
ELISA to detect TNFα was performed using the supernatants of HMDMs 
infected with strains of interest for 4 hrs at an MOI of 3, with a 20 hour chase 
following.  Culture supernatants were collected at 24 hrs post-infection. Clear, flat 
bottom ELISA plates (Costar) were coated overnight at 4 °C with human anti-TNFα 
capture antibody (BD Pharmingen Cat. 551220) at [5 µg/mL] in a binding solution of 
0.1 M Na2HPO4, pH adjusted to 6.0. All blocking steps were carried out at room 
temperature with PBS/0.05% Tween-20/10% FBS.  TNFα (BD Pharmingen Cat. 




ranging from 4,000 pg/mL to 15.6 pg/mL. A volume of 100 µL of supernatant was 
added into each ELISA well; there were 3 experimental wells per condition and 3 
triplicate measures for each of these (n=9 for each condition).  Binding was carried 
out at 4 °C overnight.  Detection antibody of biotin anti-human TNFα (BD 
Pharmingen Cat. 554511) suspended in blocking buffer was added at room 
temperature for 1 hour.  All wells were thoroughly washed, and streptavidin-alkaline 
phosphatase (Strep-AP) was added for 2 hrs.  Wells were soundly washed, and 1 
mg/mL of p-nitrophenyl phosphate (PNPP), well-suspended in 1.02 M 
diethanolamine (pH 9.8) substrate buffer, was added to each well.  The ELISA plate 
was then read 10-20 min following substrate addition, in a BioTek® “Synergy” plate 
reader. 
3.17.2 IL-1β ELISA 
 
ELISA to detect IL-1β was performed using the supernatants of HMDMs 
infected with strains of interest for 4 hrs at an MOI of 3, with a 20 hour chase 
following.  Culture supernatants were collected at 24 hrs post-infection. Clear, flat 
bottom ELISA plates (Costar) were coated overnight at 4 °C with human anti- IL-1β  
capture antibody (BD Biosciences Cat. 51-9002512) in a binding solution of 0.1 M 
Na2CO3, pH adjusted to 9.0. All blocking steps were carried out at room temperature 
with PBS/0.05% Tween-20/10% FBS.  IL-1β standard (BD Biosciences Kit Cat. 
557953) was diluted with infection media in concentrations ranging from 2,000 
pg/mL to 15.6 pg/mL. 100 µL of supernatant was added into each ELISA well; there 
were 3 experimental wells per condition and 3 triplicate measures for each of these 




antibody of biotin anti-human IL-1β (BD Biosciences Cat. 51-9002516) suspended in 
blocking buffer was added at room temperature for 1 hour.  All wells were thoroughly 
washed, and Strep-AP was added for 1 hour.  Wells were soundly washed, and PNPP, 
well-suspended in substrate buffer, was added to each well.  The ELISA plate was 




3.18 Apoptotic cell death quantification 
 
3.18.1 Terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) assays 
 
At a desired experimental endpoint post-infection, culture supernatants were 
collected from the wells of infected HMDMs and uninfected controls.  All HMDMs 
were lifted from the wells following a 37ºC,  20 minute treatment of PBS/5mM 
EDTA/10% trypsin solution. HMDM trypsinization was stopped by adding the 
previously collected supernatant back to the respective well of origin.  All viable 
HMDMs and any cellular fragments within the supernatant resulting from induced 
cell death were then collected by gentle pipetting and added to an individual 15mL 
conical tube for each well; post-lifting examination of the 24-well plate by light 
microscopy ensured removal of all adherent HMDMs. Host cell apoptosis was 
quantified by using “In Situ Cell Death Detection Kit: Fluorescein” (Roche Applied 
Sciences). TUNEL assays were carried out as described by the provided 




counterstaining cells with DAPI (ProLong Anti-fade Gold with DAPI from 
Invitrogen) and subsequent fluorescence microscopy and quantification of apoptotic 
percentages.   
3.18.2 Hypodiploid quantification 
 
At a desired experimental endpoint post-infection, culture supernatants were 
collected from the wells of infected HMDMs and uninfected controls.  All HMDMs 
were lifted from the wells following a 37 ºC, 20-minute treatment of PBS/5mM 
EDTA/10% trypsin solution. HMDM trypsinization was stopped by adding the 
previously collected supernatant back to the respective well of origin.  All viable 
HMDMs and any cellular fragments within the supernatant resulting from induced 
cell death were then collected by gentle pipetting and added to an individual 15 mL 
conical tube for each well. Post-lifting examination of the 24- well plate by light 
microscopy ensured removal of all adherent HMDMs. The HMDMs and cellular 
fragments were pelleted at 400 x g for 10 min, resuspended in chilled 70% ETOH and 
stored at -20 ºC for a minimum of 24 hrs for total fixation of the samples.  Following 
fixation, cell death was quantified by washing each sample once in PBS, pelleting at 
400 x g and resuspending the pellet in a propidium iodide/RNAse solution (BD 
Pharmingen) for the purpose of hypodiploid labeling of all apoptotic cells.  Each 
well-sample was analyzed by flow cytometry 20 min after the addition of the 
hypodiploid labeling solution.  Rates of apoptosis were assessed by histogram 





3.19 Statistical analysis 
 
Statistical analyses were performed on three independent experiments each 
with three experimental replicates unless otherwise noted within individual figure 
legends.  GraphPad Prism 5.0 software was used to create all data figures and was 
employed to analyze data by ANOVA with Tukey post-test. Error bars indicate 
standard deviation (±SD) unless otherwise noted. The range of p-values is indicated 





Chapter 4: Identification of anti-apoptotic gene(s) for a set 
genomic region of M. tuberculosis 
 
  
Previously, the Briken lab employed a large gain-of-function (GoF) genetic 
screen in an effort to identify genes within the M. tuberculosis genome that mediate 
apoptotic-suppression [53]. The screen used 312 randomized gene segments from the 
Mtb genome (average segment size was approximately 40kbp, total clone pool 
represented a 3x coverage of the total genome) and vector-expressed these regions 
within the less virulent, fast-growing (4 hrs doubling time), high apoptosis inducing 
relative species M. smegmatis (Msmeg).  The GoF vector-carrying Msmeg were used 
to infect a human cell line (THP-1) which was screened for a reduction in apoptosis 
compared to an empty-vector control post-infection. Three unique Mtb genomic 
segments were positively identified- J21, M24 and K20.  This dissertation specifically 
investigates genes of the K20 genomic region of Mtb.  Chapter 4 describes the 
experiments employed and results obtained in the attempt to identify a novel Mtb 
gene mediating the suppression of host apoptosis.   
 
4.1 Results: Identification of anti-apoptotic gene(s) for a set genomic 
region of Mtb 
 
 
4.1.1 The K20 genomic region of Mtb confers an anti-apoptotic phenotype 
to high-apoptosis inducing mycobacteria 
 
The K20 genomic region of Mtb (see Supplemental Table ST1) was 
previously shown to play a role in the inhibition of apoptosis by way of gain-of-




unpublished).  Briefly, Msmeg transformed with the K20 GoF vector (Msmeg-K20) 
induced noticeably less apoptosis (approximately half as much) when used to infect 
THP-1 cells than Msmeg carrying empty-vector (a pYUB415 expression construct) at 
16 hrs post-infection [53], as measured by TUNEL labeling (data not shown).  
Msmeg is a very potent inducer of host apoptosis; another species of mycobacteria 
which also induces high levels of host apoptosis was chosen to repeat the assay to 
confirm the K20 GoF results initially observed.   
The relatively slow-growing M. kansasii (~20 hrs doubling time) is an 
opportunistic pathogen which induces high levels of host apoptosis, albeit at a much 
slower rate than Msmeg.  M. kansasii generates a “cleaner phenotype” in terms of 
margins of host apoptosis induction between empty-vector controls and vectors 
expressing GoF genetic information, as well as variation within sample replicates 
[53].  The K20 GoF phenotype seen in Msmeg held true when the K20 vector was 
used in a second, more stringent round of GoF screening [53] in M. kansasii (Mkan) 
(Figure 5, K20 data previously unpublished) (data by K.K. Velmurugan).  Mkan 
transformed with the K20 GoF vector (Mkan-K20) induced less than 20% host 
apoptosis as measured by TUNEL staining, far less than the 86% host apoptosis 
induced by Mkan transformed with an empty-vector (CO) control.  
As these studies were conducted in PMA differentiated THP-1 cells, it was 
decided an appropriate animal model would be needed for future characterization of 
the phenotype.  To this end, Hartley guinea pigs were employed; the Hartley guinea 
pig line is outbred, meaning researchers may anticipate slight animal-to-animal 





Figure 5. The K20 genomic region of Mtb confers an anti-apoptotic phenotype 
when used to transform the high-apoptosis inducing M. kansasii. 
A GoF screen carried out in Mkan (with previously unpublished results for K20) [53]. 
(Figure is courtesy of K.K. Velmurugan.)  The J21, K20 and M24 GoF vectors and 
empty vector (CO) were transformed into Mkan, and used to infect THP-1 cells.  
Apoptosis induction by the bacteria was compared to uninfected (UT) and Mtb 
infected cells.  Apoptosis of host cells was quantified by TUNEL assay following 5 
days of infection.  Results are averages of three independent experiments and error 
bars represent 6 standard deviation (±SD). Statistical significance is relative to levels 






4.1.1.1 The K20 genomic region confers an anti-apoptotic phenotype 
guinea pig alveolar, but not peritoneal, macrophages 
 
Alveolar and peritoneal guinea pig macrophages were obtained with 
assistance from our collaborators at Johns Hopkins University.  Animals were 
sacrificed, and then the lungs and peritoneal cavity were lavaged.  Macrophages were 
purified and then infected with empty-vector Mkan or Mkan-K20, then lifted, fixed 
and assayed by TUNEL microscopy a day post-infection (Figure 6).  The K20 
phenotype was observed in alveolar macrophages; 8.5 ± 4.2% of K20 infected cells 
were apoptotic versus 43.1 ± 4.5% of empty vector infected cells.  While the GoF 
phenotype was conserved in Mkan-K20 infected alveolar macrophages, there was no 
difference in Mkan-K20 and empty-vector infections of macrophages obtained by 
peritoneal lavage (Figure 7).   
These observances held true for several animal experiments, with overall 
numbers varying, likely due to the differing genetic predispositions of the outbred 
guinea pigs, but the overall trend of the GoF phenotypes remained consistent.  The 
K20 GoF phenotype was conserved in alveolar macrophages, and it was ultimately 
decided that the Hartley guinea pig would be a suitable animal model for future 




                                                     
 
Figure 6.  Hartley guinea pig alveolar macrophages infected with M. kansasii-
K20 and M. kansasii-null vector. 
Alveolar macrophages were infected with Mkan-K20 and null-vector control at MOI 
of 3 for a 4 hour infection, followed by a 20 hour chase; uninfected controls (UI) 
were included in all experiments. Alveolar macrophages were seeded on 3 well slides 
and quantified by TUNEL staining and microscopy, 3 data points/sample; a minimum 
of 400 cells/well were counted and additionally validated by blinded counts.  
Representative data from one animal is presented. Statistical significance bar 
highlights relative differences between Mkan-K20 and empty-vector control induced-






Figure 7.  Hartley guinea pig peritoneal macrophages infected with M. 
kansasii-K20 and null-vector.  
Peritoneal macrophages were infected with Mkan-K20 and null vector control 
at MOI of 3, for a 4 hour infection followed by a 20 hour chase; uninfected 
controls (UI) were included in all experiments. Peritoneal macrophages were 
seeded in 24 well plates and quantified by TUNEL staining and flow 
cytometry, 3 replicates/sample.  Representative data from one animal is 





4.1.2 Loss-of-Gain-of-Function (LoGoF) screen identifies possible anti-
apoptotic genes of Mtb  
 
 Mtb has previously been shown to actively inhibit the apoptosis of host 
macrophages. This is quite likely a survival mechanism of the pathogen, enabling 
Mtb to avoid detection by the immune system and retain the shelter of a viable host 
cell.  Genes such as nuoG [53], pknE [107], secA2 [106, 111], Rv3165c (S. Gurses, 
unpublished), Rv3167c (S. Gurses, unpublished), and Rv3654c-55c [94] are all 
involved in the Mtb-mediated inhibition of host apoptosis.  As the Briken lab 
routinely explores this particular component of host-pathogen interaction, we looked 
into a potential role for a gene or genes of the K20 genomic region of Mtb in 
modulating host cell apoptosis.   
Having previously established and confirmed an anti-apoptotic role for the 
K20 genomic region of Mtb in Msmeg and Mkan ([53], data not shown) by way of a 
gain-of-function, forward genetics approach, our attention turned to identifying the 
specific gene(s) responsible for the observed GoF phenotype. Importantly, the GoF 
screen depended on a particular Mtb gene or set of genes carried on an episomal 
vector to confer an increased ability to suppress host apoptosis by the relatively high-
inducing Msmeg and Mkan species.   
In the original GoF screen that led to the identification of the K20 genomic 
region of Mtb, a positive GoF phenotype was indicated when the level of host 
apoptosis induced by Msmeg or Mkan was reduced by a particular Mtb gene region 
carried on an expression vector relative to apoptosis levels induced by a genetically-
null copy of the expression vector; the Mtb gene regions were all carried on a 




extra-chromosomal genetic information to the transformed species that does not 
naturally occur.  All genetic information on this expression vector must be translated 
and transcribed by the transformed bacteria, meaning Mtb-specific 
promoters/repressors/etc. carried on the GoF expression vectors may not be 
recognized by the Mkan and Msmeg; additionally, the gene-products must 
successfully integrate with the pre-existing machinery of a transformed bacterium in 
order to effect a GoF phenotype. 
In order to capitalize on this effect from another angle, Briken lab member 
Serdar Gurses employed in vitro transposon mutagenesis of K20 (Figure 4) in order 
to ablate the function of each individual gene carried on the vector and allow for 
identification of the specific gene(s) responsible for the anti-apoptotic phenotype.  To 
do this, HyperMu Transposase
TM
, a kanamycin-transposon insertion/selection 
cassette, and the K20 GoF vector were incubated together.  The transposon insertion 
elements were randomly inserted into the 19-gene region of K20, and the altered K20 
mutants were used to transform E. coli, which was then plated onto kanamycin-
containing plates for selection.  Individual colonies were selected, and episomal DNA 
was extracted and sequenced with bidirectional primers to determine the point of 
transposon insertion.  Individual transposon mutants with an insertion occurring in in 
a single K20 gene were selected from the pool; of this transposon mutant pool, 15 of 
the 19 total K20 genes were mutated with a single transposon insertion and 






Figure 8.  Schematic representation of the K20 LoGoF transposon mutant pool. 
Above is a schematic representation of the K20 genomic region with green, vertical 
dashes indicating the transposon insertion location for each of the individual 
transposon mutants generated.  Approximate size of each gene (indicated by hollow, 
open red arrows; lower scale provided in 500nt/tick mark) and gene orientation on (+) 
genomic strand are indicated; all size and orientation data are in silico predictions 
obtained through “TB Database” website, tbdb.org [161]. Note: Sequencing results 
for the original K20 vector (K.K. Velmurugan [53], data not shown) revealed that an 
additional distal gene, Rv2617c (the entire gene and severe truncations of two 
neighboring genes), is attached to the rest of the K20 region as an unexpected artifact 
of the Mtb genomic library creation process. The single transposon mutant generated 





4.1.2.1 LoGoF screen in mc
2
-155 background identifies two possible anti-
apoptotic genes of Mtb 
 
An individual K20 transposon mutant was selected for each of the 15 
interrupted genes (Supp. Table ST2).  Each transposon (each annotated as 
“sgRv26XX”) mutant was used in the transformation of mc
2
155, a high-competency 
lab strain of Msmeg.  To carry out the screen, PMA-differentiated THP-1 cells were 





155-K20 (carrying the original K20 GoF vector) and mc
2
155-null vector. 
As previously mentioned, the original GoF screen identified positives as those 
expression vectors carrying an Mtb gene cluster conferring an ability to suppress host 
apoptosis, masking the normally high-apoptosis-inducing phenotype of the given 
model species of mycobacteria.  The K20 transposon mutagenesis screening 
employed a “Loss-of-Gain-of-Function” (LoGoF) strategy, where positives are those 
individual transposon mutants that lose the ability to suppress host apoptosis relative 
to the original K20 GoF phenotype.   
At 16 hrs post-infection, the THP-1 wells were visually inspected by 
microscopy and assessed by experimentally-blinded observers for obvious, visible 
differences in degree of cell death (S. Gurses and V. Briken; data not shown).  
Following the visual scoring, the cells were lifted and stained with propidium iodide 
(PI) to quantify the level of induced cell death.   The LoGoF screen suggests a role in 
the anti-apoptotic phenotype when a particular transposon mutant induces greater 
levels of host cell death than the original, unaltered K20 GoF vector.  The LoGoF 
screen in mc
2




transposon mutants, sgRv2666 and sgRv2667/clpC2 (Figure 8), consistently induced 
apoptosis at levels above the K20 GoF background.   
However, as demonstrated in Figure 8, the degree of the shift, 26.9 ± 1.9% for 
sgRv2666 and 26.4 ± 2.2% for sgRv2667/clpC2 versus 20.9 ± 1.8% for K20, was 
statistically non-significant in the mc
2
155 model background.  However, the 
difference in cell death induction by K20 and the null-vector control (31.9 ± 2.5%) 
was a paltry 10%, putting the roughly 6-7% shift of the two LoGoF mutants into a 
broader context. 
 
4.1.2.2 LoGoF screen in M. kansasii identifies two possible anti-apoptotic 
genes of Mtb 
 
 As in the initial GoF screen that identified the K20 region as an anti-apoptotic 
region, the first round of LoGoF screening was carried out in the relatively rapidly 
growing mc
2
155 model species.  This initial screening was followed by a second 
round of screening in the much slower-growing Mkan (ATCC 12478) species with a 
limited, more refined pool of LoGoF mutants. As a modeling species of host 
apoptosis-induction, Mkan generates a “cleaner phenotype,” meaning it affords a 
much greater discrepancy between positive (K20) and negative (null-vector) controls. 
When this screen was repeated in the Mkan background with the selected LoGoF-
vectors of greatest interest, we once again saw the LoGoF mutants sgRv2666 and 





Figure 9. LoGoF mutants sgRv2666 and sgRv2667 are slightly higher inducers of 
host death than K20 in the mc
2
155 background. 





155-null vector, and the listed transposon mutants; all 
experiments included uninfected (UI) THP-1 control wells.  At 30 hrs post-infection, 
the THP-1 cells were lifted and cell death was quantified by staining with propidium 
iodide. A threshold was set (horizontal red dashed line) at the level of cell death 
induced by the original K20 GoF carrying mc
2
155. Data is pooled from three 
independent experiments; a minimum of 10 replicates per condition are shown. Error 





 Figure 10 presents the results of two such experiments in the Mkan 
background and includes the Mkan-carrying null-vector, the original K20 GoF vector, 
the two LoGoF mutants of primary interest and LoGoF mutants of the two genes 
upstream and downstream of the predicted Rv2666-Rv2667 operon (see Figure 11).   




LoGoF screen, variances in the degree of host-apoptosis induction were far more 
significant when using the Mkan model species.   
In Figure 10, pooled results gave a mean value of 70.6 ± 1.7% for Mkan-null-
vector induced death and 20.9 ± 3.9% for Mkan-K20-induced apoptosis.  LoGoF 
mutants of interest, sgRv2666 and sgRv2667/clpC2, induced 51.6 ± 7.7% and 59. 6 ± 
3.4% host apoptosis, respectively.  Both LoGoF mutants induced host death at 
statistically significant levels above Mkan-K20 (p ≤ 0.01 for Rv2666 and p ≤ 0.001 
for sgRv2667, both p-values relative to K20 induction levels) and generated non-
significant levels of apoptosis relative to empty-vector control.  The resulting trend of 
the Mkan-LoGoF screen was consistent over multiple experiments.  Host death was 
minimally induced by the experimental control LoGoF mutants (corresponding to 
genes bordering the predicted Rv2666-Rv2667 operon), sgRv2665 (17.5 ± 1.6% host 
apoptosis) and sgRv2668 (35.9 ± 8.1% host apoptosis).  The control LoGoF clones 
did not induce host cell apoptosis at levels significantly varied from the K20 parent 
vector.  These results suggest the specific importance of the Rv2666 and Rv2667 
genes to the K20 anti-apoptosis phenotype.  Overall, the repetition of the LoGoF 




anti-apoptotic genes of interest and confirmed LoGoF-screening results initially 
observed in the mc
2







Figure 10.  LoGoF mutants sgRv2666 and sgRv2667 induce more  host apoptosis 
than unaltered K20 in the Mkan background. 
THP-1 cells differentiated with PMA overnight were infected at MOI of 5 for 4 hrs 
with Mkan-K20, Mkan-null vector, and the listed transposon mutants; each 
experiment includes infected (UI) THP-1 control wells.  At least 48 hrs post-
infection, the THP-1 cells were lifted and apoptosis of THP-1 cells was quantified by 
TUNEL staining and subsequent analysis by flow cytometry. Data is pooled from two 
independent experiments at least 48 hour post-infection and is representative of 
numerous experiments; a minimum of 4 replicates per condition are shown. Error 
bars indicate ±SD.  **, p < 0.01 (Mkan-K20 vs. Mkan-sgRv2666); ***, p ≤ 0.001 






Figure 11.  Detailed transposon insertion map of the 4 LoGoF clones screened in 
Mkan.   
The above figure reveals individual insertion points for each of the four LoGoF 
transposon mutants employed in the Mkan screening. Each predicted gene is uniquely 
color coded in addition to the indicative subscript labels: Rv2665 (red), Rv2666 
(blue), Rv2667/clpC2 (green) and Rv2668 (yellow).  Vertical black dashes ( | ) 
indicate specific points of insertion for each of the transposon mutants.  Rv2665: 
H37Rv nt pos. 2,982,827+, (pos. 128/282 of the gene); Rv2666: H37Rv nt pos. 
2,983,632+, (pos. 561/803 of the gene); Rv2667: H37Rv nt pos. 2,984,057+, (pos. 
161/758 of the gene); Rv2668: H37Rv nt pos. 2,984,050+, (pos. 154/521 of the gene).  
Subscript annotations immediately preceding each dash provide the unique 
experimental working name (text in red) for the respective LoGoF mutant; a (>) 
symbol indicates a (+) strand oriented insertion while a (<) symbol indicates a (–) 




4.1.3 A transposon mutant of Rv2666 suggests anti-apoptotic role for the 
gene 
 
 Having previously employed a LoGoF screen in two separate modeling 
backgrounds and following the identification of the putative two gene Rv2666-
Rv2667 operon as carrying the gene(s) of interest, our attention turned to confirming 
our observation in Mtb. Employing deletion or gene abrogation mutants of Mtb in a 
loss-of-function (LoF) approach is a direct way of examining any potential anti-
apoptotic phenotype.  As in all avenues of production, it is inevitably more efficient 
to employ tools already available than to reinvent the wheel.  To that end, we 
searched lists of available transposon mutants provided by the TARGET 
(Tuberculosis Animal Research and Gene Evaluation Taskforce) research project; the 
TARGET mutant collection is essentially a very large pool of randomly generated 
Himar1 transposon (Tn) mutants created in the CDC1551 Mtb strain background 
[158].  The collection has been assembled, and is currently maintained, as a 
collaborative research effort between Johns Hopkins University [155], Colorado State 
University [156] and other interested institutions.   A handful of transposon mutants 
generated in the K20 genomic region was available by request through the TARGET 
repository.  One of the transposon mutants available within the library of mutants is 
the 804 nt, hypothetical transpose gene Rv2666 (BEI catalog number NR-14775; 
position of transposon insertion is at 322 nt from the putative start site).   There was 
no transposon mutant available in the TARGET library for the other gene of primary 
interest, Rv2667/clpC2.  The TnRv2666 mutant was employed in a LoF, reverse 
genetics study to determine the role of Rv2666 in modulating host apoptosis. 




macrophages (HMDMs) at an MOI of 5.  Infections proceeded for 4 hrs and were 
followed by a chase period of 4 days.  HMDM apoptosis was then quantified by 
hypodiploid labeling and flow cytometry.  Results from two separate experiments are 






Figure 12. The Himar1 transposon mutant of Rv2666 induces increased host cell 
apoptosis compared to WT Mtb. 
HMDMs were infected with WT CDC1551 and TnRv2666 at MOI of 5 for 4 hrs 
followed by a 4 day chase; all experiments include uninfected HMDM wells as a 
control.  HMDMs were collected and hypodiploid labeling was used to assess levels 
of host apoptosis.  Quantification of hypodiploid positives was made by flow 
cytometry.  Data shown are the results of two independent experiments employing 
HMDMs derived from two unique donors; a minimum of 7 measurements per 
condition were made in total. Statistical significance bar indicates apoptosis 
differences between WT Mtb and the TnRv2666 mutant. Error bars indicate ±SD.  





While WT Mtb and the TnRv2666 mutant both induced levels of host 
apoptosis greater than the uninfected control (6.3 ± 0.8% of all cells underwent 
spontaneous apoptosis), the level of host apoptosis in HMDM infected with 
TnRv2666 induced more than twice as much host-death as WT Mtb- 33.0 ± 2.8% and 
15.7 ± 1.7% induced macrophage apoptosis, respectively.  The trend of these results 
was consistent across several experiments in HMDMs, and the phenotype was also 
seen in the THP-1 cell line as compared to many other transposon mutants in the 
CDC1551 background (B. Hurley and S. Shah, data not shown).  Ultimately, the LoF 
approach employed to study the potential anti-apoptotic role of Rv2666 validated 
results previously observed in mc
2
155 and Mkan LoGoF screens.  All of this 
evidence, taken together, strongly implicates that the hypothetical transpose-like 
element Rv2666 is involved, by a yet-undetermined manner, in suppressing host-
apoptosis as part of an Mtb-mediated survival strategy.   
 
4.1.4 Complementation of TnRv2666 confirms anti-apoptotic role and 
identifies Rv2666 as contributing to the K20 phenotype 
 
Having previously established a potential role for Rv2666 as a K20, anti-
apoptotic gene of interest, our attention turned to confirming this phenotype by 
genetic complementation of the Himar1 transposon mutant of Rv2666.  This was 
done by transforming the kanamycin-resistant TnRv2666 with a non-constitutive, 
integrating expression pDB60
streptomycin
 plasmid.  This expression plasmid carries the 
Mtb sequence for Rv2666, including the 90 nt region upstream of the gene to attempt 
inclusion of the native promoter sequence.  The pDB60
streptomycin




designed for silent integration into the attB site within the targeted genome; it also 
confers a high degree of streptomycin resistance to the transformed bacteria for 
selection purposes.  
In order to validate the anti-apoptotic phenotype of Rv2666, the LoF assay 
previously described was repeated with the inclusion of the complemented TnRv2666 
(Figure 13).   As before, HMDMs were infected with bacterial strains of interest at 
MOI 5 for 4 hrs and the infection was followed by a 4-day chase.  Analysis and 
quantification of host apoptosis was once again established by hypodiploid labeling 
of collected HMDMs and flow cytometry.  As in the initial LoF study, TnRv2666 
induced significantly more host apoptosis (p ≤ 0.001) than the WT, 28.1 ± 0.2% and 
13.0 ± 0.9%, respectively.  The complement-induced 11.8 ± 1.1% host apoptosis, 
significantly less than the transposon mutant (p ≤ 0.001); these values have no 
statistical difference from WT CDC1551.  These results establish Rv2666 as a player 
in the anti-apoptotic phenotype mediated by Mtb.   
Additionally, the successful complementation of TnRv2666 negated the 
question of a LoGoF-screen phenotype that was the possible result of polar effects in 
the sgRv2667 LoGoF mutant.  Polar effects of this nature would have resulted from 
transposon insertion into Rv2666, and would have meant that the sgRv2666 LoGoF 
phenotype was actually a red herring and that Rv2667 was the true gene of interest in 








Figure 13.  Complementation of TnRv2666 confirms anti-apoptotic role and 
identifies Rv2666 as contributing to K20 phenotype. 
HMDMs were infected with WT CDC1551, TnRv2666, and TnRv2666::complement 
at MOI of 5 for 4 hrs followed by a 4-day chase; uninfected (UI) HMDM wells were 
included as controls in all experiments.  HMDMs were collected and hypodiploid 
labeling was used to assess levels of host apoptosis.  Quantification of hypodiploid 
positives was made by flow cytometry.  Data shown are the results of HMDMs of a 
single donor with a minimum of 3 values per group. Significance bar indicates 
differences between WT Mtb and TnRv2666; this level of significance applies to 
TnRv2666 vs. the complement as well. Error bars indicate ±SD.  ***, p ≤ 0.001. 






Figure 13 shows complementation of TnRv2666 and returns host death to WT 
levels.  Similar results were also observed when corresponding experiments were 
carried out in the THP-1cell line (S. Shah, Figure S1a).   Quantification of host cell 
death by TUNEL staining, as opposed to hypodiploid staining, and the additional host 
background, THP-1 cell line as opposed to HMDMs, offers added levels of support to 
our findings.  Additionally, adenylate kinase (AK) release assays were employed to 
establish that TnRv2666- induced cell death was definitively host-mediated apoptosis, 
rather than death by uncontrolled necrosis, that would result in substantial loss of 
cellular membrane integrity and ensuing AK release.  Host necrosis has previously 
been shown to be induced by Mtb in later stages of infection as a probable 
mechanism of escape and dissemination [162, 163].  This Mtb-mediated necrosis 
significantly increases AK release due to the great degree of host cell lysis.  A 
dramatic upsurge in host necrosis was not observed in THP-1 infected with TnRv2666 
(Supp. Figure S1b), discounting the chance that the observed phenotype involves 
necrotic host death.   
Ultimately, the successful complementation of the TnRv2666 phenotype, that 
is, the restored ability of the mutant to suppress host apoptosis, confirms the initial 
findings of the LoGoF and LoF assays.  With at least one “K20 anti-apoptosis” gene 
identified and confirmed, our attention turned to the study of Rv2667/clpC2, the other 






4.1.5 Creation and confirmation of clpC2 abrogation mutant 
 
 Prior results from a LoGoF screen in two separate mycobacterial species 
(Figures 9, 10) implicated both Rv2666 and Rv2667/clpC2 (hereafter denoted clpC2) 
as potentially involved in the K20 anti-apoptosis phenotype.  Our work to 
characterize the Rv2666 gene in Mtb, previously discussed as the in-operon gene 
immediately preceding clpC2, was tremendously expedited as a transposon mutant of 
the gene was available through the TARGET research collaboration [155].  As the 
TARGET library has no corresponding transposon mutants available for clpC2, it was 
necessary to produce a specifically targeted gene abrogation mutant.  This was 
accomplished by employing a system of specialized phage transduction to “knock 
out” Mtb clpC2 by way of homologous recombination [159].  This approach was 
employed in order to vastly increase the relative rate of homologous recombination 
and generate a strain of Mtb that did not express the clpC2 gene product.  The 
specialized phage transduction method is frequently used in Mtb genetics work 
because the rate of obtained recombinant mutants obtained by more traditional 
electroporation/transformation methods is typically too low to be considered practical 
[160]. 
 Sequences flanking the clpC2 gene were amplified using primers that would 
eliminate the vast majority of the clpC2 coding sequence upon homologous 
recombination, but would leave the first and last few nucleotides of clpC2 intact in 
order to ideally prevent alteration of the expression of the genes immediately 
upstream and downstream of the target.  The flanking sequences were cut with the 




cloning vector, which carries dual multiple-cloning-sites flanking a hygromycin-
resistance cassette. Briefly, following the generation of this p004S
hygromycin
 plasmid 
designed for homologous recombination with clpC2, the sequence confirmed plasmid 
was linearized by PacI restriction enzyme digestion; the vector was then ligated into 
phage DNA (for the creation of phasmid DNA); phasmid DNA was packaged into 
viable phage; high titers of this phage were produced; and, ultimately, purified phage 
was transduced into the WT H37Rv laboratory strain of Mtb (Figure 3), creating 
recombinant ΔclpC2 mutant Mtb.  The resultant ΔclpC2 mutants were confirmed as 
true clpC2 ablation constructs by PCR analysis of genomic DNA (Figure 14), 
Southern blotting of genomic DNA (Supp. Figure S2), and RT-PCR analysis (Figure 
15).  In addition to the clpC2 mutant, a complementation plasmid was also generated 
using the kanamycin-resistant, constitutively expressing, episomal mycobacterial 
vector pMV261 (Figures 14,15). As seen in these figures, the ΔclpC2 mutant is 
verified as a true clpC2 gene abrogation mutant and the complement produces a 
clpC2 gene product.  These tools enabled a thorough loss-of-function and 






Figure 14.  PCR confirms abrogation and complementation of clpC2. 
 0.8% agarose gel featuring PCR employing genomic DNA (and plasmid DNA in the 
case of the complement) and primer sets amplifying gene regions for sigA (control), 
clpC2 and encoding a hygromycin resistance cassette.  Genomic DNA was obtained 
from bacterial cultures grown under standard in vitro growth conditions.  Cultures 
were grown in complete 7H9 media to OD600= 0.800.  Samples were acquired from 
WT Mtb H37Rv, ΔclpC2 and ΔclpC2 pMV261-based complement; the original K20 
GoF control was also included for clpC2 primer control.  Primers amplified small 





Figure 15.  RT-PCR of purified bacterial RNA from WT Mtb, ΔclpC2, and 
ΔclpC2-complement confirms clpC2 gene expression level.   
0.4% agarose gel featuring RT-PCR generated cDNA synthesized from purified 
RNA.  RNA was obtained from bacterial cultures grown under standard in vitro 
growth conditions.  Cultures were grown in complete 7H9 media to OD600= 0.800.  
RNA samples were acquired from WT Mtb, ΔclpC2 and a ΔclpC2 pMV261-based 
complement (expressing clpC2 with GroEL2 heat-shock promoter).  cDNA was 
generated from RNA extracted from each culture of interest; RNA samples were free 
of genomic DNA contamination as determined by the inclusion of a RT control (far 
right lanes). Primers amplifying small approximately 200nt regions targeted for SigA 






4.1.6 ΔRv2667/clpC2 is dispensable for a salient role in modulating host 
anti-apoptosis effects by Mtb  
 
 Following validation of ΔclpC2, the mutant and the WT H37Rv were 
employed in infections of HMDMs at MOI of 3.  Infections were carried out for 4 hrs 
and were followed by a chase period of 4 days.  HMDMs were then collected.  In 
order to quantify levels of host apoptosis, hypodiploid labeling and flow cytometry 
were carried out (Figure 16). 
 Unexpectedly, the results of ΔclpC2 LoF experiments consistently showed a 
lack of any significant differences in induced host apoptosis levels between WT 
H37Rv (12.7 ± 2.3% induced apoptosis) and the ΔclpC2 mutant (9.8 ± 1.9% induced 
apoptosis) in HMDMs.  These results held true for HMDMs derived from several 
unique monocyte donors and cannot be dismissed as a donor dependent occurrence.   
Additionally, there were no significant differences in host apoptosis when WT 
(9.5 ± 3.0%) and ΔclpC2 (4.2  ±  2.3%) Mtb strains were used in the infection of 
alveolar guinea pig macrophages (Figure 17).  Taken together, the results of these 
LoF experiments suggest that ClpC2 has no obvious role in modulating host apoptosis 
effects by Mtb.  Ultimately, this may indicate that, of the hypothetical Rv2666-
Rv2667/clpC2 operon, the Rv2666 gene alone is responsible for the “K20 phenotype” 







Figure 16.  Infection of HMDMs with WT Mtb and ΔclpC2 indicates no 
significant differences in host apoptosis induction.   
No significant differences in apoptosis were observed in HMDMs infected with WT 
and ΔclpC2 Mtb.  HMDMs were infected at MOI 3 for 4 hrs followed by a 4 day 
chase; uninfected (UI) controls were included in all experiments.  Host apoptosis 
levels were quantified by hypodiploid staining and flow cytometry.  Results shown 
are the mean from two independent experiments employing unique donors; (n=10).  
Error bars represent ± SD.  Significance bar compares WT Mtb and ΔclpC2. 






Figure 17.  Infection of alveolar guinea pig macrophages with WT Mtb and 
ΔclpC2 indicates no significant differences in host apoptosis.   
No significant differences in apoptosis were observed in alveolar macrophages of 
outbred Hartley guinea pigs infected with WT and ΔclpC2 Mtb.  Alveolar 
macrophages were infected 4 hrs at MOI of 3 followed by a 4 day chase; uninfected 
(UI) controls were included in all experiments.  Infections and chase were carried out 
in triplicate wells on chamber slides for each condition. TUNEL staining and DAPI 
labeling were employed to quantify percentages of apoptotic host cells against the 
total number of macrophages present.  Values were established by fluorescence 
microscopy imaging and counting DAPI-TUNEL co-labeled cells against DAPI-only 
cells; the values were then additionally verified by blinded counting of the same 
images (former Briken lab member Duc Nguyen).  A minimum of 400 cells/well were 
counted. Results shown are the average of two experiments using alveolar 
macrophages of two unique animals. Error bars represent ± SD. Significance bar 
compares WT Mtb and ΔclpC2.  Statistical analysis employed ANOVA with Tukey 
post-test. 
  































4.2 Discussion: Identification of anti-apoptotic gene(s) for genomic 
region of Mtb 
 
 The apoptosis of a macrophage carrying a bacterial burden is a common form 
of immune defense employed against a wide variety of pathogens, notably M. 
tuberculosis. Previous work by Dr. K.K. Velmurugan initially established that the 
K20 genomic region of Mtb as conferring an anti-apoptotic gain-of-function (GoF) 
phenotype when a vector carrying the region was used to transform M. smegmatis 
mc
2
155.  The subsequent screen used 312 randomized gene segments from the Mtb 
genome (the average segment size was approximately 40,000 nt; the total size of the 
clone pool was estimated to be roughly “3X coverage,” or (40,000 x 312)/ total Mtb 
genome nt) and vector-expressed these regions within the aforementioned 
nonpathogenic, fast-growing, high-apoptosis-inducing relative species M. smegmatis 
mc
2
155 (Msmeg).  The vector-carrying Msmeg were used to infect a human cell line 
(THP-1).  THP-1 cells were infected with individual Msmeg clones, each transformed 
with a unique genomic region-carrying vector from the GoF library.  The THP-1 cells 
were screened for a reduction in apoptosis relative to the levels of cell death induced 
by an Msmeg clone transformed with an empty-vector control, and those clones with 
the strongest anti-apoptotic phenotype were chosen for further rounds of screening at 
higher stringency.  The chosen GoF clones were individually transformed into the 
slow-growing, high-apoptosis-inducing opportunistic pathogen M. kansasii Hauduroy 
(Mkan) to confirm their apoptosis-suppressing phenotype.  The screen was repeated 
in the Mkan background; the K20 region, along with two other unique genomic 
regions [53], was confirmed as carrying a gene or genes that conferred a host-




It is quite possible that the 3x coverage of the Mtb the GoF library did not 
allow for complete screening of the Mtb genome.  The 3x genome coverage is an 
estimate based on the number of nucleotides generated for the entire GoF library.  It 
is important to note that this determination is distinct from the manner in which “x-
values” are assigned in the process of whole genome shotgun sequencing (that is 
based on the total number of sequence reads).  However, if assessed in the “WGS x-
coverage manner,” the 3x value means that there will be a predicted ~5% gap in the 
number of nucleotides that are needed, in theory, to cover the entirety of the Mtb 
genome (the entire GoF library contains roughly 12,480,000 nt while the Mtb genome 
is 4,411,532 nt, roughly 3x the raw nt value of the genome).  Also, it is possible that 
the GoF clones are not “contiguous regions” or that they cannot be assembled into an 
approximation of the Mtb genome due to redundancy of some genomic regions and 
the absence of others within the library.  Ultimately, the initial GoF screen may very 
well have missed several anti-apoptotic genes of Mtb because of these issues.  
Furthermore, even if all anti-apoptotic genes of Mtb were included in the GoF library, 
it may be possible that the Mkan and Msmeg species lack the genetic background to 
successfully implement the gene-products of interest to an anti-apoptotic end.  
Finally, Mtb may encode anti-apoptotic genes that have a function dependent upon 
the presence of a distal gene or genes and their respective products; the nature of the 
GoF screen limits each vector to an average of 40,000 nt, meaning anti-apoptotic 
effects dependent on distal genes would have been rendered moot and any of the 





4.2.1 The K20 genomic region of Mtb displays an anti-apoptotic phenotype 
in several host models. 
 
 The K20 region of Mtb (H37Rv nucleotide region 2,978,367 to 2,990,637, + 
strand) is 12,271 nt in length, plus an additional distal genomic region (2,945,437 to 
2,946,738, + strand) that is 1,302 nt in length.  There are a total of 19 complete, 
predicted Mtb genes [164] included in the K20 vector (Supp. Table ST1).     
 The initial GoF studies that identified K20 were carried out in the THP-1, 
monocytic cell that was driven to activation with PMA.  As immortalized cell line 
experimentation results may not always align with primary cell testing outcomes, we 
repeated the K20 GoF assays in additional host models for further validation of the 
genetic region’s suspected anti-apoptotic phenotype.  We were able to confirm our 
positive GoF findings obtained from the THP-1 host model K20 screen in both 
primary human monocyte-derived macrophages (HMDMs) and alveolar guinea pig 
macrophages (Figure 6).   
These results alleviated our concerns that the observed anti-apoptotic 
phenotype conferred by the K20 gene region was potentially an artifact of cell-line 
experimentation that was not indicative of in vivo host-pathogen interactions.  
Confirming immortalized cell-line phenotypes in primary cell lines is quite important, 
especially considering our particular GoF phenotype of interest (host cell suicide) 
could be adversely affected by the mechanisms causing cell-lines to indefinitely 
propagate. 
Also, in the course of our preliminary experimentation and optimization of 
potential model systems, we attempted several infections of the murine alveolar 




laboratory by immortalizing Balb/cJ alveolar macrophages with simian virus 40 
(SV40) [165]; MH-S are commonly employed to model alveolar macrophages under 
in vitro conditions [177, 178].  Although this cell-line seems like a promising model 
given that alveolar macrophages are the native habitat of Mtb, our experiments 
determined MH-S were far too resistant to pathogen-induced apoptosis to operate as a 
feasible model for our work (Figure 18). The SV40 immortalization that created the 
MH-S line likely interferes with pathways important for host apoptosis following 
infection with mycobacteria.   
With further regards to infeasible model systems, our studies also revealed 
that resident peritoneal macrophages of Hartley guinea pigs were not a practical 
model for studying host-pathogen apoptosis events (Figure 7), although peritoneal 
macrophages were far more plentiful than alveolar macrophages from the very same 
animal.  It may be that these peritoneal macrophages, generally sheltered from 
antigenic insult due to their location in the peritoneal cavity, are extremely sensitive 
to encounters with foreign particulates and respond far more robustly than alveolar 
macrophages, which are continuously exposed to foreign particulates due to their in 
situ locale in the alveoli of the lung.  The David McMurray research group published 
a 2008 report that supports our interpretation [77].  The McMurray paper suggests 
that alveolar macrophages, being constitutively activated by environmental artifacts, 
will exhibit an innately diminished inflammatory cytokine response to minimize 
damage to surrounding lung tissue.  This may explain why Hartley alveolar 








Figure 18.  Murine alveolar macrophage cell line (MH-S) is not a viable option 
for the study of Mtb-mediated suppression of host apoptosis.   
MH-S cells were infected with WT Mtb or ΔnuoG Mtb (a positive control for apoptosis 
induction) at an MOI of 5 for 4 hrs; uninfected (UI) control wells were included in all 
experiments.  A chase of 2, 4 or 7 days followed.  Cells were analyzed for percentage of 
apoptosis induction by hypodiploid labeling and flow cytometry.  Individual values were 
obtained for each well and are graphed with the mean value indicated by a horizontal bar.  





4.2.2 Loss-of-Gain-of-Function (LoGoF) screening approach to identify 
possible K20 GoF phenotype genes of Mtb 
 
 The loss-of-gain-of-function (LoGoF) genetic screen to identify anti-apoptotic 
genes of Mtb (see sections Materials and Methods-3.3 and Results-4.1.2) is a 
relatively novel approach; this screening technique was used for efficiency, and was 
employed due to the extensive growing time required for Mtb knockout generation 
and confirmation [160].  Understandably, the LoGoF screening approach is by no 
means the only secondary screening approach that could have been used to identity 
genes of interest in the K20 Mtb genomic region and corresponding GoF vector.  
However, former Briken lab member Dr. Serdar Gurses had previously generated and 
sequenced a sizable pool of LoGoF mutant clones (Figures 4 and 8; Supp. Table 
ST2), and it was assumed that employing these pre-assembled constructs to identify 
specific K20 genes of interest would have greater cost efficiency (from both time-
invested and financial perspectives) than other secondary screening approaches.  
Additionally, we felt that the LoGoF screen would better identify individual genes 
critical to the K20 GoF phenotype.  We believed LoGoF screening was ultimately a 
more efficient approach than alternative methods (such as a repetition of the K20 GoF 
screen with smaller, genetic subunits of the K20 region) in terms of our ultimate goal 
of specific-anti-apoptotic gene identification.  Alternative GoF approaches may result 
in the same problems inherent to the initial GoF screen that identified the K20 region; 
namely, screening individual K20 genes in a second, “subunits of K20” GoF 
approach may have provided erroneous results as more than one of the K20 genes 
may have been responsible and/or required for the anti-apoptotic phenotype.  LoGoF 




resultant from transposon mutation, detects those individual K20 genes critical for the 
anti-apoptotic phenotype of interest. 
 
4.2.2.1 Loss-of-Gain-of-Function (LoGoF) screen in mc
2
-155 background 
identifies possible K20 GoF phenotype genes of Mtb 
 
The initial LoGoF screening was carried out in the Msmeg mc
2
-155 
background (Figure 9).  The results were reproducible in four different large-scale 
screening rounds using the Msmeg model species and ultimately two LoGoF clones, 
sgRv2666 and sgRv2667, were the highest inducers of host cell death.  However, 
there was very little variation of differences between the highest and lowest inducers 
of cell death.  This is clearly demonstrated in total difference of THP-1 death induced 
by the K20 positive control and the null-vector control, which amounts to a roughly 
10% decrement (Figure 9).  One of  the primary reasons for these unimpressive 
differences may be the enormous intensity with which Msmeg induces apoptosis in 
host macrophages [168].   
The Msmeg-THP-1 host-pathogen modeling system is a severely limited 
model, as the conditions to which Msmeg is subjected in an experiment such as this 
are far outside the normal life cycle of the nonpathogenic Msmeg; the bacteria’s 
native environment is topsoil [51], a habitat far-removed from the caustic 
phagosomes of alveolar macrophages.  The relative contribution of GoF vectors to 
Msmeg’s suppression of host-apoptosis is likely insubstantial due to masking of the 
GoF phenotype by the bacteria’s innate tendency to generate extreme host-apoptotic 




to trypan blue exclusion) is a rapid readout for “cell death,” it may not be the most 
accurate indicator of true apoptosis, and the statistical differences in any GoF or 
LoGoF phenotype may be masked by necrotic death as well. Though Msmeg LoGoF 
screening results were reproducible, the lack of strong statistical correlations and 
distinctions compelled us to repeat our LoGoF study in a second species, M. kansasii. 
 
4.2.2.2 LoGoF screen in M. kansasii identifies two possible anti-apoptotic 
genes of Mtb 
 
 The second round of LoGoF screening was carried out in the Mkan model 
species in order to validate the findings of the Msmeg study and to take advantage of 
the species’ “cleaner phenotype” in terms of host apoptosis-induction.  While anti-
apoptotic GoF/LoGoF screening in the Msmeg background resulted in slight 
differences in host death induction between the highest and lowest inducers, 
screening for this phenotype in the Mkan background provided much cleaner 
resolution and a clearer picture of what K20 genes are, and are not, contributing to the 
suppression of host cell death.  In terms of experimental efficiency, the robust 
statistical significance of results gained by studying the K20 anti-apoptotic phenotype 
in the Mkan background greatly compensated for the enormous speed but weaker 
statistical correlation of findings generated by our work employing Msmeg as a 
model. 
 The four LoGoF clones used for screening in Mkan (Figure 11), sgRv2665, 
sgRv2666, sgRv2667 and sgRv2668, were chosen based on the initial findings of four 




sgRv2666 and sgRv2667 (encoding transposon mutants of Rv2666 and 
Rv2667/clpC2/clpX’) were consistently the strongest inducers of host cell death in all 
Msmeg LoGoF repetitions (sgRv2665 and sgRv2668 were included in the Mkan 
screen as border-gene controls for the gene-pair of interest), suggesting these genes 
were possibly responsible for conferring the K20 anti-apoptotic phenotype.   
We found clear differences in the LoGoF-clone host-apoptosis induction with 
our Mkan experiments.  TUNEL staining and flow cytometry indicated a statistically 
significant 30% or more increase (p ≤ 0.01) in host-apoptosis in both of our LoGoF 
clones of interest, sgRv2666 and sgRv2667, compared to the levels of host death 
induced by the original K20 GoF vector (Figure 10).  At this point, we felt that the 
functional ablation of at least one of these genes (or possibly both genes if polar 
effects created by transposon disruption were not a factor) from K20 GoF vector 
eliminated the ability of the GoF vector to confer a protective anti-apoptotic response 
to typically high apoptosis-inducing species of mycobacteria.  Furthermore, the 
control LoGoF clones, sgRv2665 and sgRv2668 did not induce significantly more 
host apoptosis than the K20 parent vector (Figure 10), further suggesting the validity 
of our results implicating Rv2666 and/or Rv2667.  The sum of these findings (looking 
at data generated by modeling in both Mkan and Msmeg) suggests that the LoGoF 
screening method is valid as an approach for the study and identification of anti-
apoptotic genes of mycobacteria. 
At the time of these findings, major Mtb annotation and investigative 
databases using in silico analysis and statistical correlations to study mycobacterial 




gene operon and was co-regulated as such [175,  180].  This raised the question of 
whether the LoGoF phenotypes observed were due to one or both of these genes.  It is 
possible that if these two genes truly lay in a co-regulated operon, then the insertion 
of a transposon into one of the genes may have resulted in polar effects, negatively 
affecting the expression of the partner gene.  Though both the sgRv2666 and 
sgRv2667 LoGoF clones had a transposon interruption in a point that could 
significantly affect the functionality of the gene product (Figure 11, insertions at 
nucleotides 561 of 803 nt and 161 of 758 nt, respectively), it was fair to assume polar 
effects may be occurring due to the nature of transposon insertion and mutations [181, 
182].  It was therefore necessary to employ a separate approach in order to 
conclusively establish which of these genes is ultimately responsible for the anti-
apoptotic effects of the K20 genomic region. 
 
4.2.3  Rv2666 is an Mtb gene contributing to the K20 anti-apoptotic GoF 
phenotype 
 
In an effort to identify the specific gene(s) responsible for the K20 phenotype, 
we moved forward with the characterization of possible anti-apoptotic roles for 
Rv2666 and Rv2667/ClpC2 separately.  Simultaneously, it was important to validate 
our findings within Mtb itself.  Our attention turned first to Rv2666 (H37Rv 
nucleotide region 2,983,071-2,983,874, + strand), a hypothetical truncated 
transposase-like gene [161] of Mtb and the “upstream” gene of the hypothetical 
Rv2666-67 operon.  (It is important to note that at the time of initial experimentation 




hypothetical two gene operon [164]; however, more recent analyses, employing 
alternative analytical tools, have lowered the confidence of those initial predictions 
[171] and cast doubt on the validity of  assigning of these genes to a shared operon.) 
No literature of note has been published explicitly examining Rv2666 at this 
time; very little literature has been published with regards to the transposases of Mtb 
beyond their use in clinical detection of the pathogen or phylogenetic 
analysis/genotyping of the Mtb complex [130, 131, 184, 185].  No currently 
circulated report has discussed Mtb transposases as contributing a possible role in 
virulence to the pathogen, and data linking bacterial transposases or insertion 
elements to anti-apoptotic phenotypes have not been published as of this writing.   
 
 
4.2.3.1  The Rv2666 gene of Mtb and the TnRv2666 transposon mutant: 
overview 
 
 It is accepted that it requires a substantial amount of time to generate a gene-
deletion within Mtb [159, 160].  Compared to fast-growing mycobacteria like Msmeg 
[159, 160], it can take approximately 2 to 3 months to create and confirm a Mtb 
knock-out.  As previously described, we obtained TnRv2666, a Himar1 based 
transposon mutant of Rv2666 in the CDC1551 genetic background of Mtb [158].  
Transposon mutants from the TARGET project have been employed in genetic 
screens and characterization studies by other Mtb research groups [185, 187, 188] to 
an experimentally satisfactory end, generating consistent and reproducible results for 




The TARGET project provided TnRv2666 mutant has an insertion point that 
begins at nucleotide position 322 of 804 nt total (Supp. Figure S3); this disruption 
should, at the very minimum, prevent the final 60% of the gene product from being 
transcribed and translated into functional product.  Incidentally, this final 60% of the 
Rv2666 encodes a region possessing MULE (Mutator-like element) transposase-like 
homology [177]; MULE homology may indicate possible metal chelation and DNA-
binding properties for the gene product [178].  The entirety of Rv2666 seems to 
encode a truncated IS1081 transposase insertion; IS1081 is a 1,324 nt length insertion 
element that  is exclusive to the Mtb complex (Mtb, M. bovis, M. africanum and M. 
microti, but not M. bovis BCG) and has been used to distinguish Mtb and M. bovis 
BCG in various clinical isolates from HIV patients in years past [184, 185].  The 
IS1081 class element is also extremely stable relative to IS986, another major class of 
transposase insertion element found in Mtb.  In fact, the 267-amino acid sequence of 
Rv2666 is completely conserved across all sequenced strains of Mtb, including both 
laboratory and clinical isolates [161]; five of these strains contain a synonymous SNP 
mutation for a single nucleotide position (H37Rv genome nucleotide position 
2,983,873 + strand, an adenine to guanine substitution), and no other Mtb SNPs are 
presently known to exist for this gene [179]. 
Furthermore, Rv2666 expression has been shown to be greatly upregulated 
following infection of macrophages [179].  This evidence, taken with the absolutely 
conserved peptide sequence of Rv2666 across all sequenced strains of Mtb, leads us 




role is directly or indirectly implemented by the pathogen remains to be seen, offering 
a potentially interesting avenue of research for future investigations. 
 
4.2.3.2  Loss-of-function (LoF) study confirms anti-apoptotic role for the 
Rv2666 gene 
 
Using the TnRv2666 TARGET-mutant previously described, a loss-of-
function (LoF) study was undertaken.  The study used a low MOI infection of 
HMDMs with the TnRv2666 mutant and a WT Mtb control; results from this 
experiment indicated that the presence of Rv2666 may be important for the 
suppression of host-apoptosis.  These TnRv2666 results corroborated the previous 
LoGoF data generated in the Msmeg and Mkan backgrounds.   
Infecting M-CSF differentiated human macrophages with the TnRv2666 
mutant resulted in more than twice the level of induced host-apoptosis generated by 
infection with the corresponding WT strain (Figure 12).  The trend of these findings 
was similar across several experiments that employed HMDMs cultured from unique 
donor monocytes, providing an additional level of genetic diversity and greater 
validation of these results.   The evidence implicating Rv2666 as an anti-apoptotic 
gene of the K20 region was thus far quite compelling. We were able to confirm these 
initial results via complete complementation of the mutant phenotype.  This was 
accomplished by transforming TnRv2666 with an episomal plasmid expressing 
Rv2666 (cloned behind the gene’s expected native promoter region) and repeating the 




We can ultimately conclude that Rv2666 plays a role in the suppression of 
host macrophage apoptosis and that this gene is at least partially responsible for the 
K20 gain-of-function phenotype.   As an additional measure of validation, a clean 
Rv2666 gene deletion mutant could be created in the H37Rv background, fulfilling 
the gold standard of Mtb genetic analysis [180].  H37Rv is the most commonly used 
laboratory strain of Mtb, while CDC1551, our TnRv2666 background strain, comes 
from a clinical isolate [41] and is less prevalently employed in Mtb research.   
Though both strains are employed for Mtb investigation, studies have 
suggested that CDC1551 induces an increased host inflammatory response relative to 
H37Rv as determined by secretion of pro-inflammatory cytokines [42] under both in 
vitro and in vivo infectious conditions.  However, the inflammatory robustness of the 
CDC1551 isolate strain does not translate into more virulent colonization or amplified 
rate of growth relative to other strains of Mtb.  Moreover, recent experimentation has 
revealed distinct differences in host transcription of immuno-linked genes and nitric 
oxide production when macrophages are infected with CDC1551 or HN878, another 
clinical isolate [181].    
While the data of the aforementioned studies do not contradict our findings in 
any appreciable manner, subtle differences in host immune response to distinct strains 
of Mtb may affect the outcome of our experiments.  These studies reiterate the 
importance of confirming our TnRv2666 CDC1551 results with a clean deletion 






4.2.4  Relevant experimental design and controls for the identification of K20 
anti-apoptotic genes 
 
4.2.4.1 Experimental design: differentiating host apoptosis vs. necrosis outcomes 
 
More extensively on the issue of experimental design and controls employed 
in this dissertation, HMDM infections with Mtb described in this study were carried 
out for 4 hrs at an MOI of 5 (unless otherwise stated); this can be considered a 
relatively low MOI format [182].  Importantly, HMDM infections at “high” Mtb MOI 
of  ≥ 10 have consistently shown an induction of caspase-independent host 
macrophage death [101, 194, 195, 196] which closely resembles a necrotic host death 
outcome rather than the definitively apoptotic host-death of interest to our research.  
Specifically, Welin et al. demonstrated  caspase-independent host death of HMDMs 
infected at MOI ≥ 8 in a 2011 publication [101]; around the same time, Lee et al. 
published a report detailing atypical macrophage death at high MOI numbers [184].   
To that end, we took several measures attempting to ensure observed host 
death was conclusively apoptotic in our studies.   Beyond undertaking infections at a 
low MOI of 5, we employed apoptosis-specific cell death assays such as hypodiploid 
staining [185] and TUNEL labeling [186] throughout our anti-apoptotic gene 
investigation.  Moreover, AK release in THP-1 cells (Supp. Figure S1b) revealed no 
significant differences between macrophages infected with WT CDC1551 and those 
infected with TnRv2666; this further validates our finding that Mtb lacking the 
Rv2666 gene, as well as K20 transposon LoGoF mutants of Rv2666 in the Mkan 





4.2.4.2 Experimental design: cytokine differentiation of HMDMs and host 
apoptosis outcomes 
 
Much of our reported findings depend on the behavior of HMDMs following 
infection by Mtb.  The manner of monocyte to macrophage differentiation has a 
bearing on the reported findings [59, 199].  For our work, initial optimization studies 
were carried out to determine a method of HMDM differentiation that would produce 
mature macrophages that could be used to accurately assess the ability of Mtb to 
suppress host apoptosis.  It was important that the differentiated macrophages 
undergo Mtb-mediated cell death in a quantifiable and discernible manner, and that 
the model macrophages were sensitive to controllable variations in the MOI, strain 
and/or clone of Mtb employed as well as the duration of infection.  Optimization 
studies with the K20 GoF vector and Mkan-null vector in both recombinant human 
M-CSF differentiated monocytes and recombinant human GM-CSF differentiated 
monocytes (Figure 19) suggested both cytokines would generate macrophages 
possessing the desired traits for studies involving host-pathogen interaction and 
apoptotic outcomes.  However, for a yet-undetermined reason, monocytes 
differentiated with M-CSF consistently produced mature, CD14
+
 macrophages more 
frequently than GM-CSF; thus M-CSF was employed as the preferred cytokine of 






Figure 19. GM-CSF differentiated HMDMs infected with GoF vector 
transformed M. kansasii exhibit K20 GoF phenotype.  
Human monocytes were differentiated to CD14
+
 macrophage maturation by culturing the 
recombinant human GM-CSF (Peprotech) and off-the-clot human AB serum for 7 days.  
HMDMs were infected with Mkan-K20, Mkan-empty vector and Mkan-J21 [53, 109] as a 
positive control.  A 4 hour infection was followed by a 2 day chase; unifected (UI) wells were 
included as controls.  TUNEL staining and flow cytometry quantified total percentage of 





Reports published by other research groups have suggested the particular 
method of cytokine differentiation used in the monocyte-to-macrophage 
differentiation process affects the outcome of subsequent bacterial infections [59, 
[187].   Furthermore, it has been reported [59, 66] that in many respects (surface 
markers, morphology, catalase production, etc.), human monocytes cultured with 
human GM-CSF generate a mature macrophage with properties similar to resident, 
human alveolar macrophages (the primary, hallmark host of Mtb), while co-culturing 
monocytes with human M-CSF produces a peritoneal-like macrophage.  As with all 
in vitro host-pathogen modeling systems, a close approximation of clinical disease is 
the most for which a researcher can hope. 
Additionally, several experiments were carried out in human THP-1 cell line 
and produced similar results when validated by visual inspection.  An example of a 
TUNEL stained experiment can be seen in Figure S1a (Figure S1a courtesy S. Shah).  
These results suggest the TnRv2666 pro-apoptotic phenotype may be consistently 
seen in multiple models of Mtb infection. 
While repeating these experiments within a GM-CSF differentiated 
macrophage model system, as well as human alveolar macrophages, would seem to 
be an enticing proposition, a characterization of the anti-apoptotic role of Rv2666 
under in vivo conditions would also be beneficial.  Our work establishing a GoF 
phenotype for Mkan-K20 in guinea pig alveolar macrophages (Figure 6) suggests a 






4.2.5 Potential role of a hypothetical transposase, Rv2666, in Mtb virulence 
pathways 
 
To date, it has been noted that some transposase genes seem to play a 
beneficial role in certain bacterial organisms [190], with the general assumption that 
the transposase genes are functioning as promoters of genetic diversity and mutation 
in times of great environmental stress [122, 203]; this benefit generally seems to stem 
from stress induced promotion of well conserved, functional transposases.  Also, 
transposase activity may create genetic diversity by insertion of the transposase into a 
novel location within the genome, ablating gene function or repressors/promoters of a 
gene, or having other modulating/regulatory effects upon an environmentally stressed 
bacterium.   
More specifically, the hypothesis put forth most by transposase researchers is 
that organisms will continue to maintain “selfish” transposase genes that confer a 
benefit to the host; it is believed that these benefits are often a result of indirect 
regulatory effects.  These transposase-resultant effects upon “host” genomes, though 
indirect, contribute to the survival of the organism thus fulfilling the mandates of 
selective pressure.  In one example, a group working at Trinity College Dublin, 
recently noted that E. coli strains lacking the sigma factor RpoS are nonetheless able 
to adapt to a high-osmolarity environment by IS10 insertion into the promoter for the 
otsBA operon, which alters the operon’s expression from RpoS-dependent to RpoS-
independent [191].  It seems that the transposase element ultimately grants its 
beneficial phenotype by allowing for (and increasing the rate of) successful adaptive 
mutations rather than directly creating this phenotype by its own devices. In another 




which seems to have some effect on the Il-1β secretion of host macrophages (see 
section 5.2.4), though our experiments show ClpC2 to be dispensable for Mtb-
mediated suppression of host apoptosis.    
Alternatively, Rv2666 may modulate the expression or function of another 
factor important in the Mtb suppression of host-apoptosis, perhaps acting as a 
transcription factor.  The Rv2666 gene encodes a region [179] possessing MULE 
(mutator-like element) transposase homology [178].  It has been suggested that these 
MULE transpose elements have a zinc finger homology and may indicate possible 
metal chelation and DNA-binding properties [178].   Furthermore, some functional 
gene products or transcriptional regulators may have evolved from MULE transpose 
precursors.  While this phenomenon would likely be considered a novel finding in 
Mtb, the FAR1 protein, FHY3 protein and FAR1 related sequence (FRS) 
transcription factors have been well-established as regulators of gene transcription in 
Arabidopsis [205, 206] and several other plants, providing a biological precedent for 
transposase-to-transcription factor evolution. 
 
4.2.6 clpC2/Rv2667 is not an anti-apoptosis gene of Mtb 
 
After confirming Rv2666 as an anti-apoptosis gene of the K20 genomic 
region, our attention turned to characterization of the second gene identified by our 
LoGoF screens, Rv2667/clpC2/clpX’ (Figures 9, 10).  The clpC2 gene of Mtb (H37Rv 
nucleotide region 2,983,896 to 2,984,654, + strand) is a hypothetical ATPase member 
of the Clp family of proteases [194].   The essentiality of the bulk of the Mtb Clp 




screening transposon mutant libraries have shown that Clp protease subunits 
ClpP1/Rv2561c and ClpP2/Rv2460c, ATPase subunits ClpX/Rv2457c and 
ClpC1/Rv3596c, and the chaperone ClpB/Rv0384c are all requisite for in vitro 
growth of Mtb.  In the latter report [138], ClpC2 was found to be nonessential for in 
vitro culturing as several transposon-generated mutants of clpC2 were able to 
proliferate under normal culturing conditions.  We have been able to confirm those 
initial findings by the generation and confirmation (through genomic DNA and 
cDNA analysis) of a deletion mutant of clpC2 in the H37Rv genetic background 
(Figures 14, 15 and Supp. Figure S2). 
The clpC2 gene sequence bears homology to the established Clp ATPases 
clpC1 and clpX; clpC2 has been alternatively annotated as a truncated version of both 
of these genes at various times past [175, 207].  While several reports regarding ClpX 
and ClpC1 and their expression regulation have been published in recent years [139, 
140, 145], there is no literature explicitly characterizing clpC2 or its gene product.  
However, some of the aforementioned studies have suggested that ClpC2 expression 
is not regulated as part of the ClgR (Rv2745c) operon. Several reports [151, 152, 153] 
have established the ClgR operon as a key factor in the Mtb stress induced response.  
In high-stress conditions, such as a bacterium being phagocytosed by an alveolar 
macrophage, the Clp protease activity of the intracellular pathogen is critical to the 
rapid elimination of aberrant and misfolded proteins in an ATP-dependent manner 
and thus essential for the survival of the bacterium.  The lack of co-regulation with 




ClgR-linked stress response, and may play an alternative role in the well-being of 
Mtb.   
In terms of our study, the clpC2 LoGoF transposon mutant was repeatedly a 
“positive hit” in several rounds of both Msmeg and Mkan LoGoF screening (Figures 
9 and 10, respectively).  We felt that, rather than a direct link with the ClgR stress-
response, ClpC2 may play a role in virulence by supporting the Mtb-mediated 
suppression of host-apoptosis.  Additionally, clpC2 was shown to be one of  about 
100 genes upregulated in vitro following a long period of anaerobic maintenance with 
sudden reaeration [152]. This study mimicked conditions very similar to what one 
would expect following transmission of Mtb into a new host, or transitioning from a 
latent to an active state of pulmonary TB, precisely when an anti-apoptotic response 
would be most desired by the pathogen. 
 
4.2.6.1 Generation of a clpC2 deficient strain of Mtb, details and relevant 
issues 
 
A clpC2 deficient strain of Mtb was generated by homologous recombination 
in order to study the function of the gene.  Specialized phage transduction was used to 
increase efficiency of the method [159].  Homologous recombination was specifically 
targeted to leave the first 58 and final 5 nucleotides of the gene intact within the 
chromosome to avoid disruption of the neighboring genes.  The clpC2 gene is coded 
for on the + chromosomal strand and there is no known or predicted overlapping gene 
or promoter regions that could be affected by the recombination event on the 




Preliminary observations of WT H37Rv and ΔclpC2 colony formation and 
morphology on 7H10 media plates revealed no noticeable differences.  Deletion of 
the clpC2 gene was confirmed by analysis of genomic DNA (Figure 14; Supp. Figure 
S2); this was further validated by RT-PCR to validate lack of gene expression (Figure 
15).   
Genomic DNA was used to confirm the successful deletion of clpC2 in two 
ways; PCR amplification of small internal sections of genes of interest to determine 
the presence or absence of these genes, and Southern blotting which used a labeled 
probe to identify alterations to restriction enzyme patterns that would result from this 
targeted homologous recombination event.  First, PCR of genomic DNA (plus 
episomal DNA in the case of the pMV261-based complement) was carried out using 
small primers that would amplify short, internal regions of sigA (as a PCR control), 
clpC2 and the hygromycin resistance gene.  Once the PCR products were visualized 
by agarose gel electrophoresis, the presence or absence of an amplification band can 
be correlated by the respective presence or absence of the gene in question.  As seen 
in Figure 14, bands suggesting the absence of the clpC2 gene but the presence of a 
hygromycin resistance gene could be seen in the ΔclpC2 PCR product lanes; 
conversely, WT H37Rv genomic showed the presence of clpC2 but no hygromycin 
resistance gene. Moreover, the complemented mutant strain demonstrated 
amplification banding that verified the presence of both the clpC2 gene (the 
episomally provided complement copy) and a hygromycin resistance gene as 




size of the hygromycin resistance insert cassette (3,672 nt), we were unable to 
amplify across the entirety of the insert.   
As a second measure of DNA based confirmation of clpC2 abrogation, 
Southern blotting was employed.  A probe was created from the upstream portion 
(H37Rv nucleotide region 2,983,896 to 2,984,654, + strand) of the original allelic-
exchange substrate vector used for the targeted homologous recombination event.   
The labeled probe was used to identify expected shifts in Van91I restriction enzyme 
patterns that would have resulted from recombination of the clpC2 and the 
hygromycin cassette (Supp. Figure S2).  The resultant Southern blot image confirmed 
the WT H37Rv and K20 control vector having an identical band indicating probe 
hybridization with a fragment roughly 6.3kb in size, while ΔclpC2 demonstrated an 
expected absence of the 6.3kb band and presence of a heavy band approximately 
3.5kb in size.  However, unexpected smaller bands can also be seen in the image; this 
is likely the result of nonspecific binding of the probe, as this particular probe shares 
a portion of its nucleotide sequence with IS1081 sequences, of which five 
independent regions exist in the Mtb genome.  Redesigning this probe to avoid the 
transpose region would likely eliminate this background banding pattern.  
 Finally, RT-PCR was employed to suggest that RNA expression of clpC2 had 
been completely ablated by the mutation.  RNA was obtained from WT H37Rv, 
ΔclpC2 and the pMV261-based complement. The purified RNA samples were used to 
generate cDNA and “reverse transcriptase null” controls were included for each 




employed in the RT-PCR; the generated cDNA and purity-controls for each 
respective strain were used as templates.  Figure 15 shows the results.   
WT H37Rv and the episomally complemented ΔclpC2 demonstrate 
transcription of clpC2, while the mutant, as expected, does not.  Interestingly, the RT-
PCR revealed that the complemented mutant seemed to express clpC2 RNA at a 
much greater rate than WT Mtb; this is to be somewhat expected as the 
complementation plasmid employed (pMV261) includes a constitutive promoter and 
there may also be multiple copies of this plasmid in each Mtb bacterium.  Taken with 
the previously discussed genomic validation of ΔclpC2, we can confidently assume 
that we generated a homologous recombinant mutant of clpC2 in the H37Rv genetic 
background of Mtb. 
 
5.1.6.2 LoF study of a clpC2 deficient strain of Mtb  
To our surprise, the infection of HMDMs with WT H37Rv and  ΔclpC2 
consistently demonstrated no significant differences in host apoptosis between the 
strains (Figure 16); this lack of the expected ΔclpC2 pro-apoptotic phenotype was 
also observed when infections were carried out in alveolar macrophages of Hartley 
guinea pigs (Figure 17), the guinea pig being the gold-standard of TB animal models 
[189].  These results imply that ClpC2 plays no striking role in the Mtb-mediated 
inhibition of host apoptosis.  If this were true, it would contradict our initial 
hypothesis that there was an anti-apoptotic role for the gene based on the Msmeg and 
Mkan LoGoF data we generated.  However, there are many plausible possibilities that 




4.2.7 Alternative hypotheses explaining clpC2 LoGoF and LoF discrepancy 
 
 This subsection highlights possible reasons for the incongruous results 
between the our LoGoF screening results for clpC2 that implicate the gene as playing 
a role in anti-apoptotic mediation by Mtb, and our LoF study results that suggest no 
apparent part for clpC2 in this particular virulence tactic.    
 
4.2.7.1 Alternative hypotheses: Genetic redundancy 
 
The evolutionary redundancy of mechanisms and pathways critical to the 
pathogen’s survival may explain why we can attribute an anti-apoptotic effect in the 
LoGoF screens but the phenotype fails to appear in a LoF ΔclpC2-Mtb study.  For 
more than a decade, numerous research groups have reported on and dissected the 
Mtb-mediated suppression of host-apoptosis [90, 161] with many unique mechanisms 
reported; there are two other known Clp ATPases encoded by the Mtb genome.   A 
complex interplay of factors from both the host and the pathogen are clearly involved 
in a balancing act [117] not only in the host-pathogen host-cell death outcome, but in 
the formation of TB granulomas as well [208, 209].  
In terms of the process of natural selection, it stands to reason that inhibition 
or interference of a single, specific point in one of these pathways (of pathogen or 
host) critical to survival, and subsequently the replication/reproduction of the 
organism, will likely have several redundant mechanisms that will counter this loss, 
especially where an ancient pathogen such as Mtb, which has evolved as a human-
specific pathogen with countless generations of selection, is concerned.  The genomic 




mutations in the respective clpC2 gene of various strains, leading to non-synonymous 
amino acid substations between strains [194]; the occurrence of non-synonymous 
substitutions that may affect protein function or efficiency (i.e., S120G, polar side-
chain to nonpolar side-chain substitution) suggest that a fixed ClpC2 amino acid 
sequence is not a requisite for Mtb virulence and the protein may be expendable in its 
importance to the survival of Mtb in a clinical setting.   
 
4.2.7.2 Alternative hypotheses: clpC2 is a marginal player in Mtb virulence 
 
It is also possible that ClpC2 does, in fact, contribute to an anti-apoptotic 
effect in Mtb, but its effect exists as a marginal “downstream player” in its respective 
pathway and the ablation of clpC2 affects no striking phenotypic shift in host-
apoptosis outcome.  This could explain why we can confer an anti-apoptotic GoF to 
nonpathogenic Msmeg and the opportunistic pathogen Mkan when the bacteria are 
transformed with the K20 genomic region of Mtb, a phenotype that is lost by the 
LoGoF transposon interruption of clpC2.  We know from DNA sequence analysis 
that the clpC2-LoGoF clone (sgRv2667) should disrupt functional gene product from 
being expressed; likewise, RT-PCR (Figure 15) confirms the lack of clpC2 
transcription in the ΔclpC2-Mtb strain.  The incongruity of our observed host-
apoptotic outcomes may be the result of a novel ability conferred to Msmeg and 
Mkan by transformation with the K20 GoF vector, an ability that is simply a 
downstream effector in Mtb.  The differences in the evolutionary specialization and 
environmental niche [55,  210,  211, 212] of each of the mycobacterial species may 




4.2.7.3  Alternative hypotheses: clpC2 may be important in another virulence 
capacity 
 
Finally, it is possible that ClpC2 has no direct effect on host-apoptosis 
outcomes whatsoever.   The phenotype observed in our LoGoF screens could be 
simply an experimental artifact specific to that particular transposon mutant clone, 
however, we feel this is unlikely.  A second LoGoF clone of clpC2 (sgRv2667.b) was 
also screened in the Mkan background (data not shown); the findings suggested an 
inability to suppress host-apoptosis in this clpC2 transposon mutant as well.  It is 
plausible that ClpC2 may be acting in another capacity (see section 5.1.4 and 5.2.4), 
possibly affecting a LoGoF resultant phenotype as a byproduct of its action.  This 
potential for an alternative ClpC2 mechanism of virulence is further examined and 





Chapter 5: Characterization of pathogenicity of clpC2 
abrogation mutant  
 
The second portion of this dissertation details the characterization of a ΔclpC2 
mutant generated in H37Rv genetic background of Mtb.  A focus is placed on 
identification of possible roles affecting Mtb virulence.  As previously described, our 
characterization of ΔclpC2 began as the result of an attempt to identify anti-apoptotic 
genes of the K20 genomic region of Mtb.  Preliminary results from a LoGoF screen in 
Msmeg and Mkan suggested a potential role for ClpC2/Rv2667 in the mediation of an 
anti-apoptotic phenotype.  However, further testing with a ΔclpC2 mutant revealed no 
apparent role for ClpC2 in the suppression of host apoptosis.   
Very little is known or published about this particular hypothetical Clp family 
ATPase gene.  In order to further understand ClpC2, we wished to characterize the 
mutant previously generated in terms of basic fitness as well as virulence.  We 
approached this goal by comparing WT Mtb to the mutant with several assays chosen 
to reveal these differences between the two strains.   Additionally, we hoped our 
characterization of the clpC2 gene might reveal the reason for discrepancy between 
our LoGoF and LoF results.  Our hypothesis was that the Mtb clpC2 gene plays a role 






5.1 Results: Characterization of pathogenicity of clpC2 abrogation 
mutant  
5.1.1 Altering clpC2 expression has no effect on in vitro growth of Mtb in 
complete media, overexpression of clpC2 in minimal media results in 
defective replication 
 
 Mutations of ATPase function in other bacteria have been shown to alter the 
ability of the organism to function properly in terms of growth defects in vitro [200].  
The Mtb Clp protease proteolytic subunits ClpP1/P2, ATPase subunits ClpX and 
ClpC1, and a predicted chaperone (ClpB) are all known to be essential for in vitro 
growth of the pathogen [137, 138].  Additionally, the alteration of expression of the 
ATPase clpX was shown to effect a delayed rate of bacterial growth when strains 
expressing both decreased and elevated levels of ClpX were grown in vitro and 
compared to a H37Rv control [140].  Although the ATPase encoding clpX gene of 
Mtb has been found to be essential for in vitro growth, we were able to generate and 
confirm a clpC2 (previously annotated as clpX’ ) deletion mutant of H37Rv in 
complete 7H9 media.  Thus, we have established that ClpC2 is not a requisite for the 
in vitro viability of Mtb.  However, we did not yet know if altering the expression of 
the clpC2 gene would affect the rate of Mtb in vitro replication.   
In order to assess the importance of ClpC2 expression  levels for the in vitro 
replication of Mtb, WT H37Rv, ΔclpC2 and two versions of the complemented 
mutant (integrating pMV361-based complement and plasmid-based pMV261) were 
used to inoculate complete 7H9 media and Sauton’s minimal media at bacterial 
concentrations equivalent to [OD600  =  0.010], or 3.0 x 10
6
 bacteria/mL. 
Results were graphed log-scale (semi-log scale) rather than a linear OD600 




differences between the relative growth rates of WT Mtb and ΔclpC2 mutant in the 
complete or minimal medias (Figure 20), suggesting the absence of ClpC2 does not 
play a substantial role affecting bacterial growth under these conditions.    
Significant differences in the rate of bacterial replication were noted in one of 
the constitutively expressing clpC2 complement strains in our initial results (Figure 
20).  The pMV261-based extrachromosomal plasmid complement demonstrated a 
slight lagging rate of growth during the experimental growth phase compared to WT, 
mutant and pMV361-based attB integrating complement in the complete media study.  
This lagging phenotype was amplified in the minimal media study (Figure 20b); 
additionally, the WT and ΔclpC2 mutant had nearly identical growth curves in the 
same experiment.   
Further testing of this phenotype (Figure 21) was employed to determine if the 
defect in replication was an artifact or due to the presence of the kanamycin 
antibiotic, included to maintain expression of the episomal plasmid.  The initial 
experiment was repeated in complete 7H9 media, with additional controls chosen to 
establish whether the pMV261-complement was defective due to the added 
kanamycin antibiotic or if the phenotype could be attributed to the nature of this 
particular strain.   
Figure 21 suggests all strains grew in a similar manner, regardless of the 
presence of kanamycin in the media.  These results suggest that the observed rate of 
growth decrement was likely not due to the 40 µg/mL of kanamycin antibiotic in the 
media, included with the pMV261-based complement strain to maintain the 




replication  phenotype similar to the one observed following overexpression of Mtb 
ClpX [140].  From these studies, we conclude that ClpC2 abrogation has no obvious 
effect on the in vitro growth of Mtb in complete 7H9 or Sauton’s minimal defined 
media, however, overexpression of the clpC2 gene by an episomal plasmid with a 
groEL2 constitutive promoter results in an clear replication defect when grown in 






Figure 20.  In vitro growth curves of WT Mtb, ΔclpC2 and two complements of 
ΔclpC2 in complete and Sauton’s minimal media. 
Triplicate inoculations of WT Mtb, ΔclpC2, and pMV261 (extrachromosomal 
plasmid, *media contains 40µg/mL kanamycin antibiotic to retain the plasmid) and 
pMV361 (attB integrating) complements of the mutant were made in A.) 7H9 and B.) 
Sauton’s minimal medias at a concentration of [OD600=0.010], or [3.0 x 10
6
 / mL].  
Duplicate optical density readings at 600nm were taken every day for 12 days. Data is 













Figure 21.  In vitro growth curves of WT Mtb and complements of ΔclpC2 in 
complete media for study of kanamycin inclusion effect.  Triplicate inoculations of 
WT Mtb and pMV261 (extrachromosomal plasmid) and pMV361 (attB integrating) 
complements of the ΔclpC2 mutant were made in media at a concentration of 
[OD600=0.010], or [3.0 x10
6
/mL. *NOTE: “kan” annotation indicates a culture 
initially maintained in the presence of 40µg/mL of kanamycin then transferred into 
plain media lacking the antibiotic to study growth rates as a control; “kan/kan” 
annotation denotes a culture maintained in the presence of 40µg/mL of kanamycin 
then also grown in kanamycin containing media lacking the antibiotic to study 
comparative growth rates as a control; both “Mtb” and “pMV361-comp” cultures 
were initially maintained and used for this study in plain media with no antibiotic. 
Duplicate optical density readings at 600nm were taken every other day for 9 days. 





5.1.2 ClpC2 plays no salient role in mediating late-stage in vivo host 
necrosis  
 
Having established that ΔclpC2 plays no essential role in host apoptosis 
suppression by Mtb (see section 4.1.7), we sought to determine if the gene could 
possibly be contributing to other forms of cell death manipulation.   
To that end, HMDMs were infected at MOI of 3 with WT Mtb and the 
ΔclpC2 mutant strain.  Infections proceeded for 4 hrs; then the HMDMs were washed 
twice with sterile PBS to remove extracellular bacteria, and chase media was added.  
Infections were allowed to progress for 3 or 10 days; experimental endpoints were 
specifically chosen to model late-stage in vivo infections of cultured macrophages.  
At days 3 or 10 post-infection, cell-free infection media supernatants were collected 
and examined for Mtb-induced necrosis of HMDMs. Toxilight™ assays were 
employed to quantify levels of adenylate kinase (AK) release.  Levels of host cell 
necrosis in the infections were assessed by comparison of fold change relative to AK 
release in uninfected macrophages and total lysis controls.  Data pooled from multiple 
experiments is shown in Figure 22.  Lysis controls demonstrated similar levels of AK 
release at both time points (indicating little background atrophy of host cells) and AK 
release by uninfected macrophages was only slightly greater at the later time point.   
These controls suggest that observation of infected HMDM-AK release is a 
feasible measure of Mtb-mediated host-necrosis at these time points.  WT Mtb and 
ΔclpC2 infected HMDMs had no significant differences in terms of AK release at 
either day 3 or day 10 post-infection.  All infected macrophages were significantly 
lower in AK release than the total cell lysis controls at both time points as well.  




slightly higher in the mutant infected HMDMs.  Compared to the uninfected cells, 
H37Rv WT infected an approximately 2-fold difference in AK release, while ΔclpC2 
infected macrophages saw a roughly 3-fold difference, though these variations had no 
statistically significant difference when compared directly to each other (1290 ± 110 





Figure 22.  No significant differences in necrosis of HMDMs infected with WT 
Mtb or ΔclpC2 at days 3 and 10 post-infection.   
HMDMs were infected with WT or ΔclpC2 Mtb at MOI of 3 for 4 hrs; uninfected 
(UI) HMDM wells were included for all experiments.  Values are given in relative 
light units (RLUs).  Triplicate wells are shown; duplicate measures were collected 
from each well; triplicate measures were taken for a single lysis control well for each 
day (n=6 for samples; n=3 for lysis control).  Error bars represent ± SD.  Statistical 
analysis employed ANOVA with Tukey post-test.  Significance bars compare Mtb to 
ΔclpC2 at days 3 and 10, respectively.  Data is pooled from separate experiments 






WT infection induced 6164 ± 263 RLUs and HMDMs infected with ΔclpC2 
saw a generation of 6882 ± 401 RLUs at day 10.  Meaning that by day 10 post-
infection, overall necrotic induction had significantly increased in both strain-sample 
sets; however, the slight difference in the degree of AK release observed at the day 3 
time point was further diminished.   
Taken as a whole, the data suggests indicates that both strains induced 
HMDM necrosis similarly at late-stages of Mtb infection; should a difference in 
necrosis induction exist between the strains, it is found earlier in the course of 
infection.  The described day 3 differences in WT and mutant RLU values are not 
statistically significant; however, the marginal differences indicated to us that ClpC2 
may play a role in other virulence mechanisms at earlier time points.  These 
alternative roles suggested that mechanisms that might have an effect upon less 
regulated forms of host cell death, such as manipulation of cytokines affecting the 
host inflammasome response, thus having an indirect and slight effect  upon AK 
release by the ΔclpC2 mutant.  Ultimately, these experiments suggest that ClpC2 does 
not play any overwhelming role in the manipulation of host necrosis by Mtb.  
 
5.1.3 ClpC2 has no noticeable effect on in vivo replication of Mtb  
 
While we have shown clpC2 is not essential for in vitro growth (but 
overexpression may cause a growth defect in Sauton’s minimal media), we wished to 
see if altering the expression of this particular Clp family member would adversely 
affect in vivo survival and replication of Mtb due to the greatly added stress of the 




It is well-established that many of the Mtb Clp family of proteins (including 
both ClpX and ClpC1 ATPases), ClpP1,P2 protease subunits and the 
chaperone/endopeptidase ClpB are required for in vitro growth of Mtb [137, 141, 
139]; moreover ClgR, which controls a Clp stress response regulon, has been shown 
to be critical for a mediating an infection desirable for the pathogen following 
phagocytosis [151].  While clpC2 does not seem to be a member of the ClgR-regulon 
[153], its strong homology to clpX and clpC1 warranted investigation of whether it 
might be important for in vivo survival and replication following macrophage 
phagocytosis.  Likewise, observation of colony forming units (CFUs), produced by 
infection of HMDMs and collected at days 3 and 10 post-infection, revealed a 
statistically insignificant CFU variation between the WT Mtb, ΔclpC2 and the 
pMV261-based complement of the mutant at these days.  At day 3 post-infection 
CFU values were 1.5 x 10
6 
± 0.4 bacteria/mL for the WT, 1.31 x 10
6 
± 0.2 
bacteria/mL for ΔclpC2 and 1.6 x 10
6 
± 0.1 bacteria/mL for the complemented 
mutant; all CFU values at day 3 post-infection have no significant differences.  At 
day 10 post-infection, CFU values were 9.49x10
6 
± 2.86 bacteria/mL for the WT, 7.6 
x 10
6  
± 0.7 bacteria/mL for ΔclpC2 and 7.7 x 10
6 
± 0.6 bacteria/mL for the 
complemented mutant; all CFU values at day 3 post-infection have no significant 
differences.  Furthermore, CFU counts revealed all HMDMs were similarly infected 
with the three strains at day 0; this control established that any future observed CFU 
variances between strains would not be due to unexpected MOI differences. 
Figure 23 ultimately indicates the functional deletion of clpC2 has no 




data generated by these experiments suggest ClpC2 does not play a significant role in 
Mtb-coordinated necrotic host cell death induction and subsequently, its ablation has 






Figure 23.  No significant differences in CFU counts during early and late-stage 
HMDM infection with WT Mtb, ΔclpC2 and complement.  
HMDMs were infected with the three listed strains of Mtb for 4 hrs at an MOI of 3.  
Macrophages were lysed and colony forming unit (CFU) dilutions were made and 
plated on 7H10 media plates.  Error bars represent ± SD.  Statistical analysis 
employed ANOVA with Tukey post-test. Data is pooled from separate experiments 





5.1.4 ClpC2 has no role in altering TNFα secretion by HMDMs, but clpC2 
deletion elicits a significant increase in host Il-1β release 
 
 Inflammatory cytokines are known to be a critical factor modulating host 
response to infection by Mtb.  Tumor necrosis factor-α (TNFα) has previously been 
shown to be important for granuloma formation [165, 166].  TNFα-defective mice are 
exceptionally sensitive to Mtb infection and experience a high degree of extra-
pulmonary dissemination of the pathogen that is not seen in immunocompetent mice 
[203];  a similar phenotype can been reported by investigators who manipulate in vivo 
concentrations of TNFα [166, 168, 169].  Also, recent reports have indicated an 
important role for TNFα in preventing active TB outbreak in immunocomprised 
patients and those treated with anti-inflammatory compounds [19, 170, 171].   Mtb 
mutants such as ΔoppD have all been shown to have altered inductions of TNFα by 
infected macrophages [208]. Another inflammatory cytokine, interleukin-1β (IL-1β) 
also plays a critical role in the mediation of host response to Mtb infection [173, 174].  
IL-1β receptor (r) null mice infected with Mtb demonstrate a greater susceptibility to 
the pathogen; relative to a WT mouse, this IL-1r mutant mouse will be unable to 
efficiently contain the bacteria and experience diminished survival [210]. 
Given the importance of Clp protease family members in high-stress 
conditions as Mtb experiences during host infection and colonization, we wished to 
see if altering ClpC2 expression levels alters host inflammation response. To study 
this, HMDMs were infected with relevant strains of Mtb; the hallmark pro-
inflammatory cytokines TNFα and IL-1β secreted into the infection supernatant were 
subsequently quantified by ELISA.   




ΔclpC2 and the complemented ΔclpC2 at MOI of 3 for 4 hrs; this was followed by a 
24-hour chase period, after which the infection supernatants were collected for 
analysis by ELISA.  The results of two independent experiments can be seen in 
Figure 24. 
Host TNFα release had mean values of 263.6 ± 21.1 pg/mL, 309.9 ± 22.5 
pg/mL and 293.9 ± 24.8 pg/mL for WT Mtb, ΔclpC2 and complement, respectively.  
HMDMs infected with the ΔclpC2 strain secreted significantly more TNFα than was 
produced by the uninfected controls (207.9 ± 12.3 pg/mL), while there were no 
significant differences in WT Mtb and uninfected macrophage TNFα release.  There 
were no significant differences in host-TNFα secretion among any of the three strains 
used in the infections, leading us to conclude that ClpC2 has no obvious role in the 
Mtb modulation of host-TNFα secretion. 
Yet, a statistically significant difference (p ≤ 0.001) in host IL-1β secretion by 
infection with WT Mtb or ΔclpC2 was observed.  HMDMs infected with WT Mtb, 
ΔclpC2 and the complemented mutant induced 4.7 ± 2.7 pg/mL, 61.1 ± 6.4 pg/mL 
and 19.9 ± 4.7 pg/mL, respectively.  Uninfected HMDMs did not release IL-1β at a 
detectable concentration by our assay methods.  Mtb incapable of expressing ClpC2 
generated a 13-fold greater induction of host IL-1β release than WT Mtb.  We were 
also able to partially restore the mutant phenotype to WT Mtb induction levels by 
complementation of the mutant with a pMV261 plasmid expressing ClpC2.  Our 
results suggest clpC2 plays a noticeable role in modulating secretion of host IL-1β, 








Figure 24.  Host secretion of cytokines TNFα and IL-1β is differentially affected 
by infection with WT Mtb, ΔclpC2 and complemented mutant.  
 HMDMs were infected with WT H37Rv Mtb, ΔclpC2, and the pMV261-based 
complemented mutant at MOI of 3 for 4 hrs; uninfected (UI) wells were included in 
all experiments.  Supernatants were collected at 24 hrs post-infection and the amount 
of secreted TNFα and IL-1β was simultaneously assessed by ELISA.  Values 
represent 3 wells per condition, with 3 replicates per well measured.  Data is pooled 
from two experiments, with macrophages from a unique donor for each experiment 
(n=18). Error bars represent ± SD.  Statistical analysis employed ANOVA with Tukey 
post-test.  Significance bars compare (A) induction of TNFα release by all three 
mycobacterial strains and (B) Mtb vs. ΔclpC2:: complement (*, p < 0.05) AND 





5.2 Discussion: Characterization of pathogenicity of an Mtb clpC2 
abrogation mutant  
 
The intracellular regulation and recycling of aberrant and misshapen proteins by 
protease activity is absolutely essential for the survival of all organisms. Protease 
importance is even more readily apparent in pathogens, such as Mtb, that spend a 
significant portion of their life cycle dealing with the ramifications of phagocytosis by 
alveolar macrophages and subsequent acidification of the host phagosome.  The 
activity of the Clp proteases of Mtb is an essential part of the organism’s arsenal for 
dealing with the relatively high-stress conditions of the intraphagosomal space [153]. 
Investigators employing transposon site hybridization (TraSH) to study Mtb have 
previously shown that the Clp protease subunits ClpP1/Rv2561c  and 
ClpP2/Rv2460c, ATPase subunits ClpX/Rv2457c and ClpC1/Rv3596c, and 
ClpB/Rv0384c are all essential for the in vitro growth of Mtb [137].  Additionally, 
studies examining  the Clp ATPase subunits ClpX [140] and ClpC1 [139, 145], and 
the Clp proteolytic subunits [141, 142] clpP1and clpP2 have all provided additional 
evidence supporting the essentiality of these genes in Mtb.  Incidentally, the Mtb 
genome encodes three hypothetical ATPase subunits: the aforementioned clpC1 and 
clpX which are both required for in vitro growth of the bacteria, and 
clpC2/clpX’/Rv2667 (H37Rv nucleotide region 2,983,896 to 2,984,654, + strand; 252 
amino acids), a hypothetical ATPase which prior studies have deemed likely 
dispensable for in vitro bacterial replication [138].  Our generation and confirmation 
of a clpC2 deletion mutant of H37Rv has confirmed the dispensability of the gene for 
in vitro growth of Mtb within complete 7H9 media; however, this does not preclude 




To create a clpC2-specific deletion mutant, a targeted homologous recombination 
was employed with a crossing-over event that replaced the gene with a hygromycin 
resistance cassette (previously described in section 3.2.1and Figure 3).   
  
5.2.1 Abrogation of clpC2 has no effect on in vitro growth in complete or 
defined media; overexpression of the gene in minimal media generates an 
observable growth defect 
 
Reverse genetic characterization of bacterial mutants will often begin with an 
examination of potential in vitro growth defects.  This establishes a working baseline 
of understanding for any phenotypes that may arise with future characterization 
studies.  In that respect, we examined in vitro growth rates of Mtb with regards to 
altered expression of the clpC2 gene in both complete 7H9 media and Sauton’s 
minimal media.  Incidentally, the Mtb gene clpX  has been shown to affect the rate of 
bacterial division when expression of this gene is significantly altered [140], 
especially when it is overexpressed.  The authors of the study suggest the growth 
decrement is due to varied levels of ClpX expression giving rise to an alteration of a 
precise stoichiometric relationship between ClpX and FtsZ, ultimately leading to 
irregular cell division.  Additionally, it is known that manipulations of other Mtb Clp 
family members demonstrate growth defects in their respective strains when the 
expression of the Clp-gene was significantly altered [140, 141, 142].  We wondered if 
altering the expression of the clpC2 gene (formerly annotated as clpX’) would 
produce a similar phenotype.   
Our studies initially found a distinct difference in the growth rates of Mtb 




overexpression of the clpC2 gene results from being carried on a cytosolic plasmid, 
with expression driven by a constitutive groEL2 promoter (see RT-PCR comparison 
in Figure 15).  A follow-up study designed to verify these initial results and control 
against possible bacterial growth defects attributable to inclusion of the kanamycin 
antibiotic in the growth media was implemented (Figure 21).  This experiment 
employed the attB site-integrated clpC2 complement (the pMV361-based 
complement) and the plasmid-based pMV261 complement in a series of controls to 
demonstrate whether the observed clpC2 “overexpression phenotype” was 
attributable to inclusion of antibiotic, but rather was likely an artifact of the pMV261 
grown in minimal media; further study (preferably in Sauton’s defined media) will 
better establish the true reason for this defect.  Finally, RT-PCR confirms that the 
ΔclpC2 mutant is not expressing RNA to generate functional product (Figure 15), 
thus this abrogation mutant is “clean” and the lack of phenotype may be accepted at 
face-value.  From the data taken as a whole, we may assume that the total absence of 
ClpC2 expression has little bearing on in vitro replication of Mtb in 7H9 or minimal 
media; however, as in the case of ClpX, overexpression of the hypothetical ATPase 
can result in a substantial growth defect. 
  Dziedzic et al. suggest that the overexpression of ClpX leads to a growth 
defect in Mtb due to an alteration in the precise stoichiometric relationship (1 ClpX : 
2 FtsZ) that exists between the ATPase and FtsZ, limiting the ability of FtsZ to 
properly assemble and  form the Z-ring essential for cell division [140].  It is possible 
that ClpC2 also interacts with FtsZ in a stoichiometric manner and expression leads to 




Dziedzic publication suggested the N-terminal region of ClpX was important for 
interaction with FtsZ [140]; vtBLAST comparison of Mtb ClpX and ClpC2 suggests 
no obvious homology between the two proteins. 
Alternatively, overexpression of a possible ATPase such as ClpC2 is quite 
likely an energetic drain on Mtb; when this particular strain of Mtb is further taxed by 
growth in Sauton’s minimal media, the burden of the overexpressing ClpC2 plasmid 
is detrimental to normal bacterial replication.  This may be why a clpC2-pMV261 
complement demonstrates an observable defect in minimal defined media, but is not 
seen when the strain is cultured in complete 7H9 media.  Further studies are needed to 
conclusively establish if one of these hypotheses is correct.  However, we can say that 
ClpC2 is entirely dispensable for in vitro growth of Mtb in both complete and 
minimal medias; it may be that ClpC2 is made redundant by the presence of ClpX or 
other factors.    
 
5.2.2 ClpC2 plays no salient role in mediating late-stage in vivo host 
necrosis manipulation  
 
Aside from a role in suppressing host apoptosis, studies have shown that 
virulent mycobacteria will actively promote an non-apoptotic, necrosis-like death of 
host macrophages [100] and dendritic cells [211].  It is believed that this Mtb-
mediated host death is akin to necrosis in that it lacks the bactericidal effect of host 
apoptosis and allows the pathogen to migrate to surrounding tissues, immensely 




One such mechanism employed involves Mtb disruption of the host’s plasma 
membrane.  Host repair of this damage is prevented by Mtb stimulated production of 
LXA4.  LXA4 then blocks host production of PGE2, a requisite compound for 
initiating the lysosome-mediated repair of the cellular membrane [100]; this quickly 
leads to host necrosis and pathogen dissemination.  Additionally, ESAT-6 is an Mtb 
secretion that has been shown to be critical in the induction of host necrosis by way of 
inflammasome activation [99, 214, 215].  ESAT-6 is an early infection product of 
Mtb, likely secreted during times of high bacterial stress and has been linked to dose-
dependent lysis of pneumocytes [214].  Concordantly, Mtb will greatly upregulate 
transcription of Clp proteases by way of a ClgR-mediated response in times of high 
stress [108, 151, 152].  Expression of clpC2 RNA seems to be largely unaffected by 
this putative regulon [153].  However, clpC2 expression is upregulated in times of 
starvation (5-fold [215] and 8-fold  [216] ) induced stress and was shown as one of 
about 100 genes upregulated following reaeration from a hypoxic state [152].  These 
are conditions one might expect after a long period of latency and sudden reaeration; 
such events will immediately precede the spread of Mtb from a maintained granuloma 
to new tissues in the host or may result in the aerosolized infection of an entirely new 
host upon cavitation of a granuloma.  Upon stable infection of new macrophages, the 
pathogen will likely seize the initiative and quickly attempt to induce host necrosis 
upon infection by the aforementioned methods, propagating itself even further.  We 
wondered if there existed a yet undetermined role for ClpC2 in modulating host 




A low MOI infection of HMDMs was carried out to identify any significant 
differences between Mtb-mediated necrosis (as measured by AK release) at 2 
separate time points.  The chosen time points represent early (3 days post-infection) 
and later (10 days post-infection) in vivo infection models, approximating similar 
mycobacteria-mediated host-necrosis [217].  Furthermore, in our experience, 
culturing HMDMs for time periods beyond 10 days following infection will result 
significant death of uninfected macrophages and a lack of observable differences in 
infected HMDMs relative to lysis controls (data not shown).  Also, the MOI of 3 was 
employed in this study to avoid any potential for high-MOI induced necrosis [101, 
195, 196] an oft-observed phenomenon that would potentially mask any ClpC2 
necrosis-mediating phenotype of interest.   
As seen in Figure 22, there were no statistically significant differences for WT 
Mtb or ΔclpC2 in terms of induced host necrosis at either time point.  However, 
relative to WT a slight elevation in the degree of AK release in was seen in the 
ΔclpC2 infected macrophages at 3 days following infection (compared to uninfected 
wells, 2-fold and 3-fold higher necrosis inductions, respectively).  This effect was 
almost entirely diminished by 10 days out, and even at its third day peak the 
phenotypic differences in WT and ΔclpC2 are not statistically significant.  We 
conclude that there is no obvious or overwhelming role for ClpC2 in promoting host 
necrosis.  The minimal difference in AK release at day 3 post-infection may indicate 
a slight discrepancy in the MOI for the respective bacteria.  Alternatively clpC2, often 
annotated as a hypothetical gene with possible roles as an Mtb ATPase or chaperone 




possibly indirect, effect on the bacteria’s ability to mobilize a pro-host necrosis 
response at maximum efficiency during early infection. 
 
5.2.3 ΔclpC2 shows no difference in intracellular survival compared to WT 
Mtb or complemented mutant 
 
  As another measure of potential virulence, a role for ClpC2 in promoting 
survival or replication of the pathogen was studied.  Several experimental infections 
of HMDMs with relevant Mtb strains were carried out; infection supernatants 
macrophage lysates were collected at days 3 and 10 post-infection.  CFUs were 
subsequently calculated for each sample; pooled results are shown in Figure 23.  All 
zero-hour CFU controls taken to establish initial infection consistency were 
statistically similar, indicating that the bacterial load was equitable in for all 3 strains 
used in the infection.  
The lack of significant differences in CFUs between WT, ΔclpC2 and the 
complemented mutant at both early (day 3) and late (day 10) post-infection time 
points studied suggests that there is no essential role for ClpC2 survival or replication 
under these particular in vivo conditions.  These results indicate that in the clpC2 gene 
is dispensable for not only in vitro growth of the pathogen, but is also non-requisite 
for Mtb replication within the much greater in vivo stresses of intra-macrophage 






5.2.4 Mtb clpC2 has no apparent role in altering host TNFα secretion, but 
deletion elicits a significant increase in host Il-1β release  
 
 ClpC2 was recently identified as one of roughly 100 Mtb genes upregulated 
by reaeration following an extended period of hypoxia [152].  These conditions 
approximate what an Mtb bacterium might encounter upon a sudden shift from a 
latent to an active TB disease state, perhaps following the cavitation of a granuloma. 
The link between the hallmark inflammatory cytokines, TNFα and IL-1β, and 
formation and maintenance of a granuloma is well-established [166, 174, 220].  
Given the clear link between granulomatous containment and hypoxia [219], we 
wished to study a potential role for Mtb ClpC2 in effecting a change in host 
inflammatory cytokine secretion.   
 Our results suggested that Mtb ClpC2 may play some role in the Mtb response 
to inflammatory cytokines (Figure 24).  We saw statistically significant differences (p 
≤ 0.001) in IL-1β secretion by HMDMs infected with either WT Mtb or ΔclpC2 Mtb, 
but observed no significant differences in host-induced TNFα secretion between the 
strains.  The HMDMs employed in these experiments originated from the monocytes 
of unique donors, and the collected infection supernatants were split to analyze TNFα 
and IL-1β release separately; the TNFα and IL-1β ELISAs were run in tandem.  Also, 
the cytokine standards worked quite well for all experiments.  Linear correlation 
values of R
2
 = 0.99 were obtained for each set of standards, suggesting variation due 
to technical issues were likely inconsequential for the data readout, and these 
reproducible discrepancies in host cytokine induction were not produced in error. 
Moreover, the IL-1β we observed was the mature, cleaved and secreted form, 




of the cytokine that may have escaped from the host by way of necrosis [61]; Figure 
25 presents a representative sample of our infected macrophages and establishes that 
there are no significant differences in necrosis, as measured by AK release, generated 
by any of our three strains of Mtb.  Finally, though the reported concentration of IL-
1β may appear low relative to the TNFα concentration from the same supernatant, the 
values obtained are in complete agreement with a very similar study published in 
PLoS One of 2011 [101].  We therefore feel that our results are valid and interpreted 
them as such.   
In the HMDM-Mtb host-pathogen model, the deletion of the Mtb clpC2 gene 
leads to an approximately 13-fold increase in host IL-1β secretion relative to WT Mtb 
infected macrophages; additionally, we achieved partial, but statistically significant, 
complementation of the mutant back to WT induction levels (p ≤ 0.05; WT versus 
complement) (Figure 24).  The levels of host TNFα induction were statistically 
similar for all three strains of Mtb (Figure 24).  Perhaps the most intriguing 
interpretation of this difference in inflammatory cytokine secretion is that ClpC2 may 
affect Mtb virulence or survival pathways that are specifically tailored to manipulate 
host IL-1β secretion; alternatively, ΔclpC2 may act as a broad-range mechanism 
altering numerous pathways and ultimately producing a largely defective Mtb strain 
which induces host IL-1β due to a general lack of fitness.  However, in terms of in 
vitro growth in both complete and minimal media, in vivo survival and replication, 
host apoptosis suppression and Mtb-mediated necrotic induction, we have established 
that ΔclpC2 behaves quite similarly to WT Mtb, suggesting a mutation that may act in 





Figure 25. Necrosis of HMDMs at 24 hours post-infection: a quality control 
experiment for IL-1β ELISA results.   
Necrosis was not observed and no significant differences were detected between any 
of the experimental groups, thus providing assurance to the quality of the observed 
IL-1β results (Figure 2).  HMDMs were infected with WT, ΔclpC2 or complement 
mutant strains of Mtb at MOI of 3 for 4 hrs; uninfected (UI) control wells were 
included in all experiments.  Values are given in relative light units (RLUs).  
Triplicate wells shown; triplicate measures from each well; triplicate measures were 
taken for a single lysis control well for each day (n=9 for samples; n=3 for lysis 
control).  Error bars represent ± SD.  Statistical analysis employed ANOVA with 
Tukey post-test.  Data is a representative experiment employing macrophages derived 





5.2.4.1 Potential for a ClpC2 role in affecting host IL-1β secretion  
 
If ClpC2 is truly specific to pathways involving Mtb-mediated manipulation 
of host IL-1β activation, ΔclpC2 will be quite useful in the characterization of these 
virulence mechanisms.  Few Mtb mutants affecting host IL-1β secretion have been 
reported to date.  A 2011 paper published in The Journal of Immunology showed that 
ESX-1 and ESX-5 virulence factor mutants of Mtb do not induce IL-1β release, and 
this phenotype could be complemented so that host IL-1β secretion was restored 
[220].  The same paper demonstrated that this secretion defect was limited to ESX-1 
in M. marinum, which suggests Mtb has multiple IL-1β modulating systems to 
influence host inflammasome activity.  Furthermore, ESAT6 of Mtb has been 
identified as a powerful generator of host inflammasome, and IL-1β release, response 
[212].  However, these are all virulence mechanisms with broad, large-scale effects.  
In terms of genetic analysis and the characterization of complex pathogen-host-
cytokine induction interactions, employing these mutants as one’s tools may be like 
using a using a hammer where a scalpel is preferred.  Additionally, all of these 
reported mutants suppress host IL-1β induction.  If the observed ΔclpC2 phenotype, 
which induced IL-1β secretion in HMDMs, is indeed valid (and the results we 
describe are reproduced by others) then clpC2 may be the very first gene of Mtb 
encoding a product verified to suppress host IL-1β release. 
Any virulence mechanisms that actively promote a reduced host inflammatory 
response would likely be advantageous to a pathogen.  From a clinical perspective, an 
inverse relationship between induction of inflammatory cytokines and the virulence 




It can be argued that the increased pathogenicity of these isolates stems from a 
diminished host inflammatory response, which results in a delayed adaptive immune 
response, thus providing the bacteria with a head start during the earliest moments of 
infection, such as the 24-hour chase employed in our ELISA studies.  Furthermore, an 
infection of SCID mice found the ΔclpC2 mutant to be slightly, but significantly, 
more virulent than WT Mtb in terms of morbidity induction (Figure 26).  Though this 
was only an initial experiment that needs to be replicated, these results suggest that 
the ΔclpC2 induced 13-fold increase in IL-1β secretion observed in HMDMs may be 
at least partially conserved in the SCID mouse model, and may be biologically 










Figure 26. SCID mice infected with Mtb and ΔclpC2.  
8 SCID mice were infected by aerosolized Mtb or ΔclpC2 bacteria at a low MOI. (A) 
3 mice per condition were sacrificed 1 day following infection. Lungs from each 
mouse were processed to ascertain respective colony forming units (CFUs) for each 
strain. No significant differences in were seen between Mtb and ΔclpC2 CFU values. 
Statistical significance was determined by Student’s paired t-test (n=3). (B) Median 
survival for the 5 mice per condition was 33 days for mice infected with ΔclpC2 (all 
sacrificed due to morbidity), while Mtb infected mice had a median survival time of 
39 days (3 mice sacrificed due to morbidity at day 39; 1 mouse sacrificed due to 
morbidity at day 33; 1 mouse perished at day 35) Statistical significance was 
determined by a Mantel-Cox log-rank test. * p=0.01-0.5 (n=5) (Experiments carried 







Chapter 6: Summary and Conclusion 
 
It is well established that the suppression of host apoptosis is a survival 
strategy of M. tuberculosis [53,  90,  91,  117].   Previous members of the Briken lab 
employed a large gain-of-function screen in an effort to identify genes of the Mtb 
genome that mediate apoptotic-suppression of a host cell. The screen took 312 
randomized gene segments from the virulent M. tuberculosis Erdman genome and 
expressed these regions within the less virulent, fast-growing, high apoptosis-
inducing mycobacteria species M. smegmatis mc
2
-155.  The transformed mc
2
-155 
were used to infect a human THP-1 cell line, which was screened for a reduction in 
apoptosis induction relative to THP-1s infected with mc
2
-155 transformed with an 
empty-vector control.  
One of these genomic regions conferring a GoF phenotype is referred to as 
“K20” (H37Rv nucleotide region 2,978,367 to 2,990,637, + strand) is 12,271 nt, plus 
an additional distal genomic region (2,945,437 to 2,946,738, + strand) that is 1,302 
nt; K20 contains 19 complete genes).  The other anti-apoptosis encoding genetic 
regions identified in that screen, J21 and M24, were previously reported [53] and 
characterized.  This dissertation has explored and presents new details regarding the 
hitherto unreported and uncharacterized K20 genomic region of Mtb, with a primary 
focus on the identification of anti-apoptotic virulence gene(s) of Mtb and a secondary 







6.1 Novel in vitro host models identified for the study of Mtb-host 
apoptosis interactions 
 
Before beginning the identification of the specific anti-apoptotic genes of the 
region, the K20 anti-apoptotic phenotype was initially validated in human monocyte 
derived macrophages (HMDMs) and Hartley guinea pig alveolar macrophages; this 
work established that the phenotype of interest was not solely an artifact of the THP-1 
cell line as earlier experimentations had suggested (K.K. Velmurugan, [53], data not 
shown).   
In terms of novel Mtb-host apoptosis modeling systems, these initial K20 
validation studies revealed that the use of recombinant human M-CSF cytokine and 
off-the-clot human serum to differentiate donor provided monocytes into mature, 
CD14
+
 macrophages produce viable, consistent results.  The M-CSF derived human 
macrophage system was optimized specifically by the author for this dissertation, and 
the host cells were additionally used by the author to supportively confirm the 
phenotypes of other anti-apoptotic genes of Mtb, Rv3165c and Rv3167c (B. Hurley, 
relevant publication forthcoming).  This particular host modeling tool will be quite 
useful for exploring the Mtb-host apoptosis inhibition interplay in future studies by 
both the Briken lab and the greater scientific community.  
Additionally, the guinea pig has previously been described as the gold-
standard animal model for Mtb in vivo studies [189], although very little work has 
been reported describing the usefulness of these macrophages for in vitro modeling of 
Mtb infection.  To the best of our knowledge, no circulated reports to date have 
detailed guinea pig alveolar macrophage apoptotic response to mycobacterial 




Hartley guinea pigs are a feasible, plentiful source of macrophages for modeling the 
Mtb-mediated suppression of host apoptosis in vitro.  These macrophages were also 
used by the author to further validate the Rv3167c anti-apoptotic phenotype (Figure 
27, B. Hurley, relevant publication forthcoming).   This is the first reported use of 
guinea pig alveolar macrophages for in vitro modeling of Mtb-mediated suppression 








Figure 27.  Infection of Hartley alveolar guinea pig macrophages with WT Mtb 
and ΔRv3167c indicates significant differences in host apoptosis.   
Significant differences in apoptosis were observed in alveolar macrophages of 
outbred Hartley guinea pigs infected with WT Mtb and ΔRv3167c.  Alveolar 
macrophages were infected 4 hrs at MOI of 3 followed by a 2 day chase; uninfected 
(UI) controls were included in all experiments.  Results shown are the composite of 
experiments using alveolar macrophages of 4 unique animals (n ≥ 6 for all samples). 
Error bars represent ± SD. Significance bar compares WT Mtb and ΔRv3167c.  





6.1.1 Novel in vitro host models identified as impractical/nonviable for the study 
of Mtb-host apoptosis interactions 
 
At the same time we found the usefulness of the Hartley guinea alveolar 
macrophages, it was determined that guinea pig peritoneal macrophages, while 
obtainable in much greater quantities per animal, are much too sensitive to apoptosis 
induction to be a feasible modeling system for future in vitro Mtb-infection studies.  
Furthermore, the immortalized murine alveolar macrophage cell (MH-S) [176, 
224] was previously considered to a promising in vitro Mtb-host apoptosis modeling 
system due to the ability to culture the line in very large quantity as well as its many 
physiological similarities with resident alveolar macrophages (the hallmark host for 
Mtb).  However, testing by the author revealed the cell line was quite impervious to 
mycobacterial-induced cell death, establishing the MH-S cell line, like guinea pig 
peritoneal macrophages, as a poor choice for future in vitro Mtb-host apoptosis 
investigations.  
 
6.2 Loss-of-gain-of-function screening is a novel and viable method of 
anti-apoptotic gene identification 
 
A loss-of-“gain-of-function” (LoGoF) screen was employed to determine 
genes that were potentially responsible for the K20 gain-of-function phenotype.  As 
the initial gain-of-function screen previously described (see section 3.3) has been 
invaluable to the Briken lab, and the relevant techniques and methodology well 
established, it was decided that the basic approach employed could be exploited to 




In this novel screening tactic, in vitro transposon mutagenesis was used to 
disrupt individual genes of the K20 expressing vector.  (This specific portion of this 
project was previously completed by former Briken lab member, Dr. Serdar Gurses.)  
A loss of the original K20 gain-of-function effect suggested that the K20-transposon 
mutant(s) inducing the greatest host-death indicated the particular gene’s possible role 
in the K20 GoF phenotype.  The LoGoF screen was repeated several times in the mc
2
-
155 and M. kansasii mycobacterial backgrounds, to reproducible ends.  Two LoGoF 
clones were consistently amongst the greatest inducers of host cell death: sgRv2666 
(Rv2666 is annotated by most sources as a probable truncated transposase gene) and 
sgRv2667 (Rv2667 typically annotated as a possible ATP-dependent protease subunit 
of the Clp family). 
Ultimately, we were able to establish the novel LoGoF screen as a valid 
approach to identification of anti-apoptotic genes of Mtb.  The LoGoF approach 
provides a simple technique and relatively rapid turnaround compared to screening 
individual gene constructs for a GoF phenotype (traditional forward genetics screen) 
or screening deletion mutants of Mtb (traditional reverse genetics screen); this is 
provided that one has access to a pre-fabricated GoF construct to build upon.   
Additionally, some phenotypes are dependent upon the presence of multiple genes, 
LoGoF screening allows for the identification of specific gene(s) critical for a 
phenotype of interest (barring polar effects resulting from transposon insertion).  The 
LoGoF screens employed in this dissertation suggested that Rv2666 and Rv2667 may 





6.3 Identification of Rv2666 as a novel anti-apoptosis gene of Mtb, 
and a unique function for a transposase-like gene of Mtb 
 
Having identified both genes of a potential two-gene Rv2666-Rv2667 operon 
by LoGoF screening, our attention turned to confirming these findings in an Mtb 
background. It was determined that using gene-abrogation  mutants of Mtb in a loss-
of-function (LoF), reverse genetics approach would directly address and confirm our 
LoGoF screen results, firmly establishing one or both of these genes as responsible 
for the K20 anti-apoptotic phenotype.   
An Mtb Himar1 transposon mutant of Rv2666 in the CDC1551 genetic 
background was obtained through the TARGET (Tuberculosis Animal Research and 
Gene Evaluation Taskforce) project.  Experimental results showed the TnRv2666 
mutant induced significantly more host apoptosis than the WT CDC1551 strain and 
the mutant phenotype was successfully complemented with an episomal plasmid 
carrying Rv2666.  These results confirm that Rv2666 acts as an Mtb encoded anti-
apoptotic gene. There are no current publications, to the best of our knowledge, 
suggesting a role for transposase or transposase-like element virulence or anti-
apoptotic effects within Mtb, making the findings reported in this dissertation entirely 
novel.   
The specific mechanism of action for Rv2666 is presently unknown, though 
transposase-turned-transcription factors have been well-established in Arabidopsis 
[192].  Additionally, “domesticated transposases” such as TnpAREP of E. coli (indirect 
transcriptional effects [225]) and TlpA/TlpB of Clostridium difficile (transposase-
fusion proteins [226,  227]) have been observed in prokaryotes.  It is possible, and our 




transcription of factors important for the suppression of host-apoptosis; while no 
apparent Mtb “anti-apoptosis system” has been presently identified, a multitude of 
anti-apoptotic genes of Mtb have been characterized (see section 2.4.3) and it is quite 
possible that Rv2666 may modulate the expression of one or more of these.   
 
6.4  Rv2667 /clpC2 not an anti-apoptotic gene of Mtb, but does affect host 
IL-1β secretion 
 
The second gene identified by LoGoF screening, Rv2667/clpC2/clpX’, was 
not available as a TARGET transposon mutant, so a ΔclpC2 recombinant abrogation 
mutant was created in the H37Rv genetic background of Mtb.  The ΔclpC2 mutant 
was confirmed by analysis of both RNA and genomic DNA.   
 
6.4.1  Rv2667 /clpC2 not an anti-apoptotic gene of Mtb 
 
ΔclpC2 and WT H37Rv were used to infect HMDMs, and relative levels of 
host-apoptosis induction were not significantly different between the strains; these 
results held true when the infections were repeated in guinea pig alveolar 
macrophages. These results suggest Rv2667/clpC2 has no apparent role as anti-
apoptotic gene of Mtb.   The discrepancy between the ΔclpC2 results and LoGoF data 
is possibly the result of evolutionarily conserved redundancy; the anti-apoptotic 
mechanisms of Mtb may be so important for the survival of the pathogen that 
numerous backups and fail-safes negate the strong LoF phenotype that was expected 
of a ΔclpC2 mutation in Mtb.  M. smegmatis and M. kansasii may lack many of these 




may be possible that ClpC2 has no direct effect on host-apoptosis outcomes 
whatsoever and that the discrepancy between the LoGoF and ΔclpC2 studies can be 
attributed to the involvement of ClpC2 acting in another capacity unrelated to the 
suppression of host-apoptosis.   
 
6.4.2  Rv2667 /clpC2 affects host IL-1β secretion 
 
Having studied the ΔclpC2 mutant, we determined that ClpC2 plays no 
obvious role in the suppression of host macrophages.  Further characterization of the 
ΔclpC2 mutant was undertaken to confirm or refute a suspected role for ClpC2 in 
Mtb virulence.    
It is known that virulent Mtb modulates host death outcomes in a variety of 
ways, such as the suppression of host apoptosis (harmful to the pathogen) and the 
promotion of host necrosis (beneficial to the pathogen).  The Mkan/Msmeg LoGoF 
screens and ΔclpC2-LoF experimental discrepancies previously described may be 
explained by mechanisms that exist outside of Mtb’s necrotic promotion pathways, or 
may be nonessential to a pro-necrosis phenotype but contribute to Mtb host-death 
mediation in other capacities.  Therefore, we examined the ΔclpC2 mutant for defects 
in the modulation of host hallmark inflammatory cytokine response to further study 
this thought. 
We found that ΔclpC2 and WT H37Rv did not vary in their induction of host 
TNFα release; however, the ΔclpC2 strain induced significantly more IL-1β secretion 
by infected host cells (p ≤ 0.001). The phenotype was partially complemented when 




infections were repeated; this partial, but not complete, complementation may be the 
result of a burdensome overexpression of ClpC2 by the plasmid-based, groEL2 
promoter carrying pMV261 expression vector or an artifact of overabundant plasmid 
copy number.  Initial in vitro growth curve studies (Figure 20) suggested that  the 
pMV261-based complement demonstrated obvious growth defects when grown in 
minimal media; it may be that the taxing-nature of the episomal plasmid extends to 
other bacterial processes beyond replication, including the Mtb machinery needed for 
the suppression of host inflammatory cytokine release following phagocytosis by a 
macrophage.  Further studies will be needed to confirm this. 
The reason for the ΔclpC2 IL-1β secretion phenotype is presently unknown.  
Given the in silico predictions of ATPase/chaperone homology [194], it may be that 
ClpC2 is an indirect, upstream effector of a protein or system mediating the 
phenotype.  It is quite possible that ClpC2 may aid in Mtb pathogenicity by 
providing, perhaps indirectly, an effect that allows the pathogen to limit host 
inflammation thus permitting the infecting mycobacteria a “head start” against the 
host adaptive immune response.  This idea would stand in agreement with real-world 
clinical findings.  It has been determined that at least one prominent difference in Mtb 
clinical isolates is the difference in the host inflammatory cytokine response they 
respectively generate.  It may be that more virulent strains of Mtb induce lower levels 
of host-inflammatory response [228, 229], as several research groups have 
hypothesized; clpC2 may be the first Mtb gene proven to have a role in the 
suppression of host IL-1β release by Mtb.  In addition to the novelty of our finding, 




studying host IL-1β release, inflammasome activation and the potential virulence link 





Chapter 7: Future Directions 
 This chapter explores the potential future experiments and studies most 
relevant to the collected data presented in this dissertation. 
 
7.1  Future directions: model systems 
 
 Much of the material presented within this dissertation has involved the 
development and characterization of novel Mtb-host apoptosis modeling systems.  
Some of the new host models described (guinea pig alveolar macrophages and M-
CSF differentiated human monocyte-derived macrophages) will be extremely useful 
in future studies by both the Briken lab and other researchers interested in the host-
pathogen interface as it regards the suppression (or induction) of host death by 
mycobacteria; other host models (guinea pig peritoneal macrophages and the 
immortalized MH-S, murine alveolar macrophage cell line) should probably be 
avoided for studies of this nature as they are of limited usefulness in this capacity. 
 
7.1.1 Model systems: Hartley guinea pig 
 
 As previously stated, our data suggests that Hartley guinea pig alveolar, but 
not peritoneal, macrophages are an excellent source for an  in vitro host cell modeling 
system for studying the induction of cell death by mycobacteria.  Alveolar 
macrophages are the natural host cell of Mtb, but are quite generally quite difficult to 
obtain from humans (due to an uncomfortable lavage process for donors) and mice 




macrophages can be obtained in sufficient quantity for a thorough analysis of host 
death induction by fluorescence microscopy.  Alternatively, given enough animals (4 
or more), adequate quantities of alveolar macrophages can be obtained to perform 
flow cytometry analysis should a researcher wish.   
 Additionally, our results suggest that the Hartley guinea pig will possibly be a 
useful model for in vivo infection studies of pro-apoptotic mutants of Mtb.  The 
Hartley guinea pig is believed to be one of the most practical animal models for the in 
vivo study of Mtb infection [189].  Our results have extended the usefulness of the 
model to in vitro assays (where alveolar macrophages and  Mtb-mediated suppression 
of apoptosis are concerned).  The in vitro results we obtained with the pro-apoptotic 
TnRv2666 mutant of Mtb should be further investigated with an in vivo, aerosol 
infection of Hartley guinea pigs with a full characterization of the mutant’s behavior 
versus WT Mtb in this setting.  It will be especially important to note altered animal 
survival/morbidity, host granuloma formation (particularly useful information can be 
gleaned from granuloma  histology in guinea pigs as compared to the Briken lab’s 
usual murine in vivo model) and relative CFU counts to establish the critical 
importance of Rv2666 for in vivo fitness of Mtb.  
 
7.1.2 Model systems: human monocyte-derived macrophages (HMDMs) 
 
 A large portion of the data presented in this dissertation was generated in a 
HMDM host cell model system.  These HMDMs were driven to macrophage maturity 




potential for this modeling system, a steady supply of monocytes will be required; 
this was an unfortunate limiting step in the course of this particular thesis project. 
This is less an experimental issue than one of logistics, however, Mtb is 
already one of the slowest growing bacterial species commonly studied and a 
deficiency of consistent macrophages for the modeling of host infection greatly 
exacerbates the timelines for all laboratory work of this nature.  A steady source of 
HMDMs would be a tremendous boon for research output by both the Briken lab and 
all other researchers studying Mtb and other slow-growing mycobacteria.  The 
monocytes used to generate the HMDMs used in this dissertation were generously 
provided by Dr. Alan Sher (NIH, Bethesda, MD), though this source of monocytes is 
limited by the availability of blood donors at the NIH campus and the technical issues 
of monocyte transport following collection.   In order to maximize efficiency (both 
time and financial), the HMDM differentiation process and protocol should be 
retooled for smaller scale studies employing a lower quantity of monocytes obtained 
from “local” donors.  A smaller pool of monocytes can be readily obtained from an 
on-campus donor, and used to quickly generate sufficient HMDMs for infection and 
subsequent analysis by fluorescence microscopy. 
Also, as described above (see section 2.2.2) human monocytes can be 
differentiated into mature macrophages with M-CSF or GM-CSF.  It has been 
suggested that these different cytokines will generate macrophages of different 
morphological and behavioral characteristics  [59, 66], and that differentiation with 
GM-CSF may generate a mature macrophage with greater similarity to alveolar 




superior for our purposes of host apoptosis study, it may be prudent to reevaluate this 
cytokine differentiation approach for the further detailing and characterization of 
ΔclpC2, the host IL-1β-secretion-affecting mutant of Mtb.  Monocyte differentiation 
with GM-CSF may provide a more accurate representation of resident alveolar 
macrophages, thus providing a superior in vitro model for Mtb infections and a 
cleaner phenotype in terms of host IL-1β secretion variations between ΔclpC2 and 
WT Mtb infection outcomes. 
 
7.2  Future directions: screens to identify anti-apoptotic genes of Mtb 
 
 Much of the work that identified the K20 genomic region of Mtb as “anti-
apoptotic” was completed several years prior to the beginning of this particular thesis 
project.  Additionally, the important K20 loss-of-gain-of-function (LoGoF) 
transposon mutant pool was generated by Dr. Serdar Gurses prior to this author’s 
endeavors to identify the specific anti-apoptotic gene(s) of the K20 region.  However, 
future studies to identify additional anti-apoptosis genes of Mtb may employ these 
methods and a thorough understanding of the pros and cons involved will be quite 
beneficial to future researchers. 
 
7.2.1  Future screens: gain-of-function (GoF) screens to identify anti-apoptotic 
genes of Mtb 
 
 The initial GoF screen used to identify the K20 region is described above (see 
section 5.1, first paragraph).   The major benefit of this assay was a rapid turnaround 




slowly due to longer replication times and the necessity of additional lab safety 
precautions).  From a pool of 312 initial genomic regions, 3 regions were definitively 
established as conferring an anti-apoptotic phenotype to Msmeg mc
2
-155.  On the 
downside of this particular screening approach, many relevant anti-apoptosis genes 
will likely be overlooked (proof of this screening-gap exists in the identification of 
Mtb anti-apoptosis genes, such as pknE, secA2, sodA, etc., that do not occur in the 3 
GoF genomic regions identified).   The reason for these “gaps” may be due to a 
number of causes.  It is possible the genetic background of Msmeg mc
2
-155 varies 
significantly enough from Mtb that the Msmeg is unable to implement the GoF genes 
to their full anti-apoptotic potential.  Or it is possibly that many of the anti-apoptotic 
genes of Mtb are an integral part of a yet unidentified anti-apoptosis system, and are 
encoded at distally positioned intervals on the Mtb chromosome, thus a GoF screen of 
this nature would miss these genes entirely. 
 If time and financial cost were less of an issue, a more thorough GoF screen 
and analysis to identify anti-apoptotic genes of Mtb would involve a similar repetition 
of the initial GoF approach in a mycobacterial model species more closely related to 
Mtb would be quite useful.  Additionally, the initial screen was carried out in a THP-
1 cell line.  Repetition of the screen in primary macrophages would be a much better 
approximation of real-world Mtb-host interactions.  For example, the GoF library 
pool could be used to transform M. kansasii.  GoF-transformed M. kansasii may then 
be used to infect bovine alveolar macrophages or bovine monocyte-derived 
macrophages [230], readily available in enormous quantity through collaborators at 




considerable investment of time and would probably be more practical if carried out 
by a laboratory technician(s) rather than a doctoral student(s) seeking to generate self-
publications during their academic career. 
 
7.2.2  Future screens: Improvements to LoGoF screening 
 
 The previously described LoGoF screen (see section 3.3) was successfully 
employed to identify an individual anti-apoptotic gene of Mtb, Rv2666.  This 
particular screening strategy was a novel and direct way of identifying a gene that 
was critical for the K20 GoF phenotype.   
However, the LoGoF screen also suggested that Rv2667/clpC2 was a potential 
anti-apoptotic gene; further testing with a ΔclpC2 abrogation mutant of Mtb proved 
this to be untrue.  It is possible this false positive resulted from a polar effect 
generated by transposon insertion into clpC2 acting on Rv2666 expression.  
Additionally, it may be that ClpC2 does have some anti-apoptotic role in Mtb, though 
it is rendered nonessential due to genetic redundancy within the Mtb background.  
There are 2 other Clp ATPases encoded by Mtb and the suppression of host apoptosis 
is critical for the survival of Mtb in vivo, so it stands to reason that such an important 
tactic will have evolutionarily selected backups and fail-safes.  Finally, the clpC2 
gene of the K20 GoF vector may have indirectly conferred an anti-apoptotic 
phenotype to the Msmeg and Mkan model species by acting in some yet unknown, 





Future studies may employ the LoGoF screening approach to identify anti-
apoptotic genes or potentially study other phenotypes of interest.  In order to avoid 
false positives in the future, a number of approaches may be employed.   
Multiple LoGoF clones should be screened for each gene of interest.  Each 
individual clone will diminish the odds of polar effects generating false positives in 
nearby genes as well as bolstering the evidence supporting identified, true positives.  
Also, it may be worthwhile to simultaneously screen individual genes (or smaller 
subsets of genes) of interest in a GoF approach to validate the LoGoF findings.  One 
would expect these GoF clones to demonstrate a phenotype opposed to their 
corresponding LoGoF mutant(s).  Additionally, RT-PCR may identify and control for 
aberrant and undesired alterations of LoGoF mutant gene expression that may lead to 
false positives.  Furthermore, screens carried out in a mycobacterial genetic 
background more closely related to Mtb (such as the M. bovis species) may avoid 
some of these issues altogether. 
Finally, the LoGoF screening approach may be retained but, rather than 
employing random in vitro transposon mutagenesis, genes of interest that are carried 
on the vector may be disrupted by a process of targeted homologous recombination.  
This would provide clean, specific LoGoF mutants and would limit instances in 
which the only available LoGoF mutant for a given gene has an insertion point in the 








7.3  Future directions: Rv2666, an anti-apoptotic gene of Mtb 
 
 This dissertation has identified a novel anti-apoptotic gene of Mtb, Rv2666, by 
LoGoF screening and study of a Himar1 transposon mutant of the gene.  This 
subsection explores potential future directions for the characterization of Rv2666. 
 
 
7.3.1   Rv2666: confirmation of phenotype in H37Rv, gene deletion background 
 
 As previously mentioned, a transposon mutant of Rv2666 in the CDC1551 
clinical isolate background of Mtb was revealed to have a pro-apoptotic phenotype 
when used to infect HMDMs.  This phenotype was completely restored to WT 
behavior by complementation of the mutant with an expression plasmid carrying the 
Rv2666 gene.   
The first future step in the further study of Rv2666 will be the creation and 
confirmation of a specifically targeted Rv2666 deletion mutant in the H37Rv 
laboratory strain of Mtb.  This will be important as homologous-recombination 
mutants (and phenotype complementation) are the gold-standard for genetic 
assessment and characterization of interesting mutants of Mtb.  Importantly, 
CDC1551 is a less commonly employed strain of Mtb used for laboratory work, and a 
mutant in the H37Rv genetic background will be essential for widespread acceptance, 
and recreation, of our findings.  Also, an H37Rv-based ΔRv2666 mutant will allow 
researchers to experiment in a relatively well-characterized genetic background with a 
much larger pool of (potentially related) anti-apoptotic Mtb mutants and correlated 






7.3.1   Rv2666: confirmation of phenotype by in vivo studies within animal 
model 
 
 Once an Rv2666 mutant in the H37Rv genetic background of Mtb has been 
generated and confirmed, it will be important to assess the mutant’s relevance for the 
in vivo virulence of Mtb.  Not all in vitro phenotypes have clinical significance.  As 
one of major goals of this line of research is the identification of Mtb genes that may 
be useful for the future creation of a pro-apoptotic vaccine, it is essential to establish a 
baseline for ΔRv2666 virulence (or lack thereof) in an animal model.  As mentioned 
above (see Chapter 7.1.1), the Hartley guinea pig should make an excellent animal 
model for this study.  Aerosol infections of Hartley guinea pigs with ΔRv2666, the 
complemented mutant and WT H37Rv (and possibly a better-characterized pro-
apoptotic mutant of Mtb such as ΔnuoG) followed by detailed analysis of outcomes 
will establish the relative importance of Rv2666.  Additionally, this dissertation has 
established the validity of guinea pig alveolar macrophages for in vitro analysis of 
Mtb-host apoptosis response; this research opens the avenue of exploration to a broad 
range of in vitro analyses involving ΔRv2666 corresponding to and supporting the in 
vivo studies proposed above. 
 
 
7.3.1   Rv2666: confirmation of potential role as a transcription factor of 
anti-apoptotic genes of Mtb 
 
 Understanding the regulation of Rv2666 will be quite important, as is the 
establishment of our hypothesized transcriptional factor role for the gene product.  As 




Mtb is maintained in macrophages [179], this may be an excellent place to begin 
analysis of the gene.   
Currently, the groundwork for an extensive RNA-seq analysis of Mtb in a 
variety of conditions (including intra-macrophage conditions) is being undertaken by 
Briken lab member Jeff Quigley.   From these future results, analysis of the data 
generated may reveal many interesting details about Rv2666 regulation that can act as 
a basis for the design of future studies.  Additionally, it may be beneficial to see why 
Mtb-genes similar to Rv2666 (other transposase-like Mtb genes) are not upregulated 
in the same conditions [179].  Specifically, this will drive at the question of why 
Rv2666 is so unique amongst seemingly similar genes (beyond or including its 
predicted “truncation”).  
 Ideally, this RNA-seq data may be able to suggest strong correlations 
between Rv2666 transcription and other known anti-apoptotic genes of Mtb; this will 
hopefully provide future researchers with a “short-list” of candidate genes for 
identifying effector proteins directly involved in host cell apoptosis inhibition.   
Should future work link Rv2666 to regulation of known, or presently unknown, anti-
apoptosis effectors of Mtb, our hypothesis that Rv2666 (encoded by a MULE-like, 
“domesticated” transposase-like gene) acts as a transcription factor of Mtb will have 









7.4  Future directions: Rv2667/clpC2, an Mtb gene affecting host-IL-
1β secretion 
 
 This dissertation has identified a gene of Mtb, Rv2667/clpC2, that affects host 
IL-1β secretion.  This subsection explores potential future directions for the 
characterization of Rv2667/ClpC2. 
 
 
7.4.1   Rv2667/clpC2: confirmation, and possible extension, of host 
cytokine secretion phenotype of interest 
 
 The confirmation of the ΔclpC2 effect on IL-1β-secretion in additional host 
backgrounds should be paramount for future studies.  For in vitro cell culture studies, 
this additional confirmation should be carried out by way of additional HMDM 
infections (each monocyte donor has a unique genetic disposition that may affect the 
final ELISA readout) as well as extending experimentation to identify a suitable 
human cell line for future investigations (such as THP-1s).  Additionally, our in vivo 
SCID mouse infection results such be replicated and include controls to bolster our 
hypothesized link between ΔclpC2 infection and hyperinflammation in host animals. 
Additional HMDM infections will allow future researchers to add statistical 
weight to our original data set and provide added assurance that the IL-1β secretion 
phenotype reported is not a solely donor-dependent effect.  This may be important as 
clpC2 may be the first identified Mtb gene shown to suppress host IL-1β release, thus 
precedent-setting and subject to a higher degree of scrutiny.  Furthermore, as the 
phenotype has been previously observed in HMDMs, future investigators should be 
able to run additional ELISAs using infection supernatants to detect other factors 




18).  The long term goals for the study of ClpC2 will certainly entail an assessment of 
its place within the increasingly understood and critically important host-
inflammasome pathways.  It will be interesting to identify whether the clpC2 
phenotype in question is IL-1β-specific, or if it generates a wider-ranging host-
response than what is demonstrated by our findings.  It will be important to establish 
this early in the characterization of this particular phenotype as ELISA is a measure 
of “final outcome” as far as our present investigative intentions have been concerned.  
Ultimately, the result of these experiments should provide clues as to how broadly 
acting ClpC2 truly is, thus priming future expectations and experimental design.   
In terms of further characterizations, the finite supply of HMDMs will 
inevitably mandate a need for a host model available in plentiful quantity for work 
with Western blotting and similar “high-input” assays.  Briken lab member Swati 
Shah has recently begun the experimental process of ΔclpC2 infection of THP-1s and 
her work should establish the feasibility of that particular cell line for use in future 
studies of ClpC2. 
Finally, our SCID mouse infection should be repeated with the complemented 
mutant, specifically the attB-integrated complement as initial studies suggest that the 
pMV261 plasmid-based clpC2 complement strain may have fitness issues under 
higher burden conditions (Figure 20).   
The SCID mouse results presented in this dissertation come from a single 
experiment and should be validated before definitive conclusions are drawn.  Future 
experimentation should employ additional animals and make the most of these 




low-dose infections that generate corresponding responses in terms of animal 
mortality/morbidity), and any additional infections should attempt to further validate 
our hypothesized link between clpC2 deletion in Mtb and increased host IL-1β 
release.  This could be accomplished using IL-1 receptor-deficient or IL-1converting 
enzyme (ICE)-deficient mice (or alternatively, in SCID mice dosed with anti-IL-1β in 
a range of concentrations) and infecting them with ΔclpC2, WT Mtb or 
complemented mutant,  and then observing for a diminished morbidity/mortality in 




7.4.2   Rv2667/clpC2: studying potential ATPase or chaperone activity 
 
 One of the questions raised by this dissertation regards the specific 
mechanism of action of ClpC2.  In silico analysis [194] suggests ClpC2 is an ATP-
dependent subunit of a Clp-family protease, or potentially acts in a chaperone 
capacity.    
It will be interesting to see if ClpC2 interacts with other Clp-family members.  
The Clp ATPase subunits of most bacteria possess a VGF consensus sequence which 
interacts with ClpP (the protease proteolytic subunit) to form a functional protease.  
Mtb is somewhat unique in that it possesses 2 proteolytic subunits (ClpP1 and ClpP2) 
and its verified Clp ATPases (ClpX and ClpC1) have a LGF-interaction loop.  ClpC2 
lacks this LGF-sequence but does have a LGV sequence which may substitute.  In 
order to establish the potential for ClpC2 interaction with other Clp-family members, 




also be an ideal time to further examine potential ClpC2-FtsZ interactions as per 
ClpX-FtsZ interactions [140], described above (see section 5.1.1).  
Alternatively (or additionally) to two-hybrid analysis, ClpC2 can be HIS-
tagged and relevant protein-protein interactions may be determined by co-
immunoprecipitation and subsequent mass spectrometry analysis.  Such experiments 
would reveal a bit more about the general role of ClpC2 in Mtb, potentially answering 
the question of whether the protein acts as a protease subunit, a chaperone, a broadly 
acting ATPase or perhaps acting in some completely novel, unexpected capacity. 
 In silico analysis of ClpC2 also suggests regions of ATP-binding homology.  
The predicted ATPase activity of ClpC2 should be verified.  This can be 
accomplished by incubation of purified ClpC2 (HIS-tagged and nickel-column 
purified) and ATP; several colorimetric and fluorescence assays exist that will 
quantify ATP hydrolysis (free-phosphate production) in a rapid, sensitive manner.  
The known Mtb ATPases ClpC1 and ClpX may be used as controls.  Ultimately, 
establishing  whether predicted ATPase activity is truly occurring in vitro will greatly 





7.4.3  Rv2667/clpC2: study gene expression and regulation with respect to 
Mtb virulence 
 
 ClpC2 has been predicted to be upregulated upon reaeration following 
extended periods of hypoxia [194], very similar to conditions one might expect upon 




mentioned above (see section 7.3.1), Briken lab member Jeff Quigley is presently 
engaged in the early-stages of a sizable RNA-seq analysis of Mtb under a variety of 
conditions.  An extensive examination of the completed data set for clpC2 
transcription may be one of the simplest, yet productive, early-stage studies a future 
investigator may attempt.  At a minimum, we would hope that the RNA-seq data will 
decrease the initial investment of time required for optimization studies, rapidly 
identifying the ideal experimental conditions needed for a thorough characterization 






A.                                 B. 
 
 
Figure S1.  THP-1 cell line infection with TnRv2666 mutant and complement 
confirm host anti-apoptosis phenotype and exclude necrosis.   
A. THP-1 cells differentiated overnight with PMA were infected at MOI of 3 for 
4 hrs, followed by a 3 day chase; uninfected (UI) THP-1s were included in all 
experiments.  Cells were lifted, fixed with 4% PFA and apoptosis was 
quantified by TUNEL staining and flow cytometry.  Figure results presented 
are representative of the experimental trend and come from a single trial with 
2 data points per condition.  Bars indicate mean value for the each condition. 
(Figure S1A data generated by Briken lab member Swati Shah) 
B. THP-1 cells differentiated overnight with PMA were infected at MOI of 3 for 
4 hrs, followed by a 3 day chase; uninfected (UI) THP-1s were included in all 
experiments.  Supernatants were collected and an AK release assay was 
performed to evaluate host necrotic death as indicated by degree of cellular 
lysis, quantified as relative light units (RLUs) emitted.  Results presented are 
representative of the experimental trend and come from a single experiment 










Figure S2. Southern blot confirmation of clpC2 gene abrogation.   
A.  Theoretical sizes (nt) of WT H37Rv and ΔclpC2 genomic DNA digested with Van91I.  
The original K20 GoF vector was also cut as a control for the WT clpC2 gene. 
B. Southern blot confirming abrogation of the clpC2 gene in the hypothetical knock-out.*note: 








Figure S3. sgRv2666 LoGoF and TnRv2666 insertion points. 
Figure presents gene sequence of Rv2666 with labeled transposon insertions for both 
the LoGoF transposon mutant within the K20 vector (see section 3.3) and the 









Figure S4. sgRv2667 LoGoF clone insertion points and location of targeted 
homologous recombination arms within Rv2667/clpC2 interior. 
Figure presents gene sequence of Rv2667/clpC2 with labeled transposon insertions 
for both the LoGoF transposon mutant within the K20 vector (see section 3.3) and 
targeting arms of the homologous recombinant mutant of H37Rv generated by 














Position on H37Rv 
(+ strand) Orientation Predicted function 
Rv2617c  441 2945847..2946287  -  PROBABLE TRANSMEMBRANE PROTEIN 
Rv2656c  393 2978660..2979052  -  POSSIBLE phiRv2 PROPHAGE PROTEIN 
Rv2657c  261 2979049..2979309  -  PROBABLE phiRv2 PROPHAGE PROTEIN 
Rv2658c  363 2979326..2979688  -  POSSIBLE PROPHAGE PROTEIN 
Rv2659c  1128 2979691..2980818  -  PROBABLE phiRv2 PROPHAGE INTEGRASE 
Rv2660c  228 2980963..2981190  -  HYPOTHETICAL PROTEIN 
Rv2662  273 2981482..2981754  +  HYPOTHETICAL PROTEIN 
Rv2661c  390 2981187..2981576  -  HYPOTHETICAL PROTEIN 
Rv2663  234 2981853..2982086  +  HYPOTHETICAL PROTEIN 
Rv2664  255 2982097..2982351  +  HYPOTHETICAL PROTEIN 
Rv2665  282 2982699..2982980  +  HYPOTHETICAL ARGININE RICH PROTEIN 
Rv2666  804 2983071..2983874  +  PROBABLE TRANSPOSASE FOR I IS1081  
clpC2  759 2983896..2984654  +  POSSIBLE ATP-DEP. PROTEASE CLPC2 
Rv2668  522 2984733..2985254  +  POSSIBLE EXPORTED PROTEIN 
Rv2669  471 2985283..2985753  +  GCN5-RELATED N-ACETYLTRANSFERASE 
ribD  777 2986839..2987615  +  POSSIBLE  RIBOFLAVIN BIOSYNTH. 
Rv2670c  1110 2985731..2986840  -  CONSERVED HYPOTHETICAL PROTEIN 
Rv2672  1587 2987682..2989268  +  POSSIBLE SECRETED PROTEASE 
Rv2673  1302 2989291..2990592  +  POSSIBLE INTEGRAL MEMBRANE PROTEIN 
     
 
Supplemental Table ST1. Genes of the K20 Region: size, position, orientation 









(x of x nt)  
Gene position 




Rv2657c - 49 of 261 2979049..2979309 2979260 
Rv2658c - 88 of 363 2979326..2979688 2979600 
Rv2659c - 114 of 1128 2979691..2980818 2980704 
Rv2660c - 162 of 228 2980963..2981190 2981028 
Rv2663 + 192 of 234 2981853..2982086 2982045 
Rv2665 + 133 of 282 2982699..2982980 2982832 
Rv2666 + 560 of 804 2983071..2983874 2983631 
clpC2 + 160 of 759 2983896..2984654 2984056 
clpC2* + 651 of 759 2983896..2984654 2984547 
Rv2668 + 153 of 522 2984733..2985254 2984886 
Rv2669 + 422 of 471 2985283..2985753 2985705 
ribD + 213 of 777 2986839..2987615 2987056 
Rv2670c - 293 of 1110 2985731..2986840 2986547 
Rv2672 + 838 of 1587 2987682..2989268 2988520 
Rv2673 + 496 of 1302 2989291..2990592 2989787 
 
 
Supplemental Table ST2. Individual LoGoF mutants. 
Table presents the individual LoGoF clones selected for use in the initial screen in the 
Msmeg mc
2
-155 background.  Table features gene name, gene orientation with 
respect to + or – strand of Mtb chromosome, point-of-insertion for each transposon 
within its respective gene, gene position within the Mtb chromosome and transposon 
insertion point with respect to the Mtb genome. (Note: Additional LoGoF clones were 
generated, though not employed in the assay; the respective LoGoF mutant generating 
the largest predicted gene-truncations were selected for use in the assay where 
possible. Not all genes were interrupted by a transposon insertion.) clpC2* indicates a 
secondary LoGoF clone for clpC2 which was employed at one point to verify the 
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